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Abstract 
	   2 
Anti-neutrophil cytoplasmic autoantibodies (ANCA), targeting the neutrophil 
protein granules myeloperoxidase (MPO) and proteinase 3 (PR3), activate 
neutrophils in vitro, and are associated with a systemic autoimmune vasculitis, 
in which a pauci-immune crescentic glomerulonephritis is common. The in 
vivo study of ANCA pathogenesis is severely limited, both by the lack of a 
robust anti-PR3 IgG induced disease model, and by the differences found 
between human and mouse biology. Therefore the development of a disease 
model based on humanised mice, defined as mice possessing human 
immune cells, has the potential to overcome these limitations, while also 
allowing the direct study of human ANCA in vivo. The aims of this thesis were 
1) to establish in vitro assays of ANCA induced neutrophil activation, and thus 
allow the study of ANCA:neutrophil interactions and 2) to establish a 
humanised mouse model of ANCA vasculitis. ANCA were purified from patient 
plasma, and two human neutrophil respiratory burst assays were developed. 
Subsequently, it was shown that Granulocyte Colony Stimulating Factor 
(GCSF) primes neutrophils for an anti-MPO induced respiratory burst, and the 
inhibition of phosphoinositol 3-kinase β/δ abrogates the ANCA induced 
release of superoxide. Humanised mice were produced by the engraftment of 
human haematopoietic stem cells into irradiated, adult NOD-scid IL2rγ-/- mice. 
At least 8 weeks later a population of human neutrophils were identified by 
flow cytometry, and this population was expanded by treatment with GCSF. It 
was shown that these cells could respond to inflammatory stimuli in vivo, by 
modulating their expression of activation markers, and in vitro, by undergoing 
respiratory burst and degranulation. Patient derived ANCA was passively 
transferred into humanised mice that had been primed with GCSF and 
lipopolysaccharide. Mice were culled 7 days later, but there was no 
histological or biochemical evidence of disease. Thus, this work has identified 
GCSF and phosphoinositol-3-kinase β/δ as molecules of potential importance 
in ANCA vasculitis. Furthermore, the passive transfer of patient ANCA into 
humanised mice did not prove pathogenic in this study, and possible reasons 
for this are discussed. The demonstration of functional responses in human 
neutrophils does, however, suggest that this humanised mouse model has the 
potential be useful for the study of human neutrophils in vivo.  
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1.1 Overview 
 
The primary focus of this thesis is the development of a humanised mouse 
model of anti-neutrophil cytoplasmic autoantibody (ANCA) associated 
vasculitis. However, in the course of this study, the ability of ANCA to activate 
human neutrophils was also examined. Therefore, this introductory chapter 
comprises detailed reviews of ANCA associated vasculitis, with a focus on 
results obtained from both in vivo and in vitro studies, the current available 
animals models of this disease, and finally, the current state, and emerging 
potential, of humanised mouse models.  
 
The second chapter describes general methods, and this is followed by five 
results chapters, each divided into four sections: introduction, specific 
methods, results and discussion. Chapter 3 details the establishment of a 
supply of patient derived ANCA, for use in both in vitro and in vivo 
experiments, together with the development and optimisation of in vitro ANCA 
induced neutrophil activation assays. Chapter 4 begins with data from a series 
of in vitro experiments looking at the expression of antigens for ANCAs, and is 
followed by data showing a potential role for granulocyte colony stimulating 
factor in the priming of neutrophils for ANCA induced responses. The chapter 
is closed with an investigation of the potential role of phosphoinositol-3- 
kinase β/δ in signalling pathways downstream of ANCA ligation. Chapter 5 
details the development of a humanised mouse model, while chapter 6 
contains data confirming these humanised mice possess functional human 
neutrophils. Chapter 7 describes attempts to induce ANCA associated 
vasculitis in these mice. Finally, chapter 8 is a discussion of the implications, 
limitations and future directions of the work presented in this thesis. 	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1.2 Anti-neutrophil cytoplasmic autoantibody (ANCA) associated 
vasculitis 
 
1.2.1 Pathology of ANCA associated vasculitis 
 
Anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis is a 
pauci immune, necrotising, small vessel vasculitis that predominantly affects 
microscopic vessels, such as capillaries and venules, within organs and 
tissues. Thus it is a severe, systemic autoimmune disease frequently affecting 
areas rich in small blood vessels such as the kidneys and lungs. It is a leading 
cause of progressive glomerulonephritis with approximately 28% of patients 
experiencing end stage renal failure within 5 years of diagnosis [1]. Indeed, 
while disease is systemic, with joints, skin, lungs, kidneys and other tissues 
frequently being affected, necrotising crescentic glomerulonephritis (NCGN) 
and inflammation of the respiratory system are particularly associated with 
high morbidity and mortality. If left untreated mortality is approximately 80% 
[2]. In contrast, if treated with currently available therapies, patients with renal 
involvement have an 85% chance of survival 1-year post diagnosis, with this 
decreasing to 75% after 5 years [1]. Current therapy generally involves the 
induction of remission with high dose glucocorticoids and cyclophosphamide. 
Once achieved, remission is maintained with azathioprine or methotrexate [3].  
 
The two most common forms of ANCA associated vasculitis are microscopic 
polyangiitis (MPA) and granulomatosis with polyangiitis (formally Wegener's 
granulomatosis) (GPA). MPA can affect any organ or tissue, however, dermal 
venulitis, pulmonary alveolar capillaritis, NCGN and epineural arteritis are 
particularly common [4]. Although disease is described as pauci immune, 
most patients have some evidence of focal IgG and complement deposition at 
the sites of vascular inflammation [4]. The acute vascular lesions found in 
affected vessels are characteristed by a neutrophilic infiltrate and significant 
leukocytoclasia, an accumulation of nuclear remnants from unscavenged 
neutrophils, together with vessel wall necrosis and, frequently, with the 
accumulation of fibrin. Within approximately one week, acute lesions progress 
to lesions rich in monocytes, macrophages and T cells, before progressing to 
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fibrotic lesions shortly thereafter [4]. Multiple vascular lesions of varying ages 
can be observed in any given affected tissue, and this is particularly evident in 
renal biopsy specimens in which glomerular lesions range from acute lesions 
with segmental fibrinoid necrosis, to chronic lesions with segmental sclerosis 
[4].  
 
GPA and MPA are almost pathologically identical, with only the presence of 
necrotising granulomatous inflammation found in GPA patients fully 
distinguishing the two diseases [4]. In GPA, necrotising granulomatous 
inflammation can be found within affected vessels or in extravascular tissue 
[4]. Although it can occur anywhere in the body, including the skin, nervous 
system and eye, granulomatous inflammation is most common in the upper 
and lower respiratory tract of patients [4]. Indeed, approximately 90% of 
patients have upper or lower airway involvement [5]. Importantly, and in 
contrast to the monocyte and T cell rich acute lesions typically associated with 
granulomatous inflammation in sarcoidosis, mycobacterial infection, and 
fungal infection, acute lesions found in GPA are predominantly composed of a 
neutrophilic infiltrate [4]. In addition, and although necrotic vessels are not 
generally identifiable in the acute lesions, focal accumulations of fibrinoid 
material can be observed. This is likely due to substantial vascular exudation 
or vascular disruption. Importantly, the resulting acute injury leads to the 
recruitment of monocytes, which transform into macrophages and 
multinucleated giant cells, as well as lymphocytes. Thus acute lesions 
eventually transform into more classic granulomas with palisading 
macrophages and giant cells present at the margins of areas of necrosis [4].  
 
1.2.2 ANCA, neutrophils and infection: Three key mediators of disease 
 
In 1982, Davies et al. first observed anti-neutrophil cytoplasmic autoantibodies 
(ANCA) in patients with focal and segmental glomerulonephritis, identifying, in 
the blood of patients, an IgG of unknown specificity that was capable of 
staining the cytoplasm of neutrophils [6]. This finding was later confirmed, and 
expanded, in a study which showed that antibodies against neutrophils and 
monocytes were not only present in patients, but also that the levels of these 
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antibodies were related to disease activity [7]. Since then ANCA have become 
established diagnostic markers of disease. Furthermore, there is now strong 
evidence that they are in fact pathogenic and, indeed, levels of ANCA often 
correlate with disease severity, although this is not the case in all patients [8-
10].  
 
Myeloperoxidase (MPO) and Proteinase 3 (PR3) were eventually identified as 
the primary antigenic targets of ANCA, and both can be found in the 
azurophilic granules of neutrophils and the peroxidase positive lysosomes of 
monocytes [11, 12]. The most common forms of small vessel vasculitis, 
granulomatosis with polyangiitis (formally Wegener's granulomatosis) (GPA) 
and microscopic polyangiitis (MPA), are often associated with ANCA directed 
against just one of these antigens, GPA with anti-PR3 antibodies and MPA 
with antibodies against MPO. However, it is important to also note that 
antibodies associated with GPA may be present in MPA patients and vice 
versa. In addition antibodies against both are occasionally present [13]. 
Importantly, both MPO and PR3 have also been shown to be present on the 
surface of cytokine-primed neutrophils isolated from whole blood [14, 15]. It is 
therefore likely that ANCA can bind to their antigens on the surface of 
neutrophils and through this, and Fc receptor interactions (Discussed in the 
following sections), recruit transmembrane molecules leading to intracellular 
signalling cascades culminating in neutrophil activation and the subsequent 
tissue damage associated with disease. Supporting this is in vitro data 
demonstrating that ANCA are capable of activating cytokine-primed 
neutrophils resulting in respiratory burst and degranulation [14, 16], 
inflammatory cytokine release [17], neutrophil extracellular trap formation 
(NETosis) [18] and damage to endothelial cell walls [19, 20]. Finally in vivo 
evidence of the importance of neutrophils in ANCA associated vasculitis 
includes reports that the number of activated PMN cells present in the renal 
biopsies of patients with GPA corresponds with renal tissue damage as 
assessed by serum creatinine levels [21]. In addition, using a mouse model of 
disease, Xiao et al. demonstrated that neutrophil depleted mice were 
completely protected from necrotising crescentic NCGN induced by the 
passive transfer of anti-MPO antibodies [22]. Notably, under the conditions of 
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this model ANCA:monocyte interactions were unable to induce disease. Thus, 
it is thought that ANCA-neutrophil interactions are key to disease 
pathogenesis (Fig 1.1). 
 
While it has been shown that neutrophils are key effecter cells, their presence 
together with that of ANCA may not be sufficient to cause disease. Huugen et 
al. demonstrated that, in a passive transfer model of NCGN, the 
administration of lipopolysaccharide (LPS) together with the anti-MPO 
antibodies significantly increased the severity of the disease compared with 
mice treated with anti-MPO antibodies alone [23]. The effect of LPS was 
shown to be related to increased levels of circulating tumour necrosis factor 
(TNF)α and MPO. The importance of TNFα was confirmed by the use of TN3, 
an anti-TNFα antibody that completely attenuated the effect of LPS on 
disease severity. These data, together with clinical observations that infection 
frequently precedes ANCA associated vasculitis diagnosis and/or relapse 
[24], and in vitro data showing that TNFα priming is required for ANCA 
induced neutrophil activation [14, 16], suggests that ANCA associated 
vasculitis is not induced by ANCA alone, but by a combination of ANCA and 
proinflammatory stimuli (Fig 1.1).  
 
The effect of LPS in ANCA associated vasculitis was further examined in two 
recent studies. In the first study, it was shown, using intravital microscopy of 
exposed glomeruli, that LPS treatment promoted anti-MPO induced 
glomerular leukocyte adhesion in a lymphocyte function-associated antigen 
(LFA)-1 dependent manner [25]. Furthermore, it was shown that LPS 
promoted the binding of anti-MPO IgG to neutrophils. These findings, together 
with the evidence that the effect of LPS is mediated through TNFα, are 
consistent with the hypothesis that TNFα induces MPO translocation to the 
surface of neutrophils in vivo [14, 15, 26]. In the second study, the role of Toll-
like receptor (TLR) 4, the main receptor for LPS, was examined [27]. It was 
first demonstrated that LPS together with anti-MPO IgG increased TLR4 and 
chemokine (C-X-C motif) ligand (CXCL)-1 and -2 expression by glomerular 
endothelial cells, and that this in turn increase neutrophil recruitment to the 
Chapter 1 Introduction 
	   28 
glomerulus. Both bone marrow and tissue cell TLR4 was found to be 
necessary for full expression of CXCL1 and CXCL2, and thus for maximal 
neutrophil recruitment. Furthemore, TLR4-/- mice had significantly less 
albuminuria, haematuria, glomerular hypercellularity and focal and segmental 
lesions after LPS and anti-MPO treatment than wildtype controls. Finally anti-
MPO IgG induced NCGN in LPS treated mice was attenuated in mice 
pretreated with anti-CXCL1 and anti-CXCL2 antibodies. Together these 
studies suggests that LPS, and thus infection, has several roles in the 
induction of ANCA associated vasculitis including in 1) the translocation of 
ANCA antigens to the surface of neutrophils, 2) the recruitment of neutrophils 
to the glomerulus and 3) the upregulation of β2 intergrins, and thus the 
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Figure 1.1 Pathogenesis of ANCA associated vasculitis.  
Neutrophils become primed by proinflammatory stimuli in vivo, most likely as 
a result of infection. This leads to the upregulation of integrins and the 
translocation of ANCA antigens, PR3 and MPO, from their position in the 
granules to the surface of the neutrophils. In addition, the presence of 
proinflammatory stimuli leads to the upregulation of endothelial cell adhesion 
molecules. Thus, neutrophil adhesion and transmigration is increased. With 
PR3 and MPO now present on the cell membrane, circulating ANCA can bind 
their antigen and, in an Fc dependent manner, activate neutrophils leading to 
the release of reactive oxygen species (O2-), proteolytic enzymes and further 
proinflammatory cytokines. The subsequent inflammation and tissue damage 
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1.2.3 ANCA antigens 
 
1.2.2.1 PR3 and MPO  
 
PR3, human leukocyte elastase (HLE), cathepsin G and azurocidin, are 
homologous neutral serine proteases found in the azurophilic granules of 
neutrophils [28, 29]. The primary function of these enzymes is thought to be 
the degradation of extracellular proteins, such as elastin, fibronectin, type IV 
collegen and lamin, at sites of inflammation [30]. However, other roles in the 
immune system have been suggested. For example, separate to its enzymatic 
activity, PR3 has been shown to effectively kill bacteria, particularly gram-
negative strains, and fungi [29, 31]. This microbicidal role is associated with 
the ability of PR3 to inhibit macromolecule synthesis, energy dependent 
transport and oxygen metabolism, and probably occurs as a result of charge 
interactions with the pathogen plasma membrane [32]. In addition, PR3 can 
interact with cytokines, and thus potentially modify the immune response. PR3 
can inactivate interleukin (IL)6 by degradation [33] and, interestingly, activate 
latent transforming growth factor (TGF)β [34], suggesting an anti-inflammatory 
role. The ability of PR3 to inhibit the activation of the nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase [35] also suggests that under some 
conditions PR3 may be able to down regulate the immune response. In 
contrast, PR3 has also been shown to increase the activity of IL8, a pivotal 
chemokine that preferentially induces neutrophil recruitment [36]. Therefore, 
PR3 may play a role in increasing neutrophil accumulation at the site of its 
release. Finally, PR3 can cleave membrane bound TNFα [37, 38], IL-1β [38] 
and the IL2 and IL6 receptors [39], although the functionality of resulting 
products is yet to be determined. Interestingly, PR3 is also capable of 
inhibiting thrombin through its cleavage, and subsequent inactivation, of 
protease activated receptors (PAR) on platelets and endothelial cells [40, 41]. 
It is also worth noting that PR3 is not only found in the azurophilic granules of 
neutrophils, but also in the specific and secretory granules [42], as well as in 
the cytoplasmic granules of monocytes [43].  
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MPO is a member of the heme peroxidase enzyme family and a major 
constituent of the azurophilic granules of neutrophils. It is an important 
component of the phagocyte oxygen dependent intracellular microbicidal 
system, where it primarily catalyses the H202 mediated oxidation of halide 
ions, notably chloride, to hypohalous acids [44]. Separate to its enzymatic 
activity, MPO has also been implicated in leukocyte recruitment [45]. In in vitro 
chemotaxis experiments, MPO was shown to induce neutrophil movement via 
electrostatic interactions with the leukocyte plasma membrane. In addition, 
and in the same study, MPO-/- mice exhibited reduced neutrophil infiltration at 
sites of inflammation. Finally, and perhaps most importantly, the deposition of 
MPO in the vasculature of these mice led to neutrophil adhesion in otherwise 
uninflamed blood vessels. Although primarily associated with neutrophils, 
MPO is also present in the cytoplasmic granules of monocytes and a 
subpopulation of macrophages [46]. 
 
Neutrophil activation by ANCA is entirely dependent on the ability of these 
autoantibodies to bind to their target antigens. Therefore, ANCA must be 
internalised by neutrophils, or PR3 and MPO must be present on the cell 
surface. It is also possible that both may occur, with some ANCAs being 
internalised while others bind to membrane bound antigen. Further to this, 
PR3 is present on the surface of resting, isolated neutrophils and monocytes 
[47], and, in the case of neutrophils, is upregulated following stimulation with 
fMLP and cytokines such as TNFα [14, 15, 42]. Interestingly, PR3 expression 
on isolated neutrophils has a bimodal pattern [48], with those cells possessing 
high membrane PR3 expression (mPR3high) generating more extracellular 
superoxide, and undergoing increased degranulation, in response to anti-PR3 
antibodies [49]. In contrast, the level of expression of mPR3 had no effect on 
the production of intracellular reactive oxygen species in response to anti-PR3 
IgG stimulation [50]. Notably, a high population of mPR3high neutrophils is a 
risk factor for GPA and rheumatoid arthritis [51]. Studies suggest that PR3 is 
anchored to the neutrophil membrane in one of two ways. In the first, PR3 is 
inserted into the plasma membrane via interactions involving basic amino acid 
residues [52]. In the second, PR3 is bound to the GPI-linked membrane 
receptor human neutrophil antigen B1 (NB1) (also known as CD177). Indeed 
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both NB1 and mPR3 are expressed on the same subset of neutrophils, and 
these molecules co-localise and co-immunoprecipitate together [53, 54]. 
Furthermore, it has been shown that a hydrophobic patch on the PR3 
molecule mediates binding to NB1 [55]. Interestingly, it has been shown that 
only neutrophils that co-express NB1 and PR3 exhibit high levels of mPR3 
expression [56]. In addition, and unsurprisingly given earlier data regarding 
the effect of PR3 expression levels on anti-PR3 induced neutrophil activation 
[49], neutrophils that present PR3 via NB1 produced greater levels of 
extracellular, but not intracellular reactive oxygen species, and underwent 
more robust degranulation, than their NB1 negative counterparts [56]. As NB1 
is a GPI-linked membrane receptor lacking an intracellular signalling domain, 
questions remain as to how anti-PR3 binding to mPR3 induces neutrophil 
activation. While it is possible that ANCA binding to PR3 on the surface of the 
cell leads to the internalisation of the resulting antibody:antigen:receptor 
complex, this seems unlikely given the current available data. Indeed, the 
PR3:NB1 complex has been shown to exist in lipid rafts on the surface of 
neutrophils as part of a larger signalling complex that also includes 
CD11b/CD18 (Mac-1), FcγRIIIb and p22phox, an important component of the 
NADPH oxidase complex [56-58] (Fig 1.2). Therefore, it is likely that the 
ANCA signal is transduced across the plasma membrane by the 
transmembrane chains of CD11b and CD18. Further to this, blocking either of 
these  β2 integrins greatly reduces the ANCA induced respiratory burst and 
degranulation response in anti-PR3 IgG stimulated neutrophils [56]. 
 
In contrast to PR3, MPO is not found on the surface of isolated, resting 
neutrophils and the increase in surface expression after neutrophil activation 
is relatively small [49].  While there is little data on how MPO is anchored at 
the cell surface, it is possible that it is due to this highly cationic protein 
binding to negatively charged residues on the plasma membrane. Indeed, the 
ability of positively charged MPO to induce neutrophil chemotaxis via 
electrostatic interactions [45], suggests that MPO is indeed capable of 
interacting in such a manner with the neutrophil plasma membrane. Similarly 
to mPR3, it has been it has been shown that MPO on the surface of 
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neutrophils associates with membrane bound CD11b/CD18 (Fig 1.2). 
Furthermore, data suggests that this interaction plays an important role in 
anti-MPO induced degranulation, expression of integrins, and activation of 

















Figure 1.2 Surface expression of PR3 and MPO  
PR3 on the surface of neutrophils is likely to be bound to the GPI-linked 
membrane receptor NB1. It has been shown that this complex also interacts 
with Mac-1 and thus is likely to signal through the transmembrane domains of 
CD11b and CD18. There is little data on how MPO is anchored to the cell 
membrane. However, it has been shown that it associates with Mac-1, and 
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1.2.2.2 LAMP-2: An additional target for ANCA? 
 
In 1995 Kain et al. showed, having carried out a systematic search for ANCA 
antigens, that in addition to possessing autoantibodies against either PR3 or 
MPO, 14 out of 16 patients with pauci-immune NCGN also had antibodies to 
lysosomal membrane protein (LAMP)-2 [60]. LAMP-2 is a heavily glycosylated 
type I membrane protein expressed by both neutrophils and endothelial cells. 
It is a major component of the lysosomes, and is also present in the 
membranes of intracellular vesicles and, most notably, on the plasma 
membrane [60, 61]. Thus, due to this expression pattern, LAMP-2 on both 
neutrophils and endothelial cells is directly accessible to circulating 
antibodies.  
 
In 2008, Kain et al. confirmed their initial study by showing that 78 out of 84 
patients with active NCGN possessed antibodies against LAMP-2 and that 
this correlated with disease activity [62]. Furthermore, they showed that, in 
vitro, a monoclonal anti-LAMP-2 antibody could induce MPO release from 
neutrophils and apoptosis of human microvascular endothelial cells. In vivo, 
they showed that Wistar Kyoto (WKY) rats injected with polyclonal rabbit 
antibody against LAMP-2 developed severe pauci-immune NCGN. Notably, 
the potential for molecular mimicry to be involved in breaking tolerance by 
initiating anti–LAMP-2 autoantibody formation was suggested. First, it was 
shown that anti-LAMP-2 autoantibodies from individuals with pauci-immune 
NCGN bind an epitope that shares 100% sequence homology with the gram 
negative bacterial adhesin Fimbriae (Fim) H. Consequently, it was shown that 
patient antibodies cross reacted with FimH and, furthermore, that rats 
immunised with FimH developed antibodies that cross reacted with human 
and rat LAMP-2. Importantly, these rats subsequently developed pauci-
immune NCGN. Finally, it was shown that infection with FimH-expressing 
bacteria is common in patients before the development of NCGN. This then 
provided evidence that FimH may indeed be responsible for triggering anti-
LAMP-2 autoimmunity. 
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These finding, however, have been challenged by a North American study in 
which Roth et al. showed that only 21% of sera from 329 ANCA positive 
NCGN patients possessed anti-LAMP-2 autoantibodies, and that these did not 
correlate with disease [63]. Furthermore, they showed that anti-PR3 and anti-
MPO titres were 10,000 and 1,500-fold higher that LAMP-2 titres, 
respectively. Finally, they did not observe any signs of disease in WKY rats 
immunised with anti-LAMP-2 antibodies. In contrast, and in a side-by-side 
publication, Kain et al. reconfirmed their findings in an additional European 
cohort showing that, overall, 81% of ANCA associated vasculitis patients in 
this study had circulating autoantibodies against LAMP-2 [64]. The reasons 
for this discrepancy are not entirely clear but it may be related to 
methodological differences, the most obvious being with regards to the patient 
populations tested. Kain et al showed that the highest anti-LAMP-2 titres were 
consistently found in newly presented, untreated patients with active NCGN. 
Furthermore, they found that anti-LAMP-2 antibody titres were highly sensitive 
to disease activity and immunosuppression. Indeed, in their most recent 
study, anti-LAMP-2 antibodies were found to be undetectable in 36 out of 37 
patients as little as one month post treatment. In contrast, Roth et al. tested 
patients, the majority of which had received some form of treatment, with a 
range of disease activities. In addition to variation in the patient cohorts 
tested, the ELISAs used by Kain et al. and Roth et al. to measure anti-LAMP-
2 antibody titres differed in the antigen substrate used, and thus this 
represents another potential point of divergence. Whatever the reasons for 
this conflicting data, further work will be required to determine whether anti-
LAMP-2 antibodies have a role, either alone or in conjuction with anti-
PR3/anti-MPO antibodies, in the pathogenesis of ANCA associated vasculitis.  
 
1.2.4 Both the antigen binding region and the Fc portion of the ANCA 
molecule play a critical roles in neutrophil activation 
 
The binding of ANCA to its antigen begins a signalling cascade that 
culminates in neutrophil activation. The region of the ANCA molecule 
responsible for this has been the subject of intense investigation with 
conflicting data emerging. While some studies have shown that signalling via 
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the cross linking of antigen by the antibody-binding region (F(ab’)2) is 
sufficient to induce full neutrophil activation [65, 66], others have 
demonstrated a need for concurrent Fc receptor (FcR) signalling [67-69]. 
Despite this conflicting evidence, the emerging picture is that both the 
antigen-binding region and the Fc portion of the ANCA molecule play critical 
roles in neutrophil activation. Using microarray gene chip analysis Yang et al. 
demonstated that ANCA IgG and ANCA-F(ab')2 fragments induce the 
transcription of leukocyte genes [70]. Importantly, some of the transcribed 
genes were found to be unique to either the whole IgG or the F(ab')2 region, 
while others were found to be common to both fragments. Further to this, 
signalling via both the antigen-binding region and the Fc portion of the ANCA 
molecule was shown to be necessary for full neutrophil activation, with ANCA 
F(ab')2 fragments stimulating G protein coupled pathways and FcγR signalling 
activating tyrosine kinases [71] (Fig 1.3). Interestingly, both FcγRIIa and 
FcγRIIIb were shown to be involved, with the inhibition of either significantly 
reducing superoxide production in response to ANCA. This was not the first 
study to show a potential role for both FcγRIIa and FcγRIIIb in ANCA 
associated vasculitis and, indeed, ANCA has been shown to bind to both 
receptors. In addition, it has been established that FcγRIIa inhibition 
abrogates ANCA induced neutrophil activation. The data regarding FcγRIIIb 
blockade is, however, less clear [65-69]. Perhaps the most compelling 
evidence with regards the role of Fcγ receptors in ANCA induced neutrophil 
activation comes from in vivo data showing that anti-MPO IgG failed to induce 
leukocyte adhesion or transmigration in Fc receptor γ chain-/- mice [72]. This 
suggests that, whatever the role of FcγRIIa and/or FcγRIIIb ligation in the 
ANCA induced respiratory burst, it is likely that the FcγRs are necessary for 
neutrophil adhesion to endothelial cells, and thus disease pathogenesis.  
 
Interestingly a recent study investigated the consequences of differences in 
the FcγRIIIb genotype on ANCA associated vasculitis [73]. Two common 
genetic varients exist, NA1 and NA2, with the NA1 allele producing stronger 
neutrophil response including phagocytosis, respiratory burst, and 
degranulation. Although no difference was found in the frequency of these 
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alleles among patients with GPA compared with healthy controls, the 
presence of the NA1 allele was associated with more severe renal disease. 
Similarly the allelic phenotype of FcγRIIa was shown to strongly influence the 
ability of anti-PR3 and anti-MPO to induce the production of neutrophil 
reactive oxygen species in vitro [67]. The presence of either a histidine or an 
arginine at position 131 of the receptor determines whether a high or low 
responding version of the receptor is expressed, with neutrophils possessing 
the high-responder variant showing a stronger ANCA response [67]. These 
data taken together suggest that the FcR genotype influences the phenotype 
of ANCA associated vasculitis. 
 
While the majority of studies have focused on the role of IgG ANCA, and thus 
FcγRs, in ANCA associated vasculitis, there is some evidence that IgA ANCA, 
and thus FcαRs, are also important. In a recent study by Kelley et al. IgA 
ANCA was found to account for 27% of the ANCA present in GPA patients 
[73]. Interestingly, IgA ANCA was found to be less frequent in patients with 
severe renal disease, while it appeared to be more frequent in patients with 
upper airway involvement. In addition, this study also examined the genotype 
of the FcαR found in GPA patients. Two allelic variants of the FcαR have 
been identified, the result of a	  single-nucleotide polymorphism (SNP) that 
changes a serine (A) residue to a glycine (G). Importantly, the presence of the 
A allele is associated with a decreased immune responses, such as 
proinflammatory cytokine release, while the G allele is associated with 
increased cellular activation and phagocytosis. Kelley et al. demonstrated that 
the G allele was less common in patients with severe renal disease and more 
common in patients with upper airway involvement. Furthermore, neutrophils 
with the G allele were shown to undergo a stronger activation in response to 
IgA ANCA in vitro, perhaps unsurprising given the generally proinflammatory 
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1.2.5 ANCA binding activates intracellular signalling leading to 
neutrophil activation 
 
Various intracellular signalling molecules (Summarised in Fig 1.3) have been 
reported to have important roles in ANCA stimulated neutrophil activation. 
In 1999, Radford et al. showed that tyrosine kinases and protein kinase C 
(PKC), probably the βII isoform, were required for ANCA induced superoxide 
release [74]. Using a similar approach, that is introducing specific inhibitors 
into neutrophil activation assays in vitro, Kettritz et al. showed that the 
mitogen activated protein kinase (MAPK) pathway had a crucial role in ANCA 
induced neutrophil activation [26]. In this study the inhibition of both 
extracellular signal-regulated kinase (ERK) and p38 MAPK significantly 
reduced the TNFα dependent, ANCA stimulated release of superoxide. 
Interestingly, it was shown that the inhibition of p38 MAPK, but not ERK, 
prevented the TNFα induced translocation of PR3 and MPO to the surface of 
neutrophils, thus suggesting that p38 MAPK activation is responsible for 
making these antigens available to circulating ANCA. ERK, in contrast, was 
thought to inhibit the TNFα mediated priming of neutrophils, required for the 
maximal generation of reactive oxygen species.  
 
The role of phosphoinositol 3-kinase (PI3K) in ANCA associated vasculitis 
was investigated in a number of studies. Ben-Smith et al. first demonstrated 
that the PI3K inhibitors LY294002 and wortmannin were capable of 
suppressing the ANCA stimulated release of superoxide, thus suggesting that 
PI3Ks play an important role in ANCA signalling [75]. Furthermore, they 
showed that ANCA induced neutrophil activation results in the generation of 
the PI3K product phosphatidylinositol 3,4,5-triphosphate (PIP3). Importantly, it 
was also shown that ANCA stimulation did not lead to the recruitment of the 
p85/p110 isoform of PI3K. Instead, the ability of Pertussis toxin to inhibited 
ANCA induced superoxide release, via the inhibition of G protein coupled 
receptors, indirectly suggested that ANCAs were likely to activate the 
p101/p110γ isoform. Kettritz et al. later confirmed that PI3K inhibition 
abrogates ANCA stimulated superoxide generation [76]. Furthermore, they 
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demonstrated that ANCA induced PI3K and p38 MAPK, but not ERK, 
activation leads to the phosphorylation and subsequent activation of Akt, an 
important serine/threonine-specific protein kinase that plays a role in 
mediating the neutrophil respiratory burst [77]. Importantly, Williams et al. 
showed that a combination of tyrosine kinase activation, requiring intact IgG 
ANCA signalling, and the recruitment of heterotrimeric G proteins, including 
Ras, by IgG ANCA F(ab’)2 fragments, is necessary for ANCA induced PI3K 
activation and subsequent superoxide generation [71].  
 
Syk is a cytosolic protein and a member of the Src family of tyrosine kinases. 
It is essential for FcγIIa mediated leukocyte functions and is activated 
upstream by a receptor associated Src kinase. Targets of Syk include 
phospholipase C (PLC)γ and p85-PI3K. Importantly, it was found that the 
inhibition of Syk abrogated ANCA stimulated superoxide release [78]. In 
addition, Syk was shown to be phosphorylated, and thus activated, by the 
incubation of human neutrophils with intact IgG ANCA, but not with ANCA 
F(ab’)2 fragments, suggesting that its activation is linked to FcγR ligation. 
Indeed, anti-FcγRIIa and anti-FcγRIIIb antibodies partially inhibited Syk 
phosphorylation and subsequent superoxide release. Interestingly, antibodies 
to CD18 also reduced Syk phosphorylation in response to ANCA. The ability 
of Syk to activate PLCγ suggests a potential role for diacylglycerol (DAG) and 
inositol triphosphate (IP3), products of the PLCγ mediated cleavage of 
phosphatidylinositol 4,5-bisphosphate (PIP2), in ANCA induced neutrophil 
activation. Indeed, DAG is required for PKC activation, which, as mentioned 
previously, has a role in the ANCA induced generation of superoxide [74]. 
Further to this, Williams et al. showed that ANCA stimulation led to the DAG 
kinase catalysed formation of phosphatidic acid (PA) from DAG, and that this 
had an important role in Mac-1 mediated, ANCA induced, neutrophil adhesion 
[79]. The subsequent generation of PIP2 from PA by the action of 
phosphoinositol (4) phosphate-5-kinase Iγ (PIPKinIγ) was suggested as the 
mechanism of this PA dependent adhesion, with PIP2 going on to activate 
Mac-1 through interactions with talin, a cytoskeletal protein known to be 
involved in intergrin activation. 
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In vitro data does not always reflect the in vivo situation and thus animal 
studies are an important step in the elucidation of signalling pathways in 
disease pathogenesis. Despite convincing in vitro results combined with data 
showing that activated p38 MAPK was identified in the glomerular lesions of 
patients with ANCA associated vasculitis [80], in vivo inhibition of p38 MAPK, 
using a daily oral treatment protocol on mice that had received a passive 
transfer of anti-MPO IgG, had only modest protective results [81]. While both 
treatment and pre-treatment with the p38 MAPK inhibitor slightly decreased 
the number of glomerular crescents and the influx of macrophages, there was 
no effect evident on albuminuria or haematuria. These results show that 
although p38 MAPK has a pivotal role in ANCA induced neutrophil activation 
in vitro, there are likely to be other more important molecules at work in vivo. 
Once such molecule may be PI3Kγ. As previously discussed, in vitro data 
using PI3K inhibitors [75, 76], together with data showing the importance of 
signalling molecules downstream of PI3K [71, 75, 76], have identified it as a 
possible key signalling molecule in ANCA associated vasculitis. Importantly, 
Schreiber et al. recently examined this in vivo using their bone marrow 
transplantation model of disease [82]. In this study, PI3Kγ deficiency 
completely protected mice from disease induced by anti-MPO antibodies. 
Furthermore, mice expressing normal levels of PI3Kγ, when treated with the 
PI3Kγ inhibitor AS605240, were also protected from anti-MPO induced 
NCGN. Although the results from this study are promising, the authors failed 
to address issues regarding the role played by PI3Kγ in neutrophil 
chemotaxis. Several studies have shown that PI3Kγ deficient neutrophils 
exhibit impaired migration in response to fMLP [83-85], IL8 [84] and C5a [84, 
85]. Thus, it is possible that the protective effect of PI3Kγ loss is due, not to an 
effect on ANCA signalling, but is instead the result of insufficient neutrophil 
trafficking to the kidneys of mice. Despite this, the combination of in vitro data 
using human cells and data derived from in vivo mouse work, though 
incomplete, suggests that PI3Kγ may be an important potential therapeutic 
target for the treatment of ANCA associated vasculitis. 
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Figure 1.3 ANCA signalling.  
This figure shows the potential key signalling molecules involved in the IgG 
ANCA induced neutrophil respiratory burst. PR3 exists in lipid rafts on the 
surface of neutrophils as part of a larger signalling complex that also includes 
Mac-1 and FcgRIIIb. In addition, MPO has also been shown to be associated 
with Mac-1 on the surface of neutrophils. The binding of ANCA to PR3/MPO 
stimulates G coupled protein pathways, likely via these antigens interacting 
with Mac-1. This leads to the activation of the MAPK pathway, as well as to 
signalling via PI3K, culminating in the activation of the neutrophil respiratory 
burst. Meanwhile, FcgR ligation by the Fc portion of the ANCA molecule leads 
to the activation of Src family tyrosine kinases, and thus to an increase in 
neutrophil adhesion, via generation of PIP2 , and reactive oxygen species 
production, primarily via pathways downstream of PI3K. 
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1.2.6 A role for Complement in ANCA associated vasculitis? 
 
The observation that mice treated with cobra venom factor (CVF), and thus 
depleted of complement, were protected from anti-MPO antibody induced 
disease was the first evidence that the complement system plays an important 
role in ANCA associated vasculitis. Indeed, it was shown that it is most likely 
the alternative pathway, and not the classical or lectin pathways of 
compliment activation, that is important in disease pathogenesis [86]. While 
C4 deficient mice developed disease comparable to wildtypes when treated 
with anti-MPO antibodies, factor B deficient mice appeared to be resistant to 
anti-MPO IgG induced NCGN. Furthermore, mice lacking the complement 
component C5, an important protein involved in neutrophil chemotaxis and 
activation, were completely protected from disease induced by the passive 
transfer of anti-MPO antibodies.  In addition to this, the importance of C5 was 
confirmed in a separate study in which mice treated with an anti-C5 
monoclonal antibody were protected from NCGN induced by the passive 
transfer of anti-MPO antibodies [87]. In vitro experiments showed a specific 
role for C5a with the observation that the supernatant from TNFα primed, 
ANCA stimulated neutrophils was sufficient to cause the generation of C3a 
and C5a in normal serum but not in serum lacking C5 [88]. Furthermore, the 
blockade of the C5a receptor was shown to inhibit the ANCA induced 
respiratory burst. The importance of the C5a receptor was then confirmed in 
vivo using a bone marrow transplant model of disease, with mice receiving 
C5aR deficient bone marrow developing relatively mild GN in response to 
anti-MPO IgG when compared mice receiving wildtype bone marrow. These 
data suggest that the alternative pathway, and particularly C5a, may 
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1.3 Animal models of ANCA associated vasculitis 
 
1.3.1 Anti-MPO antibody induced models of disease 
 
1.3.1.1 Spontaneous disease (Table 1.1 Model 1) 
 
The spontaneous crescentic glomerulonephritis/Kinjoh (SCG/Kinjoh) strain of 
mice spontaneously produces anti-MPO antibodies while simultaneously 
developing necrotizing vasculitis and crescentic GN [89]. Consequently this 
strain has been suggested to represent a possible model of ANCA associated 
vasculitis. However, as these mice are the result of selective breeding, for a 
high percentage of glomerular crescent formation, among the offspring of 
mated siblings of (BXSB/Mp x MRL/Mp-lpr/lpr) F1 hybrid mice, they also 
possess anti-nuclear autoantibodies [90] that may contribute to kidney 
pathology. Furthermore, disease is associated with significant immune 
complex deposition, and thus does not mirror the pauci-immune NCGN 
typically observed in patients. Therefore, while these mice may provide useful 
data on the spontaneous generation of anti-MPO autoantibodies, the study of 
monoclonal anti-MPO from these mice has already provided insight into their 
structure [91], they are not suited to the study anti-MPO induced tissue 
damage.  
 
1.3.1.2 Passive transfer model (Fig 1.4 A, Table 1.1 Model 2) 
 
Xiao et al. were the first to show, using a mouse model, that anti-MPO 
antibodies were pathogenic [92]. This was achieved using a passive transfer 
model. Anti-MPO antibodies were raised by the immunisation of MPO-/-  mice 
with murine MPO, and these antibodies were found to induce a pauci-immune 
NCGN when subsequently transferred to either wild type or recombinase 
activating gene (RAG) 2-/- mice, a strain lacking functional T and B cells. 
Although disease was mild, with less than 5% of glomeruli affected in wild 
type mice, this represented a major breakthrough in the study of ANCA 
induced disease. Not only did it provide evidence that anti-MPO antibodies 
alone were sufficient to induce pathological changes, but it also presented a 
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model of disease that could be used to both explored the pathogenic 
mechanisms of ANCA associated vasculitis, and to test potential therapeutic 
interventions. In the same study, the transfer of whole splenocytes from MPO 
immunised MPO-/- mice into either wild type or RAG2-/- mice induced a far 
more severe NCGN. However, this was associated with significant immune 
complex deposition, and thus did not represent the pauci-immune vasculitis 
seen in man. The presence of these immune complexes, not seen in the IgG 
transfer model, is likely due to the proliferation of transferred lymphocytes.  
 
The relatively mild manifestation of disease is a major drawback of the 
passive transfer model. However, in a subsequent study Huugen et al. 
demonstrated that the administration of LPS together with the anti-MPO 
antibodies could exacerbate disease, although not to extent seen in patients 
[23]. This was shown to be the result of an increase in circulating TNFα and 
MPO. As TNFα has been shown to induce the translocation of MPO to the 
surface of human neutrophils in vitro, and thus to be important for in vitro 
ANCA assays [14, 16, 26], it is likely that LPS serves, at least partially, to 
prime mouse neutrophils for anti-MPO IgG induced activation. In addition, 
LPS has been shown to be important in other models of GN due to its ability 
to stimulate renal cells via the activation of TLR4 [93, 94]. Therefore, effect of 
LPS on disease severity may be the result of the activation of numerous 
signalling pathways. 
 
1.3.1.3 Bone marrow transplant model (Fig 1.4 B, Table 1.1 Model 3) 
 
Using a similar approach, that is immunising MPO-/- mice with murine MPO, 
Schreiber et al. developed an alternative model of anti-MPO induced NCGN 
[95]. In this model MPO-/- mice that have been primed with MPO, and thus 
have developed anti-MPO antibodies, are irradiated and then reconstituted 
with wildtype bone marrow derived cells. As antibody-producing plasma cells 
are generally able to survive irradiation, anti-MPO titres are kept relatively 
constant, and, with the transplanted bone marrow providing neutrophils 
possessing MPO, a mild NCGN is induced.  
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A minor drawback of this approach, however, especially when compared with 
the passive transfer model, is that the reconstitution of these bone marrow 
chimeras takes time and consequently disease can take approximately 8 
weeks to develop. Despite this the bone marrow transfer model provides (1) 
further evidence that ANCA are directly pathogenic, (2) evidence that bone 
marrow derived cells are sufficient targets for ANCA to induce disease, (3) 
another model of ANCA associated vasculitis that may be used to both 
examine mechanisms of disease, particularly through the use of bone marrow 
derived from genetically modified strains of mice, and to test possible 
therapies.    
  
1.3.1.4 Mouse model of autoimmune vasculitis (Fig 1.4 C, Table 1.1 
Model 4) 
 
Another recently described model involves the immunisation of wild type mice 
with MPO, thus allowing both cellular and humoral immune responses to be 
raised against the native mouse protein [96]. Despite this, and perhaps due to 
the relatively low levels of anti-MPO antibodies generated, immunisation with 
MPO is not sufficient to induce renal damage. This issue can, however, be 
overcome by the administration of an anti-glomerular basement membrane 
antibody. The glomerular binding antibody used is a polyclonal sheep 
antibody raised against a crude glomerular preparation and serves to attract 
neutrophils to the glomeruli leading to the deposition of MPO, which then acts 
as a planted autoantigen for anti-MPO antibodies and, importantly, specific 
CD4+ T cells, resulting in significant NCGN.  
 
The main disadvantage of this model is the need for a glomerular binding 
antibody to trigger disease induction. As there is no equivalent to this seen in 
ANCA induced disease in patients, this complicates the model leading to 
questions regarding its relevance to the human condition. Despite this, and in 
contrast to the other models described, this approach allows the study of 
cellular anti-MPO immune response and their role in NGCN associated with 
anti-MPO autoimmunity. Indeed, this model has been used to demonstrate 
the importance of anti-MPO CD4+ T cell responses, with their depletion prior 
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to disease induction found to be protective in a manner independent of the 
anti-MPO antibody titre [96]. Furthermore, this model has been used to 
implicate Th17 cells, a highly proinflammatory subset of CD4+ T cell, in the 
pathogenesis of anti-MPO induced disease [97]. Following on from this, the 
same group showed that TLR2 and TLR9 are likely to have roles in the 
pathogenesis of ANCA associated vasculitis [27]. Interestingly, TLR2 
activation was shown to enhance disease via the stimulation of Th17 
responses, including IL17 production, while TLR9 ligation induced Th1 
responses, primarily interferon (IFN)γ production, and a through this an 




Figure 1.4 Mouse models of ANCA associated vasculitis.  
Summary of the three most commonly used mouse models of ANCA 
associated vasculitis. (A) The passive transfer model, (B) the bone marrow 
transplantation model and (C) the mouse model of autoimmune vasculitis. 
MPO-/-- myeloperoxidase deficient mouse, WT-wildtype (C57BL/6) mouse  
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1.3.1.5 Rat model of autoimmune vasculitis (Table 1.1 Model 5) 
 
In addition to mouse models of disease an experimental autoimmune model 
of vasculitis has also been developed in rats [98]. In the initial study, the 
immunisation of WKY rats with human MPO in Complete Freund's Adjuvant 
(CFA) led to the generation of high levels of cross-reactive anti-MPO 
antibodies in all rats tested. Between 6 and 8 weeks post immunisation 
approximately 60% of the immunised animals had developed a mild form of 
NCGN. Interestingly, approximately 40% of the immunised rats showed signs 
of pulmonary haemorrhage. A subsequent study by the same group confirmed 
that human MPO administration could induce anti-MPO antibody generation 
and associated GN, and pulmonary damage, in WKY rats [99]. Furthermore, 
this study showed that the disease severity depended on the dose of MPO 
administered and, interestingly, that the addition of pertussis toxin to the CFA 
during the immunisation stage allowed disease to be induced in all immunised 
rats. As pertussis toxin has been shown to not only activate naïve CD4+ T 
cells but to also stimulate TLR2/4 activation, and thus skew for Th1/Th17 
responses [100], this result reiterates the potential role of these factors, 
shown to be critical in the mouse model of autoimmune vasculitis, in disease 
induction [27, 97].    
 
In should be noted that to date disease has only been induced in the WKY 
rats, an inbred strain already known to be susceptible to GN. Interestingly, the 
Lewis, Wistar Furth and Brown Norway strains of rats appeared resistant to 
disease, despite generating similar levels of anti-MPO antibodies upon 
immunisation [99]. This suggests that there are also other complex, and likely 
multi-genetic, components involved in susceptibility to disease. 
 
1.3.2 Anti-PR3 antibody induced models of disease 
 
Various attempts have been made to develop an in vivo model of PR3-ANCA 
induced vasculitis, and thus provide evidence of a pathogenic role for anti-
PR3 antibodies. Unfortunately, and despite the development of anti-PR3 
antibodies in both mice and rats, there has been limited success in inducing 
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disease in rodents. An early study showed that mouse specific PR3 
antibodies could be generated by immunising PR3/neutrophil elastase double 
deficient mice with recombinant mouse PR3 [101]. However, these PR3 
antibodies failed to induce disease when transferred into LPS primed wildtype 
recipients, although, interestingly they did significantly increase inflammation 
in TNFα primed skin. This suggests that while anti-PR3 antibodies have an 
effect, they are insufficient to induce histological and subsequent functional 
changes in the kidneys of mice in and of themselves. In another study, van 
der Geld et al. immunised mice and rats with chimeric human/mouse PR3 
leading to the development of circulating anti-PR3 antibodies [102]. However, 
while both mice and rats had high anti-PR3 antibody titres, they did not 
develop any signs of disease. More recently, it was observed that non-obese 
diabetic (NOD) mice, immunised with recombinant mouse PR3, developed 
anti-PR3 antibodies but, as with previous studies, displayed no signs of 
disease [103]. Importantly, however, it was found that the transfer of 
splenocytes from these mice into highly immunodeficient NOD/SCID mice 
resulted in vasculitis with a severe segmental and necrotising 
glomerulonephritis, ultimately leading to acute kidney failure and death (Table 
1.1 Model 6). Therefore, and taking account the lack of disease in controls, 
this study provides some of the first evidence that anti-PR3 immune 
responses are capable of inducing disease in vivo. In contrast to this, and in 
the same study, a similar transfer of splenocytes into immunodeficient 
C57BL/6-RAG-/- recipients did not result in disease. This then suggests that 
there are not only factors present in NOD mice that protect against disease 
but that there are also other multi-genetic factors involved in pathogenesis.  
 
The lack of success in developing a mouse model of anti-PR3 associated 
disease is mostly likely due to the differences between mouse and human 
PR3 [104] perhaps most importantly with regards to their expression patterns. 
While the expression of human PR3 on the surface of circulating neutrophils 
has been confirmed, and shown to be induced by treatment with TNFα among 
other cytokines, to date PR3 has not been found to be present on the plasma 
membrane of circulating mouse cells [101]. Thus mouse PR3 is likely to 
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remain unavailable to any anti-PR3 antibodies that are generated. However, 
that there do exist data showing a limited affect of anti-PR3 antibodies in vivo 
[101, 103] suggests that under certain conditions anti-PR3 antibodies are 
capable of interacting with mouse PR3. It is unknown whether this is due to 
membrane expression of mouse PR3, or some degree of ANCA 
internalisation which makes surface PR3 expression unnecessary. 
 
1.3.3 Limitations of the current models of ANCA associated vasculitis: A 
summary 
 
Each of the models of ANCA associated vasculitis described above comes 
with its own set of advantages and disadvantages and, as a result, the best 
model to use depends heavily on the question being asked. Table 1.4 shows 
a brief summary of the important points that may need to be considered when 
choosing a suitable animal model of ANCA induced disease.  
 
Of the six models described, four (Model 1 and Model 4-6) can be considered 
autoimmune. Of these only one is due to the spontaneous generation of anti-
MPO immunity (Model 1), however, this model is neither pauci-immune nor is 
pathology necessarily due to anti-MPO responses alone. Indeed both 
autoantibodies to ssDNA and dsDNA are present in these mice, thus making 
pathogenesis studies complicated. Furthermore, genetically modified strains 
of mice cannot easily be employed. Of the models of induced by anti-MPO 
immunity, Model 4 (the autoimmune mouse model) requires additional 
antibodies, against the glomerular basement membrane, to recruit neutrophils 
and thus trigger disease, while Model 5 (the autoimmune rat model) has only 
relatively mild disease. It should be noted however that new technology, 
allowing the genetic manipulation of embryos, has made the generation of 
knockout rats possible [105], thus making the use of this autoimmune model 
in the study of ANCA induced vasculitis slightly more attractive. The sole PR3-
ANCA induced disease model described requires the use of a specific strain 
of mice, and while disease is robust it is unknown whether it is pauci-immune. 
However, based on similar experiments using splenocyte transfer from mice 
immunised against MPO (Model 2a) it is likely that there is significant immune 
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complex deposition as a result of homeostatic proliferation of transferred 
lymphocytes.  
 
In contrast to the autoimmune models, disease in both the passive transfer 
models (Model 2a and 2b) and the bone marrow transplantion model (Model 
3) is the result of the generation of an immume response to a foreign antigen 
and therefore may differ to the disease induced following a break in tolerance.  
Furthermore, in the case of the Model 2a (the passive transfer model) and 
Model 3 (the bone marrow transplantation model) disease is both mild, and 
induced in the absence of cellular immune responses and indeed this may be 
why the disease observed is not as severe as that seen in patients. In 
contrast the transfer of splenocytes (Model 2b) induces a much more severe 
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1.4 Humanised mice 
 
1.4.1 A brief history 
 
Due to moral and ethical constraints, studies on human physiology and 
pathology are largely dependent on the use of surrogate in vitro assays and in 
vivo experiments carried out on small vertabrates, and to a lesser extent 
invertebrates. Sharing many basic characteristics with humans, mice in 
particular, due to their small size and reproductive characteristics (short 
gestation period, large litters, rapid sexual maturity), have become the main 
animals used for in vivo biomedical research. However, millions of years of 
evolution have led to fundamental differences in mouse and human biology, 
and thus discoveries made in mice do not always translate to humans, a fact 
that has led to a search for alternative methods to study human biological 
processes in vivo.  
 
The idea of creating more human like animals is not new. In an 1896 novel, 
The Island of Dr. Moreau by H.G. Wells, the eponymous scientist creates 
sentient human like creatures from animals and, using this device, the 
narrative explores both the distinction between man and animal and the 
potential limits of natural science. Outside the realms of science fiction, an 
early study showed that foetal sheep could be successfully engrafted with 
human haematopoietic stem cells (HSC) and could therefore express cellular 
components of the human immune system [106]. In this model, the 
transplanted human cells colonised the bone marrow where they persisted for 
many years. Importantly, these cells retained the ability to undergo 
multilineage differentiation and, furthermore, were capable of responding to 
human cytokines, with regular granulocyte-macrophage colony-stimulating 
factor (GM-CSF)	  and IL3 administration leading to an increase (from 
approximately 5-15%) in the percentage of human cells found in the bone 
marrow [106, 107]. Despite this, low levels of engraftment combined with both 
financial and time constraints, made the use of this model undesirable. Initial 
studies in mice, on the other hand, were less successful. Genetically athymic, 
and thus T cell deficient, nude mice failed to support the growth of human 
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HSCs [108]. Fortunately, three years later the first of three major 
breakthroughs that would allow for the successful engraftment of human 
HSCs into mice occurred. The discovery of a severe combined 
immunodeficient  (SCID) mouse, the result of a Prkdcscid  (protein kinase, DNA 
activated, catalytic polypeptide; severe combined immunodefiency) mutation 
in CB17 mice, provided a model lacking in both T and B cell activity, and thus 
unable to effectively reject transplanted human cells or tissues [109]. 
Following on from this, in 1988 Mosier et al. carried out the first successful 
xenogeneic graft of human immune cells into SCID mice using peripheral 
blood mononuclear cells (PBMCs) [110]. Shortly after, the engraftment of 
these mice with foetal haematopoietic liver and thymus [111], and human 
HSCs [112] was also shown to be possible. Despite these early successes 
human engraftment levels remained low, human cells represented 
approximately 0.5-5% of the mouse bone marrow, and no functional immune 
responses were observed. Reasons for this include an abundance of natural 
killer (NK) cells and other innate immune cells, which act to limit engraftment, 
and the age related “leakiness” of this model, which results in the 
spontaneous generation of functional mouse T and B cells and thus induces 
further graft rejection [113]. 	  
 
The second major breakthrough was the crossing of the scid mutation onto 
mice with a nonobese diabetic (NOD) background. The resulting NOD-scid 
mice not only lacked functional T and B cells but also had defects in their NK 
cell, macrophage and complement activity [114], thus allowing for greater 
levels of human cell engraftment post transfer of human PBMCs and HSCs 
[115-117]. Although an improvement over previous models, showing 
approximately 5- to 10-fold greater human chimerism compared to SCID 
mice, the use of humanised NOD-scid mice remained limited by residual NK 
cell activity, leading to low engraftment, and the short lifespan of the mice, 
due in part to the tendency of this strain to develop lethal thymomas [118, 
119].  
 
The third and final breakthrough was the development of mice with mutations 
in their IL2 receptor common gamma chain (IL2rγ chain). As the IL2rγ chain is 
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required for high-affinity signalling through multiple cytokine receptors, 
including IL2, IL4, IL7, IL9, IL15 and IL.21 [120], its impairment leads not only 
to the absence of T and B cells but, crucially, the loss of NK cells as well [121, 
122]. This in turn leads to an environment in which transplanted human cells 
can survive and engraft. Consequently, mice bearing mutations in their IL2rγ 
chain, whether it results in an absent [123] or truncated γ chain [121, 122, 
124], have thus far provided the best models for engraftment of human 
immune cells, with several early studies showing high levels of human 
leukocytes present in the circulation of these mice several months post 
adoptive transfer of human HSCs [125-127]. Importantly, IL2rγ-/- mice have 
similar life spans to their wild type counterparts [119]. 
 
1.4.2 Immune models 
 
IL2rγ-/- mice are available on a number of backgrounds with commonly used 
strains including NOD/LtSz-scid IL2rγ-/-, NOD/Shi-scid IL2rγ-/- (both referred to 
as NOD-scid IL2γ-/- mice), NOD-Rag1-/-IL2rγ-/- and BALB/c-Rag2-/- IL2rγ-/- [119, 
128]. In addition, a number human cell and tissue types from a number of 
different sources can be used to generate these human-mouse chimeras or 
“humanised mice”.  Furthermore, several injection routes can be used in order 
to introduce the human cells into the mouse host, depending at least partially 
on the whether mice are engrafted as neonates or adults [129]. Consequently, 
a number of techniques to generate humanised mice have been developed 
over the last few years. Notably, for the majority of models developed, the 
mouse host must first be conditioned to allow optimal human engraftment. 
This usually takes the form of sublethal γ irradiation. The dose of radiation 
required is both age and strain specific, with neonatal mice requiring smaller 
doses than adults. Furthermore, mice with the scid mutation are more 
radiosensitive, due to defects in DNA repair, than mice with the Rag1-/- or 
Rag2-/- mutations, and thus also require smaller doses of radiation [119]. The 
humanised mouse models used most frequently in the in vivo study of the 
human immune system will be summarised in the following subsections while 
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the main advantages and disadvantages of each model is further detailed in 
Table 1.2.  
 
1.4.2.1 The Hu-PBL model (Fig 1.5 A) 
 
Peripheral blood leukocyte (PBL) engraftment of both NOD-scid IL2γ-/- [119] 
and BALB/c-Rag2-/- IL2rγ-/- mice has been observed, although BALB/c-Rag2-/- 
IL2rγ-/- mice require significant conditioning, including both irradiation and 
treatment with macrophage depleting clondronate-containing liposomes, 
before the transplanted human cells are accepted [130]. In contrast, NOD-scid 
IL2γ-/- mice do not require conditioning before engraftment and thus are the 
preferred strain used to generate these mice [119]. T cells are the main 
human cell type observed in this model post PBL transfer, and thus this 
system has the potential to be used to study mature effector T cell responses, 
although the inability of these human leukocyte antigen (HLA) restricted T 
cells to interact with mouse major histocompatibitily complex (MHC) 
molecules is a significant limitation that must first be overcome [131]. In 
addition, this model has been used to study xenogeneic graft vs host disease 
[132], and with the transplantation of human skin grafts onto mice, has proved 
a useful tool for the in vivo study of human transplant rejection [133].  
 
1.4.2.2 The Hu-HSC model (Fig 1.5 B) 
 
HSCs have the potential to develop into cells of either the lymphoid or myeloid 
lineage. They are self-renewing, and once they colonise the host mouse, 
capable of providing a long-term source of human cells [134]. They can be 
derived from peripheral blood, bone marrow, foetal liver and umbilical cord 
blood (UCB). CD34, an early stage stem cell marker, is frequently used to 
identify and isolate HSCs for subsequent transfer into conditioned 
immunodeficient mice. Thus humanised mice, with high levels of engraftment, 
can be generated by the transfer of human CD34+ stem cells into a) irradiated 
adult NOD-scid IL2γ-/- mice by intravenous or, less commonly, intrafemoral 
injection or b) irradiated neonatal NOD-scid IL2γ-/- or BALB/c-Rag2-/- IL2rγ-/- 
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mice by intrahepatic or intravenous (via the facial vein or the heart) injection 
[129]. To date mice engrafted in this way have been shown to reconstitute 
human T cells, B cells, NK cells, myeloid and plasmacytoid dendritic cells 
(mDCs and pDCs, respectively), monocytes/macrophages and granulocytes 
(Discussed in detail in Section 1.4.3). Importantly, neonatal mice have been 
shown to not only have higher overall levels of engraftment, but also 
significantly greater T cell reconstitution when compared with adult mice, a 
fact likely related to thymic atrophy in older mice [128]. Importantly, this is 
perhaps the most commonly used humanised mouse model for the in vivo 
study of human immunity. 
 
1.4.2.3 The BLT model (Fig 1.5 C) 
 
This model was first described in NOD-scid mice [135], although NOD-scid 
IL2γ-/- mice are now more commonly used. It involves the implantation of 
foetal human liver and thymus under the renal capsule of adult mice. Once 
the mice have recovered from surgery, they are then irradiated and 
reconstituted with human foetal liver CD34+ stem cells. The result is a mouse 
with a relatively robust human immune system comprising human B cells, 
DCs, monocytes/macrophages and, importantly, a high percentage of HLA 
Class I and Class II restricted T cells, the result of the formation of a thymus 
like organoid of human origin [136]. In addition, these mice develop human 
mucosal immune responses and thus are have become important tools for the 
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Figure 1.5 Humanised mouse models.  
The three most commonly used humanised mouse models (A) The Hu-PBL 
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1.4.3 Engraftment: Current perspectives and steps towards a better 
model 
 
The following section will provide an overview of the human cells reconstituted 
by humanised mice.  The main focus will be on the characterisation of human 
cells in these mice, however, some of the limitations associated with 
humanised mice models, together with current and potential stratagies for 
overcoming them, will also be discussed. 
 
1.4.3.1 Lymphoid lineage cells  
 
1.4.3.1.1 Natural Killer cells 
 
Human NK cells have been reported in the bone marrow, spleen, thymus, 
lymph nodes, liver, lung and peripheral blood of humanised mice engrafted 
with human HSCs [138-141]. Furthermore, both cytolytic CD56hiCD16+ and 
cytokine producing CD56loCD16+ NK cell subsets have been identified [138, 
142]. However, the overall percentage of NK cells seen in each of these 
compartments was very low. This is likely due to the lack of cross reactivity 
between human and mouse CD15, an important regulator of NK cell 
proliferation and activation. Indeed, several studies have confirmed that 
engrafted mice treated with exogenous human IL15 develop significantly 
higher levels of human NK cells [140, 141, 143]. Furthermore, following the 
hydrodynamic tail vein delivery of plasmid DNA, containing expression vectors 
for human IL15 and Flt-3/Flk-2 ligand, humanised mice developed significantly 
more NK cells [139]. Interestingly, while human cytokine expression persisted 
for 2-3 weeks, the mice maintained elevated NK cell levels for over a month. 
Furthermore, these cells were shown to express both inhibitory (NKG2A and 
KIR) and activating receptors (NKG2D), as well as the cytotoxicity receptor 
NKp46. Importantly, these human NK cells were shown to lyse MHC class I 
deficient target cells and to produce IFNγ in response to poly I:C challenge 
both in vitro and in vivo. In addition, they appeared to be capable of mounting 
a robust response against adenovirus infection, as measured by liver damage 
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(mediated by NK cells) and serum levels of IFNγ. The functionality of 
humanised mouse human NK cells was further confirmed both in vitro and in 
vivo [138, 144]. The co-culture of spleen and mesenteric lymph node derived 
NK cells with K562 cells, a human erythroleukemic cell line, led to NK cell 
activation as measured by IFNγ production, CD107a expression (indicating 
cell degranulation) and K562 cell inhibition and death [144]. In addition, 
humanised mice injected with K562 cells had a greater survival rate than non-
engrafted controls, and this effect was lost in human CD56+ cell depleted 
humanised mice. Interestingly, these mice had not received exogenous 
human IL15, although cells were incubated with human IL15 for the in vitro 
studies. In contrast, a study on NK cells generated by humanised NOD-scid 
IL2γ-/- mice engrafted with human PBLs (the previously described study used 
BALB/c-Rag2-/- IL2rγ-/- mice engrafted with UCB derived HSCs), and lacking 
human IL15, failed to respond to either K596 cells or a combination of PMA 
and ionomycin [142] in vivo. This discrepancy suggests that the function of 
humanised mouse human cells may be dependent the strain of mice used 
and the source of human cells used to engraft them. 
 
1.4.3.1.2 B cells 
  
B cells are the most abundant human cell type reconstituted by humanised 
mice. Post engraftment both the spleen and the bone marrow were reported 
to house large populations of immature human CD24int/hi and CD38hi 
expressing B cells, with the majority of splenic B cells also expressing IgM, 
and, in some cases, IgD. In addition, human B cells were identified in the 
lymph nodes and in the peripheral blood, where they were found to express 
IgM and/or IgD [126, 127, 145]. Notably, few CD27+ memory B cells were 
detected, indicating that these humanised mouse human B cells were naïve 
[145]. Importantly, human B cell responses to both immunisation and viral 
infection have been reported. However, IgM has been found to be the main 
antibody produced in response to B cell challenge [126, 127, 146, 147]. 
Indeed, the relative paucity of IgG generated by humanised mouse human B 
cells suggested that these cells had difficulty undergoing class switching. 
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However, a recent study revealed that poor IgG production is most likely the 
result of a lack of T cell help rather than any intrinsic fault in the reconstituted 
human B cells [145]. While in vivo IgG production in response to immunisation 
was confirmed to be rare in this study, splenic human B cells cultured in the 
presence of human IL2, IL21 and an anti-CD40 antibody were found to 
produce IgM and IgG at levels comparable to that of normal B cells isolated 
from healthy volunteers. Furthermore, activation-induced cytidine deaminase 
(AID) induction and IgD-CD38+ and IgD-CD27+ expression were also observed 
under these conditions, confirming B cell differentiation into antibody secreting 
cells and memory B cells, respectively. In addition, it was demonstrated that 
IgG responses could be induced in vivo upon adoptive transfer of normal 
human T cells. Indeed, the introduction of volunteer PBMC derived T cells 
bearing a HLA matching that of the human progenitor cells, together with a 
HA peptide (HA307-319) specific T cell receptor, led to the in vivo generation of 
HA-specific IgG. Together these data suggest that humanised mouse human 
B cells have all the molecular machinery required to undergo class switching, 
and that, it is the lack of T cell-B cell cooperation, due to human T cell 
restriction by murine MHC, that is likely to be the cause of the suboptimal 
human antibody responses observed in humanised mice [148]. 
 
1.4.3.1.3 T cells 
 
Human T cells have been reported in the bone marrow, spleen, thymus, 
lymph nodes and peripheral blood of humanised mice engrafted with human 
HSCs [126, 127]. Unlike human B cells, which first appear approximately 1 
month post engraftment, human T cells first appear at about 3 months, and 
peak at 5-6 months, post transfer of HSCs [149-151]. Subsets identified to 
date include CD4+ and CD8+ αβ T cells, CD4+Foxp3+ T regulatory cells, NKT 
cells and γδ T cells [126]. Interestingly, human T cell reconstitution was found 
to be greater in mice engrafted as neonates. While the exact reason for this is 
unclear it has been speculated that it is due to thymic organogenesis, with 
adult mice undergoing thymic hyperplasia before treatment with HSCs, and 
thus being unable to support significant T cell development [128]. Regardless, 
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the number of human T cells present in the periphery of these mice remains 
very low. It was initially thought that this might be due in part to the poor cross 
reactivity between human and mouse IL7, an important cytokine with roles in 
both T cell development and survival. However, while treatment with 
exogenous human IL7 led to an increase in the number of thymocytes, this 
did not translate to an increase in the number of peripheral human T cells 
[152]. In contrast, mice treated with human IL15, which has roles in both NK 
cell and T cell proliferation and activation, showed elevated levels of both 
CD4+ and CD8+ T cells [140]. However, these cells were of an 
activated/memory phenotype [142, 147, 152, 153]. Furthermore, NOD-scid 
IL2γ-/- mice made triply transgenic for human stem cell factor, GM-CSF and IL-
3, were unexpectedly shown to have increased numbers of CD4+Foxp3+ T 
regulatory cells in their spleens but not their thymuses [154]. As the receptors 
for these cytokines were shown to be absent from the CD4+Foxp3+ T 
regulatory cells, it is likely that this was due to an indirect mechanism resulting 
in either the expansion of thymically derived T regulatory cells in the 
periphery, or the conversion of effector T cells to an induced-regulatory 
phenotype. 
 
Data regarding the ability of humanised mouse human T cells to respond 
appropriately to immune challenge has been inconsistent. Early studies 
reported the induction of human T cell responses to inflammatory stimuli, 
including proliferation in response to Epstein–Barr virus (EBV) infection [126] 
and phytohemagglutinin, as well as cytotoxicity against cell lines [155]. 
However, data from later studies indicates that reconstituted human T cells 
have several functional defects. While human splenic T cells were capable of 
proliferating and producing cytokines in response to phytohemagglutinin, anti-
CD3 antibodies and a mixure of PMA and ionomycin in vitro, the response 
observed was approximately 10-fold lower than that of normal human T cells 
[142, 145]. Interestingly, the ability of CD4+CD8- single positive thymocytes to 
produce IL2 in vitro suggested that the functional impairment might occur after 
cells have migrated to the periphery [145]. Importantly, humanised mouse 
human CD4+ T cells appear to respond poorly to immunisation with keyhole 
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limpet hemocyanin (KLH), with little IFNγ or IL4 production being induced 
following specific re-stimulation of these cells in vitro [145]. Indeed, this is 
consistent with the lack of B cell class switching, as measure by IgG 
secretion, observed in vivo in the same study. In contrast, human CD8+ T cells 
were shown to aid the survival of humanised mice infected with EBV. When 
these mice were treated with either anti-CD3 or anti-CD8 antibodies their life 
span was reduced [156]. Furthermore, CD4+ and CD8+ T cells from EBV and 
HIV infected mice were reported to produce low levels of IFNγ and display 
some cytotoxicity in response to re-stimulation in vitro [126, 150, 157]. 
However, it must be noted that despite these positive results other studies 
have reported cellular responses to be absent in virally infected humanised 
mice [147]. 
 
The lack of HLA restriction affects both the number and functionality of human 
T cells reconstituted by humanised mice. Inefficient positive selection in the 
thymus likely results in low T cell production, while the lack of HLA 
interactions leads to poor T cell responses., and consequently B cell 
functional impairment [148]. Indeed, the generation of human HLA-transgenic 
mice has confirmed the importance of HLA restriction for T cell functional 
responses, with mice expressing HLA-A2 and HLA-DR4, and engrafted with 
HLA-matching HSCs, developing appropriate HLA-restricted T cell responses, 
and thus exhibiting increased cytokine and IgG production in response to viral 
challenge [158-161]. However, as these mice still express murine MHC class I 
and II molecules, some unwanted MHC restriction may still occur, leading to a 
degree of human T cell functional impairment. However, whether the 
replacement of mouse MHC molecules with their human counterparts will 
produce a model with more robust human T, B and NK cell (HLA-NK cell 
receptor interactions promote NK cell development and functionality) 
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1.4.3.2 Myeloid lineage cells  
 
To date the majority of research into the generation of humanised mice has 
focused on the development and study of lymphoid lineage cells. 
Consequently, there is relatively little known about the reconstitution or 
functional responses of human cells of myeloid origin, although this is 
beginning to change. The lack of focus on human myeloid reconstitution in 
humanised mice is perhaps due in large part to the suboptimal engraftment of 
human cells of this lineage in the current models. While human 
monocytes/macrophages, granulocytes and both mDCS and pDCs have been 
identified in humanised mice, they represent only a small percentage of the 
total human leukocytes reconstituted [119, 145]. The likely explanation for this 
is that the mouse environment in which these human cells develop does not 
provide the correct factors to allow the differentiation of human myeloid cells. 
Notably, while many human cytokines have been shown to cross-react with 
mouse receptors, many mouse haematopoietic cytokines appear to have no 
cross-reactivity with human cells [118, 162]. Therefore, in order to overcome 
this limitation, a number of groups have introduced human factors with 
important roles in myeloid differentiation/function into these mice, with varying 
degrees of success.  
 
The hydrodynamic injection of plasmid DNA encoding human macrophage 
colony stimulating factor (M-CSF/CSF-1) into the tail vein of HSC engrafted 
mice enhanced the reconstitution of human CD14+ monocytes [139]. In the 
same study, the injection of plasmid DNA encoding GM-CSF and IL4 led to an 
increase in the percentage of human CD11c+CD209+ DCs in the blood, 
spleen, bone marrow, lung and liver of all mice tested. Similarly, human CSF-
1 knockin BALB/c-Rag1-/-γc-/-mice engrafted with human foetal liver HSCs 
demonstrated enhanced reconstitution of human monocytes/macrophages 
[163]. Further to this, the human monocytes/macrophages taken from these 
mice were shown to have improved functional properties in vitro, including 
migration, phagocytosis, and activation. In addition, the human 
monocytes/macrophages in these mice were shown to respond more 
efficiently to LPS in vivo. This was demonstrated by the significant increase 
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the number of these cells present in the spleen, combined with the enhanced 
levels of human IL6 and TNFα found in the serum, of the human CSF-1 
knockin mice 48 hours post LPS treatment. Around the same time, myeloid 
cell reconstitution in the lung was shown to be improved through the 
generation of humanised mice in which the murine IL3 and GM-CSF genes 
were replaced with human homologues [164]. The loss of murine GM-CSF 
results in pulmonary alveolar proteinosis syndrome; however, the generation 
of human alveolar macrophages by the human IL3/GM-CSF knockin 
humanised mice partially rescued them from this disorder. Furthermore, 
human alveolar macrophages correlated with improved human immune 
responses in mice challenged with influenza virus. Interestingly, NOD-scid 
IL2γ-/- mice made triply transgenic for human stem cell factor, GM-CSF and IL-
3, were found to have only modest increases in myeloid engraftment while 
having significantly higher levels of human regulatory T cells in their periphery 
[154].  
 
A recent study on the development of human myeloid subsets in humanised 
mice identified both granulocytes and myeloid lineage antigen presenting cells 
(APCs) in the bone and spleen of NOD-scid IL2γ-/- mice engrafted, as 
neonates, with human CD34+ HSCs [165]. Granulocytes identified included 
CD15+CD33lowHLA-DR- neutrophils, CD117-CD123+CD203c+ basophils and 
CD117+ CD123+CD203c+HLA-DR- mast cells, while the APC subsets 
comprised CD14+CD33+HLA-DR+BDCA-1-BDCA-3- monocytes, CD14-
CD33+HLA-DR+BDCA-1+BDCA-3+ cDCs and CD123+BDCA-2+HLA-DR+ 
pDCs. Furthermore, it was demonstrated that these cells responded 
appropriately to inflammatory stimuli in vivo and in vitro. Having first shown 
that human CD45+CD33+ cells expressed the appropriate cytokine receptors, 
it was shown that recombinant human (rh) GM-CSF, rhIFNγ and rhGCSF 
induced STAT phosphorylation in bone marrow derived neutrophils and 
monocytes, with in vivo GCSF treatment leading to an increase in myeloid 
lineage cells in the peripheral blood of 3 out of 3 mice tested. In addition, 
human monocytes and BDCA-1+ DCs were shown to express TLR2, while 
human monocytes, neutrophils and DCs were shown to express TLR4. 
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Importantly, in vivo stimulation with the TLR4 ligand LPS induced the 
production of human TNFα, IL6 and IL8. Furthermore, lung derived human 
CD45+CD33+ cells were shown to be capable of phagocytosis in vitro, while 
BM derived human monocytes/macrophages could be induced to phagocytise 
and kill Salmonella typhimurium in vitro by treatment with IFNγ. 
 
Although there have been significant advances made in our knowledge of 
human myeloid engraftment in humanised mice over the last few years, there 
are still numerous myeloid cell subsets yet to be evaluated. In addition, if we 
wish to establish the most accurate in vivo model of the human immune 
system, in which myeloid cells typically comprised approximately 50-70% of 
the human immune cells found, possible then models with significantly 
increased human myeloid cell engraftment are required. 
 
1.4.4 Discoveries made using humanised mouse models: An overview 
 
Humanised mice represent an important advancement in our ability to study 
the human immune system in vivo. Indeed, these models have already been 
shown to support infection with a number of human pathogens including HIV, 
EBV, dengue virus, Plasmodium falciparum and Salmonella typhi. In addition, 
it has been shown that humanised mice have the potential to model type I 
diabetes and various forms of cancer, including both solid tumours and 
haematological malignancies [131]. As humanised mouse models represent a 
broad and ever-expanding field, the following section will discuss a small 
selection of findings made through their use. 
 
1.4.4.1 Human Immunodeficiency Virus (HIV) 
 
Humanised mice provide a useful tool for the in vivo study of the human 
immune response to pathogens, particularly those of a viral nature that do not 
infect small laboratory animals. Thus, HIV was one of the first human 
diseases to be studied using humanised mice [166]. Subsequent studies have 
shown that the Hu-HSC and the BLT models support robust infection, 
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exhibiting both viremia in the bloodstream and dissemination of the virus to 
various organs [167]. Furthermore, the BLT model was shown to allow 
infection via the mucosal route [168]. Importantly, the infection of humanised 
mice with HIV was found to lead to the depletion of CD4+ T cells [169], 
including T regulatory cells [170], and the proliferation of CD8+ T cells [168, 
171]. Interestingly, humoural immune responses have also been reported, 
with specific IgG production observed in infected BLT mice, a response likely 
made possible by improved T cell help provided by the HLA restricted human 
T cells generated by these mice [172].  
 
To date humanised mice have been used to study the pathogenesis of HIV 
infection in vivo as well as to test potential HIV therapies. For example, 
BALB/c-Rag2-/- IL2rγ-/- mice engrafted with HSCs have been used to study the 
evolution of the HIV viral envelope gene, which encodes the viral surface 
glycoprotein (Env), a key mediator of viral entry to into cells [173]. 
Furthermore, a study using human HSC engrafted NOD-scid IL2γ-/- mice 
provided evidence that host APOBEC3s, cellular cytidine deaminases, are 
involved in inducing G-to-A mutations in the cDNA of the HIV virus in vivo, 
and thus may play a role in negatively regulating HIV infection [174]. With 
regards therapeutic trials, a mixture of Hu-HSC and BLT mice have been 
used to show that HIV infection can be suppressed by treatment with anti-
retrovirals [175] and by the use of targeted siRNA therapy [176]. In addition, it 
has been shown that vaginal, rectal and intravenous transmission of HIV can 
be prevented by pre-treatment with anti-retrovirals [177, 178].  
 
1.4.4.2 Epstein–Barr virus (EBV) 
 
To date humans are the only known natural hosts of EBV, a herpesvirus 
thought to infect approximately 90% of the adult population. While infection is 
generally asymptomatic, EBV, particularly in immunocompromised hosts, is 
associated with a number of B cell and epithelial-cell malignancies, including 
Burkitt lymphoma, Hodgkin lymphoma, lymphoproliferative diseases and 
nasopharyngeal carcinoma. The study of EBV is complicated by its inability to 
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infect non-human cells. In fact humanised mice present the only animal model 
of infection currently available [179]. Indeed, humanised mice have been 
shown to support EBV infection with high viral doses leading to the formation 
of lymphoproliferative diseases that resemble, by their expression of latent 
EBV proteins, tumours found in patients [180]. Furthermore, EBV infection of 
humanised mice is associated with T cell proliferation, CD4+/CD8+ T cell ratio 
inversion [126, 135, 181] and the generation of activated memory T cells [135, 
158]. In addition, the generation of protective T cell response have been 
shown to be dose-dependent [135, 158]. However, as previously discussed, T 
cell responses in humanised mice are suboptimal, with human T cell 
education in the mouse thymus leading to a lack of HLA restriction, and thus 
low numbers of weakly responding human T cells. Importantly then, NOD-scid 
IL2γ-/- HLA-A2 transgenic mice engrafted with HLA-matching HSCs developed 
appropriate HLA-restricted T cells responses, including cytotoxicity, in 
response to EBV epitopes [159].  
 
Notably, the use of humanised mouse models of EBV has led to the discovery 
that the absence of the EBNA3B gene, a virus encoded tumour suppressor, 
leads increased viral evasion of the host immune response as well as virus 
driven lymphomagenesis [182]. In addition, humanised mice have been used 
to provide evidence that lytic EBV infection, EBV can infect cells in latent or 
lytic forms, plays an important role in the development of B cells lymphomas 
[183, 184]. 
 
1.4.4.3 Dengue Virus 
 
Dengue virus is small, enveloped RNA flavivirus, of which there are four 
serotypes, transmitted by mosquito bite. Infection can result in either a flu-like, 
self-limiting illness called dengue fever (DF), or, particularly after secondary 
infection with a different serotype, a severe and often fatal disease called 
dengue hemorrhagic fever (DHF). There is no specific treatment or 
vaccination available, which may be due, at least in part, to the lack of 
appropriate animal models. While non-human primates can support dengue 
virus infection, neither DF nor DHF are observed in these models. 
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Furthermore, while some mouse models do exist they require either 
unphysiologically high levels of virus to induce disease, or the use of 
immunocompromised mouse strains [179]. Humanised mice support infection 
with dengue virus, with infected mice developing an elevated body 
temperature, rash and thrombocytopenia [185]. In addition, B cell responses, 
with the production of dengue virus specific antibodies, have been reported in 
infected humanised mice [186, 187]. Furthermore, T cells from HLA-A2 
transgenic humanised mice have been shown to respond to specific 
restimulation by producing IFNγ, IL2 and TNFα [160], thus showing their 
responsiveness to dengue virus infection. Importantly, TNFα production by 
human DCs in humanised mice infected with dengue virus has been shown to 
be suppressed by siRNA directed against TNFα [188]. As TNFα is thought to 
play a major role in pathology, this then represents a possibly future therapy. 
 
1.4.4.4 Autoimmunity and Cancer 
 
In addition to providing tools for the in vivo study of human pathogens, 
humanised mice have also been used in translational biomedical research to 
study diseases including type I diabetes and various forms of cancer. For 
example, in the case of type I diabetes, HLA-A2 transgenic humanised mice 
were used to identify autoantigens that are potentially involved in disease 
pathogenesis [189]. In addition, humanised mice have been used to evaluate 
various potential cancer treatments including cell-based therapies, with 
transplanted activated NK cells being shown to be cytotoxic against leukemic 
cells [190], humanised antibodies, showing the efficacy of rituximab in treating 
B cell lymphomas [191], and tumour-growth inhibitors, showing that NFκB 
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1.5 Conclusions  
 
ANCA associated vasculitis is a complex human disease, the study of which 
is limited by inadequate animal models, and the lack of an anti-PR3 antibody 
induced model in particular. Indeed, the ability of anti-PR3 antibodies to 
induce NCGN, or pulmonary inflammation, often associated with disease, 
remains unconfirmed. Consequently, the development of a new model in 
which the ability of anti-PR3 antibodies to activate neutrophils, and thus 
induce renal and/or pulmonary disease, would represent a major 
advancement in the field of ANCA associated vasculitis research.  
 
As discussed, the fundamental differences in human and mouse PR3 may 
well be responsible for the difficulties encountered in establishing a suitable 
model of anti-PR3 induce disease. Furthermore, the differences in rodent and 
human biology make results derived from animal studies difficult to interpret 
from the perspective of attempting to understand the pathogenesis of human 
disease. For example, and with regards ANCA associated vasculitis, it is 
noteworthy that while inhibition of the MAPK pathway prevented ANCA 
induced neutrophil activation in human neutrophils in vitro, it appeared to have 
only a mild protective effect with regards the induction of disease in mice. This 
discrepancy may be due to a number of reasons, however, the most obvious 
is species differences.  
 
Importantly, a humanised mouse model of ANCA associated vasculitis would 
have the potential to overcome these limitations, providing a model in which 
human neutrophils, expressing both human PR3 and human signaling 
molecules, could be used to test the ability of human anti-PR3 antibodies to 
induce disease in vivo and ultimately serve as an alternative method to study 
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1.6 Aims of thesis 
 
The aims of the present study are summarised below: 
 
• To optimise the purification of ANCA from patient plasma, so that it 
may be used for both in vitro and in vivo studies 
 
• To establish in vitro ANCA assays and use them to examine novel 
processes with potential roles in ANCA associated vasculitis 
pathogenesis 
 
• To establish a humanised mouse model 
 
• To determine if human neutrophils can be reconstited by humanised 
mice and if so whether they are functional 
 
• To determine if a humanised mouse model with functional human 
neutrophils can be used to study human ANCA induced pathology in 
vivo	  
 
The following chapters detail the methods used in the course of this study and 
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General procedures used are described in this chapter, with further methods 




All chemicals were purchased from Sigma unless otherwise stated. 
 
Saturated Ammonium Sulphate  
Prepared by dissolving 300g NH4SO4 in 500ml tissue culture H2O. This 
required heating at ~56-60˚, with frequent shaking. The solution was then 
cooled overnight, with crystal formation indicating saturation. 
 
0.1M Glycine, pH 2.7 
Prepared by dissolving 3.75g Glycine in 500ml tissue culture H2O. The pH 
was the adjusted with HCl. 
 
1M Tris, pH 9 
Prepared by dissolving 24.23g Tris in 200ml tissue culture H2O. The pH was 
the adjusted with HCl. 
 
Red Cell Lysis Buffer, pH 7.3 
Prepared by dissolving 4.17g NH4Cl, 0.0185g EDTA and 0.5g NaHCO3 in 500 
ml tissue culture H2O. 
 
Bouin’s Solution 
Prepared by adding 3 volumes of picric acid 1.2% saturated solution to 1 
volume formaldehyde 40%. Just before use acetic acid was added to the 
stock solution at a dilution of 1:20. 
 
Phosphate-lysine-periodate (PLP) 
A paraformaldehyde solution was made up by dissolving 4g 
paraformaldehyde in 100ml of distilled H2O. This was stored at -20°C.  
A lysine stock solution was made up by combining 3.65g/100ml lysine 
monohydrochloride to an equal volume of 3.58g/100ml disodium hydrogen 
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orthophosphate. The pH was adjusted to 7.4, and this solution was also 
stored at -20°C. Immediately before use, 1 volume paraformaldehyde was 
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Flow cytometry antibodies 
 
Target Isotype Clone Fluorophore  Supplier 
CD3 Mouse IgG1, κ UCHT1 APC BD 
CD3 Mouse IgG2a, κ BW264/56 APC Miltenyi 
CD11b Mouse IgG1, κ CBRM1/5 APC Biolegend 
CD11b Mouse IgG1, κ ICRF44 APC BD 
CD14 Mouse IgG2a, κ M5E2 PE BD 
CD14 Mouse IgG2a, κ M5E2 APC BD 
CD16 Mouse IgG1, κ 3G8 APC BD 
CD16 Mouse IgG1, κ 3G8 PerCP-Cy5.5 BD 
CD19 Mouse IgG1,κ HIB19 FITC BD 
CD34 Mouse IgG2a, κ AC136 PE Miltenyi 
CD45 Mouse IgG1, κ HI30 V450 BD 
CD45 Mouse IgG1, κ HI30 PE-Cy7 BD 
CD62L Mouse IgG1, κ DREG-56 PerCP-Cy5.5 Biolegend 
CD63 Mouse IgG1, κ H5C6 PE BD 
CD66b Mouse IgM, κ G10F5 FITC BD 
CD66b Mouse IgM, κ G10F5 PE Biolegend 
CD66b Mouse IgM, κ G10F5 PerCP-Cy5.5 Biolegend 
PR3 Mouse IgG1, κ PR3G-2 FITC Hycult 
Isotype control Mouse IgG1, κ MOPC-21 FITC Biolegend 
MPO Mouse IgG1, κ MPO-7 APC Dako 
Isotype control Mouse IgG1, κ MOPC-21 APC Biolegend 
 
Table 2.1 Anti-human antibodies used for flow cytometry. All antibodies were 
obtained from commercial sources. Antibodies were titrated to give optimal 
concentration for use. BD-Becton Dickinson, Oxford, UK. Milenyi-Miltenyi 
Biotech, Germany. Biolegend-San Diego, CA, USA. Hycult-Hycult Biotech, 
The Netherlands. Dako-DakoCytomation, Denmark.   
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Target Isotype Clone Fluorophore  Supplier 
CD45 Rat (LOU) IgG2b, κ 30-F11 FITC BD 
CD45 Rat (LOU) IgG2b, κ 30-F11 PE BD 
CD45 Rat (LOU) IgG2b, κ 30-F11 PerCP-Cy5.5 BD 
Ly-6G Rat (LEW) IgG2b, κ IA8 AlexaFluor 700 BD 
CD11b Rat (LEW) IgG2b, κ M1/70 FITC BD 
CD11c Armenian Hamster IgG N418 PE Biolegend 
CD62L Rat IgG2a, κ MEL-14 Pacific Blue Biolegend 
 
Table 2.2 Anti-mouse antibodies used for flow cytometry. All antibodies were 
obtained from commercial sources. Antibodies were titrated to give optimal 
concentration for use. BD-Becton Dickinson, Oxford, UK. Biolegend-San 
Diego, CA, USA.  
 
Monoclonal neutrophil activating antibodies 
 
Target Isotype Clone Supplier 
Human Proteinase 3 Mouse IgG1 PR3-G2 Hycult Biotech 
Human Myeloperoxidase Mouse IgG1 266.6K2 IQ Products 
NA/LE Isotype Control Mouse IgG1 107.3 BD 
 
Table 2.3 Monoclonal anti-human anti-PR3 and anti-MPO IgG used in 
neutrophil activation assays. Both antibodies were obtained from commercial 
sources as indicated. Hycult Biotech, Uden, The Netherlands. IQ Products, 
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2.2 Methods 
 
2.2.1 Flow cytometry 
 
Whole blood from humanised mice was blocked by incubation with 10% AB 
serum (Sigma, Poole, UK) and 1µg/ml mouse BD Fc Block (Becton Dickinson, 
Oxford, UK) for 20 minutes at room temperature. Isolated human cells, 
resuspened at 1x107 cells/ml, were blocked with 10% AB serum. Isolated 
humanised mouse cells, at the same concentration, were blocked with 10% 
AB serum and 1µg/ml mouse BD Fc Block. The appropriate antibodies were 
added and the whole blood or cell suspension was kept in the dark for 20 
minutes at room temperature. Red cells were lysed using BD FACS Lysing 
Solution (Becton Dickinson, Oxford, UK) according to manufacturers 
instructions. Briefly, 2ml of a 1:10 dilution of BD FacsLyse was added to 
approximately 100µl whole blood and incubated for 10 minutes at room 
temperature and in the dark. This was then spun at 280g for 5 minutes. Cells 
were washed with 2ml phosphate buffered saline (PBS) (Sigma, Poole, UK) 
containing 0.1% sodium azide, spinning at 280g for 5 minutes. Finally the 
cells were resuspended in 300µl PBS containing 0.1% sodium azide and 
stored in the fridge until flow cytometric analysis could be carried out.  
 
Flow cytometry was performed on either a FACS Canto flow cytometer 
(Becton Dickinson, Oxford, UK) or a LSR II flow cytometer (Becton Dickinson, 
Oxford, UK) using FACSDiva software (Becton Dickinson, Oxford, UK). At 
least 10,000 events were collected per sample, and data was analysed using 
FlowJo software (Treestar, Ashland, OR, USA). 
 
2.2.2 Cells counts 
 
An Olympus BX51 microscope (Olympus Microscopy, Southend-on-sea, UK) 
set to phase contrast and a counting chamber (Improved Neubauer 
haemocytometer) was used for calculating cells numbers. To determine cell 
viability, cells were with diluted 1:1 using Trypan blue dye (Sigma, Poole, UK). 
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Non-viable cells stained blue and were excluded from the cell count. To 
perform white blood counts, whole blood was diluted 1:10 in Turk's solution 
(Sigma, Poole, UK). Turk's solution is a mixture of acetic acid and gentian 
violet that haemolises red blood cells and stains the nuclei of white cells 
purple. The total number of cells within the 25 grid square was counted. This 
was multiplied by the dilution factor and 104 to obtain the number of cells/ml of 
medium i.e. cell concentration. The cell concentration was multiplied by the 
volume of the cell suspension to obtain the total cell yield.  
 
2.2.3 IgG Purification 
 
All blood and plasma samples, from both patients or healthy controls, were 
taken with informed consent and ethical approval (NRES committee London—
London Bridge 09/H084/72). Plasma exchange samples were obtained from 
patients with active ANCA associated vasculitis in the renal units of Kent and 
Canterbury, Royal Sussex County, King’s College, St Helier and Guy’s and 
St. Thomas’ hospitals. All patients had evidence of active renal involvement 
with some also exhibiting other clinical manifestations of disease. For further 
information on the patient samples used throughout this project please see 
Table 3.6 and Table 3.7.  
 
2.2.3.1 Ammonium sulphate precipitation 
 
Plasma stored at -80ºC was defrosted in a water bath at 37ºC. In order to 
precipitate out the antibody, and thus to remove fibrin that may block a Protein 
G column, saturated ammonium sulphate was used. A 25% saturated 
ammonium sulphate solution of the plasma was first obtained by adding 
saturated ammonium sulphate at a third of the volume of the plasma slowly at 
room temperature. Only proteins with a high molecular weight such as fibrin 
precipitate out at this stage. The plasma was left to precipitate for 6 hours at 
4ºC. The sample was spun at 1000g for 30 minutes and the supernatant was 
removed. A 50% saturated ammonium sulphate solution of the supernatant 
was obtained by adding a volume (x) of saturated ammonium sulphate slowly 
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at room temperature. The following calculation was used to determine the 
volume (x) required  
 
(% saturation of sample) (volume) + (% saturation of stock) (volume (x)) 
volume + volume (x) 
 
The plasma was left to precipitate overnight at 4ºC. The sample was spun at 
1000g for 30 minutes. The supernatant was removed and the pellet was 
resuspended in a minimum volume of PBS. This was then transferred to 
dialysis tubing and dialysed in a large volume (~5 litres) of PBS at 4°C. The 
dialysis was completed the following day after at least 2 changes of PBS. The 
contents of the dialysis tubing were emptied into a 50ml falcon, spun at 1000g 
for 30 minutes, and the supernatant was passed through a 0.2µm filter before 
purification using a HiTrap HP Protein G column (GE Healthcare Life 
Sciences, Buckinghamshire, UK). 5ml Protein G columns were first washed 
with 50ml 0.2µm filtered PBS. A syringe pump set at 60ml/hr was used to 
pass the PBS through the column. The filtered sample was run through the 
column at 20ml/hr. The column was washed with 20ml sterile filtered PBS, 
and the bound IgG was eluted by passing 0.2µm filtered 0.1M glycine, pH 2.7, 
through the column at 60ml/hr. The eluate was collected in 1.5 ml fractions 
into eppendorfs containing 150µl 1M Tris, pH 9. The wavelength of each 
fraction of the eluted antibody was measured at 280nm using a 
spectrophotometer, and samples with an OD greater that 0.5 were pooled. 
They were then transferred to dialysis tubing and dialysed in a large volume 
(~5 litres) of PBS at 4°C. The dialysis was completed the following day after at 
least 2 changes of PBS. The final concentration of antibody was determined 
using a quartz cuvette and spectrophotometer at 280nm. The following 
equation was used to calculate the final concentration: 
 
Absorbance280 / 1.4 = concentration, 
were 1.4 = Absorbance280 of 1mg/ml IgG 
 
= 50% 
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The antibody was concentrated to a working stock concentration of between 5 
and 50mg/ml and stored in small aliquots at -20ºC.  
For some samples a 1ml Protein G column was used as described below. 
 
2.2.3.2 Sodium chloride precipitation 
 
Plasma stored at -80ºC was defrosted in a water bath at 37ºC. Solid sodium 
chloride was added at 18g/100ml of plasma to remove fibrin. The plasma was 
left to precipitate overnight at 4ºC. The sample was spun at 1000g for 30 
minutes and the supernatant was removed and diluted 1 in 5 in endotoxin 
free, tissue culture water before being passed through a 0.2µm filter for 
purification using a Protein G column. 1ml Protein G columns were first 
washed with 10ml 0.2µm filtered PBS using a syringe pump set at 20ml/hr 
before the filtered sample was run through the column at 10ml/hr. The column 
was washed with 5ml sterile filtered PBS and the bound IgG was eluted by 
passing 0.2µm filtered 0.1M glycine, pH 2.7, through the column at 20ml/hr. 
The eluate was collected in 1.5 ml fractions into eppendorfs containing 150µl 
1M Tris, pH 9. The wavelength of each fraction of the eluted antibody was 
measured at 280nm using a spectrophotometer and samples with an OD 
greater than 1.5 were pooled and buffer exchanged into PBS using a PD10 
Desalting column (GE Healthcare Life Sciences, Buckinghamshire, UK). The 
final concentration of antibody was calculated and the antibody was aliquoted 
and stored at -20ºC. 
 
2.2.4 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
Patient IgG samples were diluted to 250µg/ml in PBS and 26µl of this was 
added to 10µl NuPAGE® Sample Buffer  (Invitrogen, Paisley, UK) and 4µl 
NuPAGE® Reducing Agent (Invitrogen, Paisley, UK). The mixture was 
incubated at 95ºC for 5 minutes and then immediately transferred to ice. 
Approximately 12µl of SeeBlue® Prestained Standard (Invitrogen, Paisley, 
UK) was loaded into the first well of a NuPAGE®  4-12% Bis-Tris Gel 
(Invitrogen, Paisley, UK) and 15µl of sample was loaded per well after that. 
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Gels were run for 35 minutes at 200V, 120mA and 25W using the NuPAGE® 
SDS-PAGE Gel System (Invitrogen, Paisley, UK). Gels were washed three 
times each for 5 minutes in distilled water before being stained with 
SimplyBlue® Safe Stain (Invitrogen, Paisley, UK) for 1 hour. Gels were then 
left in distilled water for at least 24 hours before being washed in fresh distilled 
water for 1 hour and dried using Gel Drying Kit (Invitrogen, Paisley, UK).  
 
2.2.5 PR3 and MPO ANCA binding ELISA 
  
ELISAs for antibodies against PR3 and MPO were carried out using the 
Weislab Capture PR3 and MPO ELISA Kits (Euro Diagnostica, Malmö, 
Sweden). Patient IgG samples were diluted to give a final concentration of 
either 20µg/ml or 50µg/ml in PBS. 100µl per well in duplicate of Calibrator 1-6, 
positive control, negative control and diluted patient IgG was pipetted into pre-
coated 96 well plates. This was incubated at room temperature for 1 hour. 
The plate was washed three times with 300µl washing solution per well. The 
plate was then gently tapped dried using absorbent tissue and 100µl 
conjugate was added per well. This was incubated for 30 minutes at room 
temperature. The plate was washed as before and 100µl substrate pNPP was 
added to each well. This was incubated for 30 minutes at room temperature 
and in the dark. 100µl stop solution was added to each well and the 
absorbance at 405nm was read on a SpectraMax Plus384 Microplate Reader 
(Molecular Devices, California, USA). 
 




Sodium Citrate, ethylenediaminetetraacetic acid (EDTA) or heparin anti-
coagulated blood from healthy controls was gently layered over an equal 
volume of Polymorphprep (Axis-Shield, Oslo, Norway) and spun for 45 
minutes at 380g, 20ºC and with the brake off. The lower band was harvested 
and washed with an equal volume of 1:1 H20:PBS, spinning at 280g and 20ºC 
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for 10 minutes. The supernatant was discarded and the pellet washed with 
PBS, spinning at 280g and 20ºC for 10 minutes. To remove contaminating red 
cells the pellet was then either resuspended in 36ml water for 10-20 seconds 
before 4ml 10 x PBS was added or resuspended in 1ml red blood cell lysis 
buffer for 5 minutes before the volume was made up to 50ml with PBS. In 
both case this was spun at 280g and 20ºC for 10 minutes. The red cell lysis 
was repeated if necessary. Finally the cells were resuspended in Hanks 
Balanced Salt Soltion (HBSS) (Sigma, Poole, UK) with 1M HEPES (Sigma, 
Poole, UK) or PBS with calcium chloride and magnesium chloride (Sigma, 
Poole, UK) depending on the assay. The cells were counted using a 1:10 
dilution of Turk's Solution to exclude any contaminating red cells. Figure 2.1 




Heparinised blood from healthy controls was diluted 1:1 with HBSS. In 15ml 
tubes, 8ml of the blood/HBSS mixture was carefully layered on top of 4ml 
Ficoll-Paque™ PLUS (GE Healthcare Life Sciences, Buckinghamshire, UK).  
This was spun for 20 minutes at 380g, 20ºC and with the brake off. The upper 
layer including the lymphoctyes was aspirated with circular movement. Gentle 
tapping loosened the pellet and 10 ml RBC lysis buffer was added to remove 
the erythrocytes. The tube was inverted several times and incubated on ice 
for 5 minutes, with occasional mixing. This was spun at 380g and 20ºC for 5 
minutes. The supernatant was aspirated, being careful not to disturb the cell 
pellet which was then resuspend in 10 ml RBC lysis buffer and incubated on 
ice for 5 minutes. This was spun at 280g and 20ºC for 5 minutes. The 
supernatant was removed and the pellet was washed with ice-cold HBSS, 
spinning at 200g for 5 minutes. The cells were resuspend in HBH (500ml 
Hanks Balanced Salt soln + 5ml 1M HEPES) and counted using a 1:10 
dilution of Turk's Solution. Figure 2.1 (B) show the typical purity of neutrophils 
isolated in this manner. 
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Figure 2.1 Representative plots showing the purity of neutrophils following (A) 
isolation using Polymorphprep and (B) isolation using Ficoll followed by red 
cell lysis. The plots on the left show the  typical forward and side scatter of the 
neutrophil preparations while the plots on the right show the typical purity as 
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2.2.7 Respiratory Burst Assays 
 
2.2.7.1 Superoxide dismutase inhibitable ferricytochrome C reduction 
assay 
 
Neutrophils were resuspended at 2x106 cells/ml in HBH and primed by 
incubation with 2ng/ml TNFα (Peprotech, London, UK) together with 5µg/ml 
cytochalasin B (Sigma, Poole, UK) for 15 min at 37˚C with gentle mixing at 5  
minute intervals. For the GCSF experiments cells were primed with 50ng/ml 
GCSF (Peprotech, London, UK) under the same conditions as TNFα. 
Each well in a flat-bottomed 96 well plate had the following: 
 
Cytochrome C   10µl 
Stimulus    10µl 
SOD+/-      5µl 
Neutrophils    50µl 
HBH      To give final volume of 250µl 
 
Cytochrome C (from horse heart)(Sigma, Poole, UK) was made fresh on the 
day to give a stock of 23.25mg/ml in HBH and kept in the dark until use. 
Superoxide dismutase (SOD) (Sigma, Poole, UK) was used at a stock of 
30,000U/ml. Neutrophils were stimulated with either 250µg/ml patient IgG or 
2.5-10µg/ml monoclonal anti-PR3/anti-MPO antibodies (Table 2.3). Before 
being added to the wells IgG was spun at 16,000g in a tabletop 
microcentrifuge at 4˚C for 15 minutes to remove aggregates. 5µg/ml of N-
formyl-methionine-leucine-phenylalanine (fMLP)(Sigma, Poole, UK) was used 
as a positive control for neutrophil activation. All tests were done in triplicate. 
Neutrophils were added to each well last and the absorbance at 550nm was 
read on a SpectraMax Plus384 Microplate Reader (Molecular Devices, 
California, USA) at intervals of 5 minutes over 2 hours. The absorbances were 
then converted to nmol/105 neutrophils of O2− using the difference in O.D.550 
between the supernatants of comparable cells incubated with or without SOD, 
and the molar extinction coefficient for cytochrome c (21×103/mol/cm).  
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2.2.7.2 Dihydrorhodamine (DHR) 123 assay using isolated human 
neutrophils 
 
DHR123 is a non-reduced non-fluorescent molecule that in the presence of 
H2O2 is converted to rhodamine 123, which fluoresces at a wavelength of 
approximately 534nm, and can therefore be seen in the FITC (FL-1)-light 
channel. This allows neutrophils that have undergone a respiratory burst to be 
detected using flow cytometry. 
 
Neutrophils were resuspended at 2.5x106 cells/ml in HBH and loaded with  
17µg/ml DHR123 (Calbiochem, Nottingham, UK) together with 5µg/ml 
cytochalasin B and 2 mM sodium azide (Sigma, Poole, UK). This was 
incubated in the dark for 10 minutes at 37ºC. Cells were primed by incubation 
with 2ng/ml TNFα for 15 min at 37˚C with gentle mixing at 5 minute intervals. 
For the GCSF experiments cells were primed with 50ng/ml GCSF under the 
same conditions as TNFα. 200 µl of the cell suspension was added to each 
FACS tube (500,000 cells/tube) and stimulated with either 250µg/ml patient 
IgG or 2.5-10µg/ml monoclonal anti-PR3/anti-MPO antibodies (Table 2.3) for 
1 hour at 37˚C. Before being added to the cells IgG was spun at 16,000g in a 
tabletop microcentrifuge at 4˚C for 15 minutes to remove aggregates. 5µg/ml 
of fMLP or 0.1µg/ml phorbol myristate acetate (PMA) was used as a positive 
control for neutrophil activation. The reaction was stopped by the addition of a 
30-fold volume of cold HBSS containing 1% bovine serum albumin (BSA) 
(Sigma, Poole, UK). This was spun at 280g and 4˚C for 5 minutes. The cells 
were finally resuspended in a small volume of HBSS  (~300µl) and kept on ice 
and in the dark until measurement.  
 
Flow cytometry was performed on a FACS Canto flow cytometer (Becton 
Dickinson, Oxford, UK) using FACSDiva software (Becton Dickinson, Oxford, 
UK). At least 10,000 events were collected per sample and data was analysed 
using FlowJo software (Treestar, Ashland, OR, USA). 
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2.2.7.3 Dihydrorhodamine (DHR) 123 assay using whole blood from 
humanised mice 
 
Respiratory burst assays were carried out using heparinised whole blood from 
mice pre-treated (5 days before the assay was performed) with human 
pegylated GCSF (Neupogen® Filgrastim, Amgen, UK). For the fMLP 
response whole blood was first incubated with 2mM sodium azide, 1µg/ml 
cytochalasin B and 2ng/ml human TNFα for 15 minutes at 37°C. This was 
then stimulated with 5µg/ml fMLP for 10 minutes at 37°C. For the Escherichia 
coli (E.coli) response the whole blood was incubated with 2mM sodium azide 
together with opsonized E. coli (taken from the Phagoburst kit from Glycotope 
biotechnology GmBH, Heidelberg, Germany) for 10 minutes at 37°C. The 
stimulated blood was incubated with 17µg/ml DHR123 at 37°C in the dark for 
10 minutes. The reaction was stopped on ice and the whole blood was 
blocked and stained for flow cytometry as previously described.  
 
Flow cytometry was performed on a FACS Canto flow cytometer (Becton 
Dickinson, Oxford, UK) using FACSDiva software (Becton Dickinson, Oxford, 
UK). At least 20,000 events were collected per sample and data was analysed 




Degranulation assays were carried out using heparinised whole blood from 
mice pre-treated (5 days before the assay was performed) with human 
pegylated GCSF. For the fMLP response whole blood was first incubated with 
1µg/ml cytochalasin B and 2ng/ml human TNFa for 15 minutes at 37˚C with 
gentle mixing at 5 minute intervals. This was then stimulated with 5µg/ml 
fMLP for 10 minutes at 37˚C. For the E.coli response the whole blood was 
incubated with the E.coli for 10 minutes at 37˚C. The reaction was stopped on 
ice and the whole blood was blocked with 10% AB serum for 10 minutes on 
ice and then stained for flow cytometry for 20 minutes at room temperature. 
The red cells were lysed using BD FacsLyse.  
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Flow cytometry was performed on a FACS Canto flow cytometer (Becton 
Dickinson, Oxford, UK) using FACSDiva software (Becton Dickinson, Oxford, 
UK). At least 20,000 events were collected per sample and data was analysed 
using FlowJo software (Treestar, Ashland, OR, USA). 
 
2.2.9 Passive transfer of human neutrophils into mice 
 
Neutrophils were purified from healthy controls using Polymorphprep as 
described in Section 2.2.6.1. Approximately 1x107 neutrophils in 200µl PBS 
were injected into NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (referred to as NOD-
scid IL2γ-/-) obtained from Jaxmice (Bar Harbor, Maine, USA) via the lateral 
tail vein. Mice were bled from the saphenous vein 10, 30 and 60 minutes post 
transfer and whole blood was stained for the presence of human neutrophils 
using human CD45 and human CD66b antibodies. A small volume of blood 
was used to perform whole blood counts using Turk's solution. Flow cytometry 
was performed as previously described. Absolute numbers of neutrophils 
were calculated from flow cytometry data and total leukocyte numbers.  
 
2.2.10 CD34+ cell purification 
 
2.2.10.1 Defrosting frozen cord blood 
 
Cryopreserved human cord blood was purchased from The Anthony Nolan 
Trust. It was defrosted in a water bath at 37˚C and diluted 1:1 in thawing 
solution (47ml Dextran, 2.5ml AB serum, 960µl sodium citrate (39%w/v), 
500µl MgCl (0.5M) and 50µl DNAse-1 (106U/ml)). The sample was then 
diluted with culture media (RPMI-1640 + 5nM glutamine + 2.5% AB serum) 
and spun at 450g and 4˚C in order to remove the DMSO. The pellet was 
treated with 2 volumes of neat DNAse stock solution for approximately 5 
minutes. This was diluted with 10ml culture media and spun at 400g for 5 
minutes at room temperature. The resulting cell pellet was resuspended in 
MACS buffer (PBS with 0.5% BSA and 2mM EDTA) for CD34+ cell purification 
using the Miltenyi MACS separation system (Miltenyi Biotec Ltd., Surrey, UK).  
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2.2.10.2 CD3+ cell depletion of fresh cord blood 
 
Fresh human cord blood was purchased from the National Blood Service and 
stored overnight at room temperature. The next morning the CD3+ cells were 
depleted using the RosetteSep system (Stemcell Technologies, Grenoble, 
France). 1.25ml RosetteSep Human CD3 Depletion cocktail was added for 
every 25ml of cord blood. This was mixed and incubated for 20 minutes at 
room temperature. The cord blood was then diluted 1:4 in PBS containing 
PBS with 2% foetal calf serum (FCS) and 1mM EDTA. This was carefully 
layered over Ficoll, with 35ml of blood for 15ml of Ficoll, and spun at 400g for 
45 minutes at 20˚C and with the brake off. The enriched cells were transferred 
to a clean Falcon tube and diluted in an equal volume of PBS with 2% FCS 
and 1mM EDTA and spun at 200g for 10 minutes. CD3+ cell depleted cord 
blood cells were then either resuspended in PBS and injected into mice, 
resuspened in 90% FCS and 10% DMSO and cryopreserved, or resuspended 
in MACS buffer or PBS with 2% FCS and 1mM EDTA for further processing 
using the Miltenyi MACS separation (described in Section 2.2.10.2) or 
EasySep separation (described in Section 2.2.10.4) systems. 
 
2.2.10.3 CD34+ cell purification using the Miltenyi MACS separation 
system 
  
Cord blood cells in MACS buffer (PBS with 0.5% BSA and 2mM EDTA) were 
passed through a 40µm filter and counted in trypan blue. The cell suspension 
was spun at 130g for 10 minutes and resuspended in 300µl MACS buffer for 
up to 108 total cells. Keeping the cell suspension at 6˚C, 100µl FcR blocking 
agent together with 100µl of CD34 MicroBeads were added for up to 108 cells. 
This was mixed and incubated for 30 minutes at 6˚C. The cells were washed 
with 5-10ml buffer for 108 cells and spun at 130g for 10mins. The supernatant 
was discarded and the cells resuspended in 500µl MACS buffer for up to 108 
cells. 
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A MS magnetic separation column was placed in the magnetic field of a 
VarioMACS separator and washed three times with 500µl of buffer. The cell 
suspension was then passed through the column. Unlabelled cells that 
passed through the column were collected and the column was washed three 
times with 500µl MACS buffer. The column was removed from the separator 
and placed over a collection tube. 1-5ml of MACS buffer was applied to the 
column and the magnetically labelled cells were immediately flushed out by 
firmly pushing a plunger into the column. The yield and purity of the labelled 
fraction was determined using flow cytometry and staining for both CD34+ 
cells and contaminating CD3+ cells. 
 
2.2.10.4 CD34+ cell purification using Easysep  
 
EasySep (Stemcell Technologies, Grenoble, France) was added to cord blood 
cells in PBS containing 2% FCS and 1mM EDTA at 100µl/ml of cells (up to 
2x107 cells were suspended in 100µl, 2x107-2x108 cells were suspended at 
2x108 cells/ml and 2-5x108 cells were suspended in 1ml) and this was 
incubated at room temperature for 15 minutes. The EasySep magnetic 
nanoparticles were mixed, but not vortexed, to give a uniform suspension and 
then added to the cell suspension at 50µl/ml of cells. This was mixed and 
incubated at room temperature for 10 minutes. The cell suspension was 
brought to a total volume of 2.5ml with PBS containing 2% FCS and 1mM 
EDTA. The cells were mixed by gentle pipetting and the tube containing the 
cell suspension was placed, without a lid, into the magnet and set aside for 5 
minutes. In one continuous movement the magnet containing the tube with 
the cell suspension was inverted thus pouring off the supernatant. Once 
upright the tube was removed from the magnet and remaining cells were 
resuspended in 2.5ml PBS containing 2% FCS and 1mM EDTA. The cells 
were once again mixed by gentle pipetting and the tube containing the cell 
suspension was placed, without a lid, into the magnet and set aside for 5 
minutes. In one continuous movement the magnet containing the tube with 
the cell suspension was inverted thus pouring off the supernatant. This was 
repeated 3 times total and finally the yield and purity of the labelled fraction 
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was determined using flow cytometry before the cells were either injected into 
mice or cryopreserved in 90% FCS and 10% DMSO.  
 
2.2.11 Generating humanised mice 
 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (referred to has NOD-scid IL2γ-/-) were 
obtained from Jaxmice (Bar Harbor, Maine, USA) and bred in house, with 
some animals from Charles River (Margate, Kent, UK). All animals were 
housed in specific pathogen free conditions in filtered top cages and 
Scantainer ventilated cabinets. All animal procedures were performed 
according to UK Home Office regulations.  Humanised mice were generated 
by injecting 1x105 human cord blood CD34+ stem cells (either purified as 
described in Section 2.2.10 or purchased from Lonza, Slough, Berkshire, UK) 
into 6-12 week old NOD-scid IL2γ-/- mice approximately 4 hours post 
irradiation at 2.4Gy with a Cs-source irradiator. As NOD-scid IL2γ-/- mice are 
particularly radiosensitive, due to defects in DNA repair, this dose, while low, 
is enough to allow engraftment without leading to unacceptable losses [119].  
Engraftment of human cells in the peripheral blood was assessed using flow 
cytometry at least 8 weeks post engraftment.  
 
2.2.12 Anaesthetising mice 
 
Mice were anaesthetised using 0.15ml/kg of metomidine hydrochloride 
1mg/ml domitor (Pfizer Ltd, Kent. U.K.) and ketamine hydrochloride 100mg/ml 
vetalar (Pharmacia Animal Health Ltd, Northamptonshire, U.K.) This was 
made up to a working dilution by adding 4.16ml normal saline to 0.34ml 
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2.2.13 Sample collection  
 
2.2.13.1 Blood  
 
Peripheral blood was taken from the saphenous vein of mice and collected 
into either EDTA for flow cytometry or lithium heparin for neutrophil activation 
assays. Terminal bleeds were from the axillary vessels of mice under terminal 
anaesthesia. 
 
2.2.13.2 Spleen  
 
Whole spleens were collected into PBS. They were forced through a 40µm 
strainer using the plunger of a 5ml syringe and into approximately 10ml PBS. 
They were spun at 200g for 10 minutes at room temperature and 
resuspended in 1-5ml of red blood cell lysis buffer. This was incubated at 
room temperature for 5 minutes and then diluted to 50ml with PBS before 
being spun at 200g for 10 minutes. The cells were counted in Turk's solution, 
washed once in PBS and finally resuspended at 1x107 cell/ml in PBS for flow 
cytometry. 
 
2.2.13.3 Bone marrow 
 
Bone marrow was flushed, with PBS, from the femurs and tibiae of mice using 
a 27G needle. Large aggregates were broken apart using a 19G needle. The 
cells suspension was transferred to a 50ml falcon and centrifuged for 10 
minutes at 200g and at room temperature. The cells were resuspended in 
PBS and passed through a 40µm filtered before being counted using Turk's 




Lungs were collected into PBS and then transferred into 1-3ml DMEM 
(Invitrogen, Paisley, UK) with 10% FCS.  They were cut into small sections 
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and collagenase, type IV-S from Clostridium histolyticum (Sigma, Poole, UK), 
was added to give a final concentration of 500µg/ml. This was mixed and 
incubated for 45 minutes at 37˚C and 5% CO2. Each sample was pipetted 
vigorously to release the cells and then washed with PBS containing 1% FCS, 
spinning at 200g and room temperature for 10 minutes. The cells were 
passed through a 40µm strainer and counted in Turk's solution. Finally the 
cells were resuspended at 1x107 cells/ml in PBS for flow cytometry.  
 
2.2.14 Immunostaining for PR3 and MPO 
 
Bone marrow cells were resuspended at 2x105 cells/ml. The slides were pre-
labelled and mounted with the paper pad and the cuvette in the metal holder 
and then placed in the cytospin. 100µl of cells were loaded and this was spun 
at 100g for 5 minutes. The slides were allowed to dry at room temperature for 
at least 30 minutes. A circle was drawn loosely around the cells using a wax 
pen. 100µl of primary anti-PR3 or anti-MPO (See Table 2.1) at a 
concentration of 500µg/ml was added to the cells. This was incubated for 20 
minutes in a humidity box. The slides were washed with PBS three times for 5 
minutes each and 100µl of secondary anti-mouse IgG (Jackson 
ImmunoResearch, Suffolk, UK), FITC at a 1:200 dilution for MPO and 
Dylight488 at at a 1:400 dilution for for PR3, was added. This was incubated 
for 30 minutes in a humidity box. The slides were washed with PBS three 
times for 5 minutes each and mounted in PermaFluor mountant (Thermo 
Scientific, Loughborough, UK) together with 0.3µg/ml Hoechst 3342 dye 
(Sigma, Poole, UK) to visualise the nuclei. Cells were examined using an 
Olympus BX51 fluorescent microscope (Olympus, Southend-on-sea, UK). 
 
2.2.15 Inducing disease 
 
Mice at least 8 weeks post engraftment were given either 4mg human anti-
PR3 or MPO IgG or 10mg anti-PR3 IgG, this was day 0. Mice receiving 4mg 
antibody also received 10µg LPS subcutaneously (s.c.) and 6µg GCSF 
(Neupogen® Filgrastim, Amgen, UK) intraperitoneally (i.p.) on day 0. The 
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GCSF was given daily for the next 7 days and the LPS given again on day 4. 
Mice receiving 10mg anti-PR3 IgG were given one 50µg dose of long lasting 
pegylated GCSF (Neupogen® Filgrastim, Amgen, UK) on day 0 together with 
LPS on day 0 and again on day 4.  On day 6 the mice were placed in 
metabolic cages for urine collection. On day 7 the mice were terminally bled 
and their lungs were examined for signs of punctate haemorrhage. Finally 
their lungs and kidneys were harvested for histological analysis as described 
in Section 2.2.16.  
 
2.2.16 Histological sample processing 
 
Kidney sections were collected in Bouin's solution and transferred into 
formalin after 4 hours. Lungs were inflated with formalin and stored in formalin 
until processing. The samples were processed using an automatic tissue 
processor and then embedded in paraffin wax. Tissue sections were cut to 
1µm thickness and incubated in an oven for at least 30 minutes before being 
stained with periodic acid-Schiff stain (PAS) and haematoxylin. To stain 
sections they first were placed directly into xylene for 10 minute and then into 
100%, 90% and 70% alcohol for 20 seconds each. They were then placed 
into running water for 2 minutes, and incubated with 1% periodic acid for 10 
minutes. Following a further wash in water for 3 minutes, kidney sections were 
incubated with Schiff reagent for 20 minutes and lung sections for 5 minutes. 
Both were then washed in water for 3 minutes and incubated with 
haematoxylin for 10 minutes for kidney sections and 15 minutes for lung 
sections. Slides were then taken back through graded alcohols for 20 seconds 
each and then into xylene before being mounted in DPX. The sections were 
left to dry and analysed for evidence of injury.  
 
For immunofluorescent staining lungs were inflated with phosphate-lysine-
periodate (PLP) and fixed in PLP overnight at 4˚C. The following day they 
were transferred to 13% sucrose, again incubated overnight at 4˚C and finally 
frozen in isopentane and stored at -80˚C. Kidneys were either frozen in 
isopentane upon harvest or fixed in PLP for 4 hours at 4˚C and transferred to 
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13% sucrose overnight at 4˚C. They were then frozen in isopentane the next 
morning and stored at -80˚C 
 
2.2.17 Immunofluorescent staining 
 
Frozen sections of lung were cut to 5µm thickness. The sections were then 
incubated with the primary mouse anti-human CD66b (Serotec, Oxford, UK) 
antibody then with the secondary Dylight 488 goat anti-mouse IgG antibody 
(Jackson ImmunoResearch, Suffolk, UK) and mounted in PermaFluor 
mountant (Thermo Scientific, Loughborough, UK). Neutrophil numbers were 
taken from the average counts of 5 high-powered fields using the x40 
objective and a BX51 fluorescent microscope (Olympus, Southend-on-sea, 
UK). Counts were performed by two investigators and an average was taken 
to give the final numbers. 
 
2.2.18 Albuminuria measurement 
 
Mice were housed in metabolic cages for 24 hours for urine collections. The 
urine albumin concentration was measured by ELISA using a mouse albumin 
ELISA quantitation set from Bethyl Laboratories (Montgomery, Texas, USA). 
Flat-bottomed 96 well plates were coated with a 100µl/well of affinity purified 
mouse albumin coating antibody, diluted 1:100 in 500mM bicarbonate buffer, 
pH 9.5, for 1 hour at room temperature. The plate was washed 5 times with 
PBS containing 0.05% Tween 20 and blotted dry on clean tissue paper. 200µl 
of blocking solution (PBS with 1% BSA) was added to each well and this was 
incubated for 30 minutes at room temperature. The plate was washed as 
before. Mouse albumin (Sigma, Poole, UK) was diluted to the following 
concentrations: 250ng/ml, 125ng/ml, 62.5ng/ml, 31.25ng/ml, 15.625ng/ml, 
7.7ng/ml and 3.9ng/ml. For each well, 100µl of the appropriate concentration 
was added as a standard. Urine samples were diluted 1:1000 in PBS with 1% 
BSA, and 100µl was added to the appropriate well. The plate was incubated 
for 1 hour at room temperature and then washed as before. The horseradish 
peroxidase (HRP) detection antibody was diluted 1:30,000 in PBS with 1% 
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BSA, and 100µl was added to each well. This was incubated for 1 hour at 
room temperature. The 3,3',5,5'-Tetramethylbenzidine (TMB) substrate 
(Sigma, Poole, UK) was made up as follows: 1 TMB tablet was added to a 
1:10 dilution in H2O of 10x TMB buffer (51.4ml 1M Na2HPO4 solution and 
46.8ml 0.5M citric acid, pH 5), 2µl hydrogen peroxide was then added. 100µl 
of substrate was then added per well and the plate was incubated in the dark 
and at room temperature. After approximately 15 minutes the reaction was 
stopped using 100µl of a 1:5 dilution of H2SO4 in H20. The plate was read at 
450nm on a SpectraMax Plus384 Microplate Reader (Molecular Devices, 
California, USA) 
 
2.2.19 Urine creatinine measurement 
 
Urine creatinine was measured with the help of Dr N Dalton and Dr C Turner 
in the Department of Paediatric Biochemistry at St. Thomas' Hospital by mass 
spectrometry. The urine was diluted 1:10 in PBS and 5µl of this was diluted 
into 250µl D3 creatinine isotope and 250µl acetonitrile containing 0.5% formic 
acid. The creatinine level of each sample was then measured using Applied 
Biosystems MDS Sciex API 4000 (Applied Biosystems, Warrington, UK) and 




Statistics were performed using Graphpad Prism software (Graphpad 
Software Inc, La Jolla, CA, USA). Specific statistical tests used will be 




Chapter 3 ANCA induced neutrophil activation and ANCA purification 
	   95 
3.1 Introduction 
 
ANCA associated vasculitis is a systemic autoimmune disease that primarily 
affects the elderly, with a peak age of onset of between 65 and 74 years old 
[194]. There is substantial evidence that ANCA are key mediators of disease, 
which they induce by aberrantly activating neutrophils leading to tissue 
damage and subsequent pathology (reviewed in Chapter 1). In vitro, cytokine-
primed neutrophils isolated from healthy controls have been shown to be 
activated by incubation with IgG derived from patients positive for anti-PR3 
and anti-MPO antibodies, but not by incubation with IgG taken from ANCA 
negative controls. In addition, monoclonal anti-PR3 and anti-MPO antibodies 
have been shown to similarly activate neutrophils. Once activated, neutrophils 
carry out a number of effector functions that can be easily measured in vitro. 
These include, but are not limited to, phagocytosis, respiratory burst, 
degranulation and inflammatory cytokine release. To date the majority of 
studies investigating the role of ANCA in neutrophil activation have focussed 
on the ability of these autoantibodies to induce the neutrophil respiratory 
burst, and to a lesser degree, degranulation responses. 
 
Superoxide (O2-) is a highly reactive oxygen species produced during the 
neutrophil respiratory burst by the one electron reduction of oxygen by 
NADPH oxidase [195, 196]: 
 
O2 + NADPH   O2- + NADP+ + H+ 
 
The majority of this superoxide reacts with itself to produce oxygen and 
hydrogen peroxide (H2O2) in a reaction catalysed by the enzyme superoxide 
dismutase [195, 197, 198]: 
 
2O2- + 2H+  H2O2 and O2 
 
Both superoxide and hydrogen peroxide are important starting materials for 
the production of microbicidal substances, and thus play pivotal roles in the 
innate immune response. Cytochrome C is a small heme protein and an 
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important component of the electron transport chain in mitochondria [195, 
197]. It can accept electrons from superoxide, and thus the reduction of 
cytochrome C can be used as a measure of superoxide production [195]. In 
1990 Falk et al. first used the superoxide dismutase inhibitable reduction of 
ferricytochrome C to measure ANCA induced superoxide release, thus 
demonstrating that ANCA activates neutrophils [14].  
 
Dihyrorhodamine (DHR)123 is a non-fluorescent molecule that is taken up by 
phagocytes and converted to the green fluorescent molecule rhodamine 123 
upon oxidation by reactive oxygen intermediates, primarily H2O2, produced 
during the respiratory burst response. Consequently, rhodamine 123 
production as measured by flow cytometry has been widely used to study the 
neutrophil respiratory burst [199, 200]. Together with the ferricytochrome C 
reduction assay, which measures extracellular superoxide production, the 
DHR123 assay, which primarily measures intracellular ROS production, has 
become a standard tool in the study of ANCA induced neutrophil responses. 
 
Precipitation of immunoglobulins using ammonium sulphate has been in 
practice for many years [201]. It works on the principle that each protein in the 
solution will aggregate at a characteristic salt concentration, allowing it to be 
easily removed using centrifugation. At a 25% ammonium sulphate solution 
contaminants such as fibrin will begin to precipitate out of solution. Once 
these have been removed, a 50% ammonium sulphate solution can be used 
to precipitate out immunoglobulins [202]. Ammonium sulphate fractionation 
alone does not provide sufficient purity for in vitro ANCA analysis, however, 
when followed by Protein G affinity chromatography, a highly pure IgG 
preparation can be achieved. Protein G is a protein isolated from the bacterial 
cell wall of a human group G streptococcal strain (G148). It binds the Fc 
receptor of all human IgG subclasses as well as rabbit, mouse and goat IgG 
[203].  
 
In this chapter monoclonal anti-PR3 and anti-MPO, together with IgG purified 
from the plasma of PR3- and MPO-ANCA positive patients, was used to 
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develop neutrophil respiratory burst assays to allow the study of ANCA 




• To set up ANCA induced neutrophil respiratory burst assays 




All blood and plasma samples, from both patients or healthy controls, were 
taken with informed consent and ethical approval (NRES committee London—
London Bridge 09/H084/72) 
 
3.3.1 Superoxide dismutase inhibitable ferricytochrome C reduction 
assay 
 
Neutrophils were isolated from either EDTA, sodium citrate or lithium heparin 
anti-coagulated blood using Polymorphprep as described in Section 2.2.6.1 or 
Ficoll as described in Section 2.2.6.2. The assay was performed as described 
in Section 2.2.7.1.  
 
3.3.2 DHR123 assay 
 
In the initial experiments neutrophils were isolated from EDTA coagulated 
blood using Polymorphprep as described in Section 2.2.6.1 unless otherwise 
stated. These cells were then loaded with 1µg/ml DHR123. The assay was 
otherwise carried out as described in Section 2.2.7.2. In later experiments 
neutrophils were isolated from heparinised blood using Ficoll as described in 
Section 2.2.6.2, with assays being performed as described in Section 2.2.7.2. 
To remove aggregates from purified IgG, samples were either spun at 
16,000g in a tabletop microcentrifuge at 4°C or passed through a 300,000 
MWCO PES Vivaspin 500 centrifugal concentrator (Sartorius Stedim Biotech). 
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3.3.3 IgG Purifications 
 
IgG was purified from plasma or serum taken from either healthy controls or 
PR3 and/or MPO-ANCA positive patients. Ammonium sulphate or sodium 
chloride precipitation, as described in Sections 2.2.3.1 and 2.2.3.2 
respectively, was used to remove fibrin before HiTrap HP Protein G columns 
were employed as described. Purity and ANCA binding potential of patient 
IgG was determined using SDS-PAGE as described in Section 2.2.4 and anti-




I would like to thank Dr. Reena Popat for contributing the anti-PR3 and anti-
MPO titration data presented in Figure 3.6.  
  
3.4 Results: ANCA activates human neutrophils in vitro 
 
3.4.1 ANCA induces superoxide release  
 
The ANCA induced release of superoxide from neutrophils is shown in Figure 
3.1. Neutrophils were isolated using Polymorphprep, primed with TNFα and 
then stimulated with either a commercial monoclonal anti-PR3 or anti-MPO 
antibody. An IgG isotype control was included to discount non-specific 
superoxide production. fMLP was used as a positive control for neutrophil 
activation. Both the anti-PR3 and anti-MPO antibodies induced similar levels 
of superoxide release and this was comparable to the fMLP induced 
response. (Fig 3.1. A). To confirm that the ANCA induced response was not 
restricted to the specific monoclonal antibodies used, IgG purifed, using 
ammonium sulphate and protein G purification, from PR3- and MPO-ANCA 
positive patients was also included in the assay. IgG from healthy donors 
served as a negative control in this case (Fig 3.1. B). The MPO positive 
patient IgG induced response was comparable to that of the monoclonal anti-
MPO IgG induced response. However, the response to PR3 positive patient 
IgG was less potent than that induced by the equivalent monoclonal antibody. 
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Finally, in all cases the response was superoxide dismutase (SOD) 
inhibitable. As SOD catalyses the conversion of superoxide to hydrogen 
peroxide, thus removing superoxide from the reaction, this demonstrates that 
the reduction of cytochrome C was the result of superoxide release. 
 
3.4.2 ANCA induces the release of reactive oxygen species as measured 
by the conversion of dihydrorhodamine (DHR)-123 into fluorescent 
rhodamine 123 
 
Neutrophils were isolated from EDTA coagulated blood using Polymorphprep, 
primed with TNFα, and then stimulated with a commercial monoclonal anti-
PR3 antibody. An IgG isotype control was included to discount non-specific 
rhodamine 123 production. PMA was used as a positive control for neutrophil 
activation. Rhodamine 123 production in response to the anti-PR3 monoclonal 
antibody was comparable to that of the PMA positive control, however, a 
subpopulation of the neutrophils treated with the isoytpe control IgG also 
activated to the same extent as the anti-PR3 IgG stimulated cells (Fig 3.2 A). 
To determine if this was a problem associated with the monoclonal antibodies 
used, the assay was repeated using IgG purifed, using ammonium sulphate 
and protein G purification, from a PR3-ANCA positive patient. IgG from a 
healthy donor served as a negative control in this experiment (Fig 3.2.B). Both 
the PR3 positive patient IgG and the healthy control IgG induced rhodamine 
123 production to a level comparable to that induced by the PMA positive 
control. This raised the question as to whether aggregates in the antibody 
preparations could be activating the neutrophils. To address this concern the 
assay was repeated using antibody preparations that were either untreated or, 
in order to remove aggregates, centrifuged at high speed or forced through a 
high molecular weight Vivaspin centrifugal concentrator. Initially it appeared 
that forcing the antibody preparations through the concentrator would allow a 
marginal difference between the isotype control and ANCA induced 
responses to be identified. However, this could not be repeated (Fig 3.3, 
representative of 3 experiments).  
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Figure 3.1 ANCA induced superoxide release as measured by the superoxide 
dismutase (SOD) inhibitable reduction of ferricytochrome C. TNFα primed 
neutrophils were isolated from a healthy volunteer using Polymorphprep as 
described. (A) Neutrophils stimulated with either 10µg/ml monoclonal human 
anti-MPO IgG (n=1), 5µg/ml monoclonal human anti-PR3 IgG (n=1) or a 
relevant isotype control (n=1). (B) Neutrophils stimulated with 200µg/ml 
polyclonal anti-MPO IgG (n=2) or anti-PR3 IgG (n=2) purified from patient 
plasma. IgG purified from a healthy volunteer (n=1) was used as a negative 
control. fMLP was used a positive control for neutrophil activation. Data are 
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Figure 3.2 ANCA induced respiratory burst as measured by the conversion of 
DHR123 into fluorescent rhodamine-123. TNFα primed neutrophils were 
isolated from a healthy volunteer using Polymorphprep as described and 
stimulated with (A) 5µg/ml monoclonal human anti-PR3 IgG (n=1) or a 
relevant isotype control or (B) 200µg/ml polyclonal human anti-PR3 IgG (n=1) 
purified from patient plasma. IgG purified from a healthy control was used as 
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Figure 3.3 Filtering IgG through a vivaspin column removes aggregates but 
has minimal effect on the ANCA induced respiratory burst as measured by the 
conversion of DHR123 into fluorescent rhodamine-123. TNFα primed 
neutrophils were isolated from a healthy volunteer using Polymorphprep as 
described and stimulated with 200µg/ml polyclonal human anti-MPO IgG 
(n=1) purified from patient plasma. IgG purified from a healthy volunteer was 
used as a negative control. IgG was either untreated, spun at 16,000g for 15 
minutes in a temperature controlled table top microcentrifuged, or passed 
through a vivaspin column in order to remove aggregates that may be 
inducing a respiratory burst in the response to control IgG. Data is 
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In a recent report, Freitas et al. examined the effect of the anticoagulant used 
in blood collection during neutrophil isolation, by a gradient density 
centrifugation method using Histopaque solutions, on the PMA induced 
respiratory burst [204]. They showed that while EDTA provided the highest 
yield of isolated neutrophils compared with citrate and heparin, it also resulted 
in the lowest degree of PMA induced neutrophil respiratory burst as measured 
by chemiluminescence. To determine if this was also true for the ANCA  
induced release of reactive oxygen species, and thus responsible for the lack 
of difference seen between the ANCA and control IgG induced production of 
rhodamine 123, blood was collect using EDTA, sodium citrate or lithium 
heparin, and a DHR123 assay using a commercial monoclonal anti-PR3 
antibody was carried out (Fig 3.4). The difference between the three 
anticoagulants was marginal, however, it was decided to use lithium heparin 
in blood collection for neutrophil isolation from this point onwards. It should be 
noted that while there was a small response to anti-PR3 antibodies seen in 
this experiment, this was not typical. 
 
It has been established that isolation of neutrophils can lead to phenotypic 
and functional changes that may affect neutrophil activation [205]. With the 
view of setting up a reliable ANCA induced DHR123 assay, neutrophil 
isolation using Polymorphprep was abandoned and the more widely used 
method of isolating neutrophils using density gradient sedimentation to 
remove the PBMCs, the neutrophils pellet with the red cells, followed by red 
cell lysis was adopted. Figure 3.5 shows ANCA induced rhodamine 123 
production by neutrophils isolated using the Ficoll method described in 
Section 2.2.6.1. Neutrophils were primed with TNFα and then stimulated with 
either a commercial monoclonal anti-PR3 or anti-MPO antibody. An IgG 
isotype control was included to discount non-specific rhodamine-123 
production. fMLP was used as a positive control for neutrophil activation. Both 
the anti-PR3 and anti-MPO antibodies induced similar levels rhodamine-123, 
with the anti-PR3 IgG induced response being marginally stronger (Fig 3.5 A). 
To confirm that the ANCA induced response was not restricted to the specific 
monoclonal antibodies used, IgG purifed from PR3- and MPO-ANCA positive 
patients was also tested. IgG from healthy donors served as a negative 
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control in this case (Fig 3.5 B). The PR3- and MPO-ANCA positive patient IgG 
induced rhodamine 123 production to a strong degree, comparable to that 
induced by the fMLP positive control. Although never formally compared side-
by-side with Polymorphprep, using this method of neutrophil isolation a 
reliable assay was established.  
 
To further optimise the DHR123 assay for future use in the investigation of 
ANCA induced neutrophil activation, titrations of the anti-PR3 and anti-MPO 
monoclonal antibodies were performed (Fig 3.6). For the monoclonal anti-PR3 
antibody, 5µg/ml was found to give optimal activation with lower 
concentrations inducing less neutrophil activation (Fig 3.6 A). In contrast, the 
anti-MPO antibody was found to induced similar levels of activation when 
used at 5, 2.5 and 1.25µg/ml of IgG (Fig 3.6 B). 
 
3.5 Results: Purification of human IgG from anti-PR3 and anti-MPO 
ANCA positive patients 
 
3.5.1 IgG Purifications 
 
Using SDS PAGE under reducing conditions, Figure 3.7 shows the various 
stages of human IgG purification from plasma using ammonium sulphate 
precipitation followed by Protein G purification. The IgG heavy and light 
chains can be seen at approximately 55kDa and 25kDa, respectively, in all 
samples with the exception of the flow through. Post ammonium sulphate 
precipitations, one at 25% to remove fibrin and one at 50% to precipitate out 
the antibody, a number of impurities remain. These impurities are largely 
absent after protein G purification.  
 
3.5.2 Optimisation of IgG purification protocol 
 
Ammonium sulphate precipitation has a number of disadvantages. Firstly, a 
large volume of saturated ammonium sulphate solution must be added to the 
plasma to achieve 50% saturation. Secondly, the ammonium sulphate must 
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Figure 3.4 The effect of the anticoagulant used during blood collection on the 
ANCA induced respiratory burst as measured by the conversion of DHR123 
into fluorescent Rhodamine-123. TNFα primed neutrophils were isolated, 
using Polymorphprep, from blood taken from a healthy volunteer and 
collected into one of the following anticoagulants: EDTA, sodium citrate or 
lithium heparin. Neutrophils were then stimulated with (A) 5µg/ml monoclonal 
human anti-PR3 IgG (n=1) or a relevant isotype control or (B) 200µg/ml 
patient derived anti-PR3 IgG (V8, n=1). IgG purified from a healthy volunteer 
was used as a negative control. (C) Shows the data from (A) and (B) with a 
direct comparison of the effect of the anticoagulant used on the level of 
rhodamiine-123 production. 
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Figure 3.5 ANCA induced respiratory burst as measured by the conversion of 
DHR123 into fluorescent rhodamine-123. TNFα primed neutrophils isolated 
from heparinised blood, using Ficoll and red cell lysis as described, were 
stimulated with (A) either 5µg/ml monoclonal human anti-PR3 IgG (n=1), 
10µg/ml monoclonal human anti-MPO IgG (n=1) or a relevant isotype control 
(B) either 200µg/ml polyclonal human anti-PR3 IgG (V16) (n=1), polyclonal 
human anti-MPO IgG (V30) (n=1) purified or a relevant control (L1) (n=1). 




Chapter 3 ANCA induced neutrophil activation and ANCA purification 
	   107 
 
 
Figure 3.6 Monoclonal anti-neutrophil antibody titration. TNFα primed 
neutrophils isolated from heparinised blood, using Ficoll and red cell lysis as 
described, were loaded with DHR123 and stimulated with (A) 5, 2.5 or 
1.25µg/ml monoclonal human anti-PR3 IgG (n=1) or (B) 5, 2.5 or 1.25µg/ml 
monoclonal human anti-MPO IgG (n=1). An irrelevant isotype control was 
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Figure 3.7 Testing the purity of the IgG preparation from both patient and 
control plasma after the various stages of purification using SDS PAGE under 
reducing conditions. L1=healthy volunteer IgG, V2=patient anti-PR3 IgG, V3= 
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be exchanged for PBS using dialysis before the antibody preparation can be 
Protein G purified, thus lengthening the time required to isolated the antibody. 
However, in order to avoid blocking the Protein G column fibrin must be 
removed from plasma, and therefore some form of precipitation to remove 
contaminants must be carried out. One alternative to ammonium sulphate 
precipitation that was examined was precipitation using sodium chloride. 
Sodium chloride works in a similar manner to ammonium sulphate, however, 
as solid sodium chloride was used only a small amount was required 
(18g/100ml). The contaminants were removed by centrifugation after a single 
precipitation step and once the supernatant containing the antibody was 
diluted 1:5 with water, the sample was ready to be put through the Protein G 
column. There was no distinguishable difference found between antibodies 
purified using these two methods (Fig 3.8 A). To examine the effect of sodium 
chloride precipitation relative to ammonium sulphate precipitation, antibody 
preparations purified side-by-side using both methods were compared. 
 
Table 3.1 shows, using a MPO antibody binding ELISA, that the binding ability 
of individual patient anti-MPO IgG was similar regardless of the precipitation 
method used. Table 3.2 compares the yield and ability to induce neutrophil 
respiratory burst of antibodies purified using both methods. For 2 of the 3 
patient samples tested the yield was unaffected by precipitation method used. 
For the third sample the yield was higher when ammonium sulphate 
precipitation was used. With regards functionality of the antibody, anti-MPO 
antibodies isolated from patient samples using sodium chloride induced a 
greater respiratory burst, as measured by rhodamine 123 production, than 
that isolated using ammonium sulphate, in 2 out of 3 patient samples tested  
(Fig 3.8 B). However, this was not great enough to be statistically significant. 
 
3.5.2 Summary of IgG preparations  
 
Table 3.3, 3.4 and 3.5 list the control IgG, patient anti-PR3 ANCA positive IgG 
and patient anti-MPO ANCA positive IgG isolated, respectively, together with 
the volume of plasma and the precipitation method used as well the 
concentration and volume of the final product after purification. Table 3.6 lists 
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Figure 3.8 Comparing ammonium sulphate (NH4SO4)  and sodium chloride 
(NaCl) precipitation with regards to (A) the purity of the IgG preparation (n=2), 
and, (B) the ability of 200µg/ml of the resulting purified ANCA to induced a 
respiratory burst in TNFα primed neutrophils isolated from heparinised blood 
using Ficoll and red cell lysis (n=3). V41, V45, V54 and V57 are patient anti- 
MPO IgG preparations. V-Vasculitis patient 
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Sample ID Preparation MPO Binding ELISA 
(U/ml) 
V41 NH4SO4 precipitation 17.6 
V41 NaCl precipitation 17.8 
V7 NH4SO4 precipitation 174.3 
V7 NaCl precipitation 147.2 
 
Table 3.1 MPO Capture ELISA results comparing the binding of antibody 
purified on the same day using either a NH4SO4 precipitation or NaCl 
precipitation. Antibody was used at a concentration of 20µg/ml. V7 and V41 
are patient anti-MPO IgG preparations. V-Vasculitis patient 
 
Sample ID Preparation Yield Respiratory Burst 
(MFI) 
V41 NH4SO4 precipitation 23mg 465 
V41 NaCl precipitation 
 
24mg 3051 
V54 NH4SO4 precipitation 5.7mg 202 
V54 NaCl precipitation 
 
3mg 526 
V57 NH4SO4 precipitation 9mg 1698 
V57 NaCl precipitation 8.4mg 1321 
  
Table 3.2 Comparing the yield (from 5ml of plasma) of, and respiratory burst 
induced by, antibody purified on the same day using either a NH4SO4 
precipitation or NaCl precipitation. V41, V45, V54 and V57 are patient anti-
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Sample ID Preparation Concentration  Volume 
L1  25ml Plasma, NH4SO4 Precipitation 4.56mg/ml 10ml 
L1  5ml Plasma, NaCl Precipitation 1.77mg/ml 3ml 
L2 50ml Plasma, NH4SO4 Precipitation 4.61mg/ml 20ml 
L2 5ml Plasma, NaCl Precipitation 7mg/ml 3ml 
L2 5ml Serum 4.4mg/ml 3ml 
L1, L2 90ml Plasma, NH4SO4 Precipitation 50mg/ml 1.2ml 
L13 5ml Plasma, NaCl Precipitation 1mg/ml 3ml 
L17 5ml Plasma, NaCl Precipitation 2mg/ml 3ml 
L18 5ml Plasma, NaCl Precipitation 2mg/ml 3ml 
L18 5ml Plasma, NaCl Precipitation 3.4mg/ml 3ml 
L27 5ml Plasma, NaCl Precipitation 3.89mg/ml 3ml 
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Sample ID Preparation Concentration Volume 
V2 45ml Plasma, NH4SO4 Precipitation 4.97mg/ml 20ml 
V3 40ml Plasma, NH4SO4 Precipitation 4.36mg/ml 20ml 
V4 45ml Plasma, NH4SO4 Precipitation 5.97mg/ml 12ml 
V5 50ml Plasma, NH4SO4 Precipitation 4.5mg/ml 12ml 
V8 50ml Plasma, NH4SO4 Precipitation 6mg/ml 10ml 
V8 5ml Plasma, NaCl Precipitation 2mg/ml 3ml 
V12 90ml Plasma, NH4SO4 Precipitation 4.78mg/ml 20ml 
V13 45ml Plasma, NH4SO4 Precipitation 4.87mg/ml 5ml 
V14 45ml Plasma, NH4SO4 Precipitation 5.34mg/ml 15ml 
V14 45ml Plasma, NH4SO4 Precipitation 20.72mg/ml 2.6ml 
V14 45ml Plasma, NH4SO4 Precipitation 50mg/ml 1.6ml 
V14 5ml Plasma, NaCl Precipitation 4.68mg/ml 3ml 
V16 5ml Plasma, NaCl Precipitation 4.23mg/ml 3ml 
V18 5ml Plasma, NaCl Precipitation 4.36mg/ml 3ml 
V20 5ml Plasma, NaCl Precipitation 3.7mg/ml 3ml 
V21 5ml Plasma, NaCl Precipitation 4.25mg/ml 3ml 
V42 5ml Plasma, NH4SO4 Precipitation 4.68mg/ml 3ml 
V43 5ml Plasma, NaCl Precipitation 8.63mg/ml 3ml 
V44 5ml Plasma, NH4SO4 Precipitation 7.69mg/ml 3ml 
V49 5ml Plasma, NaCl Precipitation 7.36mg/ml 3ml 
V51 5ml Plasma, NH4SO4 Precipitation 3.9mg/ml 3ml 
V52 5ml Plasma, NaCl Precipitation 8.2mg/ml 3ml 
V56 5ml Plasma, NaCl Precipitation 6.6mg/ml 3ml 
 
Table 3.4 List of purified IgG from patients with PR3 positive granulomatosis 
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Sample ID Preparation Concentration Volume 
V7 50ml Plasma, NH4SO4 Precipitation 5.7mg/ml 10ml 
V7 5ml Plasma, NaCl Precipitation 2mg/ml 3ml 
V26 45ml Plasma, NH4SO4 Precipitation 4.98mg/ml 16ml 
V30 45ml Plasma, NH4SO4 Precipitation 20mg/ml 1ml 
V30 5ml Plasma, NaCl Precipitation 3.75mg/ml 3ml 
V31 90ml Plasma, NH4SO4 Precipitation 50mg/ml 1.4ml 
V32 5ml Plasma, NaCl Precipitation 8mg/ml 3ml 
V33 5ml Plasma, NaCl Precipitation 4mg/ml 3ml 
V35 5ml Plasma, NaCl Precipitation 5mg/ml 3ml 
V38 5ml Plasma, NaCl Precipitation 8.47mg/ml 3ml 
V41 5ml Plasma, NH4SO4 Precipitation 7.7mg/ml 3ml 
V41 5ml Plasma, NaCl Precipitation 8mg/ml 3ml 
V45 5ml Serum 8.47mg/ml 3ml 
V46 5ml Plasma, NaCl Precipitation 7.5mg/ml 3ml 
V48 5ml Plasma 8.25mg/ml 3ml 
V50 5ml Plasma, NaCl Precipitation 3.7mg/ml 3ml 
V54 5ml Plasma, NaCl Precipitation 4.48mg/ml 3ml 
V54 5ml Plasma, NH4SO4 Precipitation 1.9 mg/ml 3ml 
V54 5ml Plasma, NaCl Precipitation 1mg/ml 3ml 
V57 5ml Plasma, NaCl Precipitation 6.79mg/ml 3ml 
V57 5ml Plasma, NH4SO4 Precipitation 3.19mg/ml 3ml 
V57 5ml Plasma, NaCl Precipitation 2.81 mg/ml 3ml 
V59 5ml Plasma, NH4SO4 Precipitation 3.4mg/ml 3ml 
 
Table 3.5 List of purified IgG from patients with MPO positive microscopic 
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V2 12 35 Yes Eyes/ent/chest/ns 1±1 0 
V3 12 31 No Chest/ns/ent/skin 1±1 56 
V4 12 19 Yes Skin/eyes/ns 3±1 103 
V5 12 32 Yes Eyes/ns/abdo 1±1 195 
V8 12 14 Yes No 5±2 32 
V12 12 27 Yes Ent/chest/eyes 3±2 232 
V13 12 33 Yes Ent/chest/eyes/ns 2±2 114 
V14 12 21 Yes Ent 0 2719 
V16 12 15 Yes No 6±2 4407 
V18 12 19 Yes Skin 471±5 6725 
V20 12 23 Yes Ent/chest No data 395 
V21 12 23 Yes Eyes/chest 0 1433 
V31 12 15 Yes No No data No data 
V43 12 21 Yes Ent No data 13 
V44 12 27 Yes Ent/chest 8±7 34 
V49 10 14 Yes Ent/eyes No data 69 
V51 12 24 Yes Ns 15±6 93 
V56 12 30 Yes Eyes/ent/chest 7±6 200 
 
Table 3.6 List of purified IgG from anti-PR3 ANCA positive patients including 
relevant clinical information and ability to induce a respiratory burst as 
measured by O2- (presented as mean values ± SEM of triplicate wells of 
triplicate wells) and rhodamine-123 production. All patients had evidence of 
active renal involvement, which was confirmed by renal biopsy in most cases. 
Clinical evidence of other tissue involvement (ent-ear, nose or throat, ns-
nervous system, abdo-abdomen) is also indicated. V-Vasculitis patient. BVAS-
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the IgG isolated anti-PR3 ANCA positive patients including relevant clinical 
information. Data on the ability of these patient derived ANCA to induce a 
respiratory burst as measured by both a ferricytochrome C reduction assay 
(Fig 3.9) (O2- production with data presented as mean values ± SEM of 
triplicate wells of triplicate wells) and a DHR123 assay (Fig 3.10) (rhodamine 
123 production) is also included. Table 3.7 lists the same information for IgG 
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V7 12 20 No Chest/ent 15±3 9 
V26* 12 22 Yes Ent/chest 9±1 0 
V30 12 18 No Chest 18±1 6020 
V32 12 15 Yes No No data 56 
V33 12 18 Yes Ent/chest 6±1 2632 
V35 6 10 Yes Eyes/skin No data 13 
V38 12 18 No Chest 8±2 21 
V41 12 15 Yes No 0 2998 
V42 12 25 No Skin/eyes/ent 14±2 208 
V45 12 15 Yes No 40±2 158 
V48 12 12 Yes No 12±5 10 
V50 12 12 Yes No 5±0 139 
V54 12 12 Yes No 16±2 310 
V57 12 15 Yes No 3±0 127 
V59 12 12 Yes No 6±1 108 
 
Table 3.7 List of purified IgG from anti-MPO ANCA positive patients including 
relevant clinical information and ability to induce a respiratory burst as 
measured by O2- (presented as mean values ± SEM of triplicate wells of 
triplicate wells) and rhodamine-123 production. All patients had evidence of 
active renal involvement, which was confirmed by renal biopsy in most cases. 
Clinical evidence of other tissue involvement (ent-ear, nose or throat) is also 
indicated. V-Vasculitis patient. BVAS-Birmingham Vasculitis Activity Score. 
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Figure 3.9 ANCA induced superoxide release as measured by the superoxide 
dismutase inhibitable reduction of ferricytochrome C. TNFα primed 
neutrophils isolated from heparinised blood using Ficoll and red cell lysis as 
described were stimulated with 200µg/ml of polyclonal human (A) anti-PR3 
(n=14) or (B) anti-MPO IgG (n=13) purified from patient plasma. O2- 
production above control was obtained from the O2- production of the ANCA 
stimulated cells minus the average O2- production of the isotype control  (n=3) 
stimulated cells. Data are presented as mean values ± SEM of triplicate wells. 
V-Vasculitis patient 
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Figure 3.10 ANCA induced respiratory burst as measured by the conversion 
of DHR123 into fluorescent rhodamine-123. TNFα primed neutrophils isolated 
from heparinised blood, using Ficoll and red cell lysis as described, were 
stimulated with 200µg/ml of polyclonal human (A) anti-PR3 (n=17) or (B) anti-
MPO IgG (n=15) purified from patient plasma. Activation above control was 
obtained from the median fluorescence intensities (MFI) of the ANCA 
stimulated cells minus the average MFI of the isotype control (n=3) stimulated 
cells. V-Vasculitis patient 
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3.6 Discussion 
 
ANCA induced respiratory burst assays 
 
Using both monoclonal, and patient purified polyclonal, anti-PR3 and anti-
MPO antibodies, two respiratory burst assays to measure the ANCA-induced 
activation of neutrophils were developed. The superoxide dismutase inhibitible 
ferricytochrome C reduction assay measures extracellular superoxide release. 
In this assay both monoclonal anti-PR3 and anti-MPO antibodies were 
capable of inducing high levels of superoxide release (Fig 3.1).  
 
In the DHR123 assay, DHR123 is taken up by phagocytes and converted into 
the fluorescent dye rhodamine-123 in the presence of reactive oxygen 
species. As the positively charged rhodamine-123 accumulates specifically in 
the mitochondria [206], and any DHR123 converted to rhodamine-123 by 
extracellular reactive oxygen species (ROS) should be removed during the 
various wash steps, the DHR123 assay primarily measures intracellular ROS 
production. In this assay, the method of neutrophil isolation appears to be 
very important. This may be due to the sensitivity of this assay combined with 
the differing basal activation levels of neutrophils purified using different 
isolation methods [205]. Using a version of the Ficoll method of PBMC 
isolation, modified to purify the PMN cells, a reliable DHR123 assay for use in 
ANCA studies was established (Fig 3.5). In this assay both monoclonal and 
patient polyclonal ANCA antibodies induced high levels of ROS production as 
measured by rhodamine 123 generation. 
 
Both assays have their advantages and disadvantages. Fewer patient 
samples gave reliable responses in the ferricytochrome C assay (Tables 3.6 
and 3.7). As assays were done on different days, and with different donors, 
the two responses could not be formally correlated and this is simply an 
observation. Conversely, it does allow ROS production to be examined over 
time, which is not possible using the DHR123 assay. Furthermore, as 
extracellular ROS production may be involved in endothelial cell damage 
during disease progression, the ferricytochrome C reduction assay may 
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provide a more relevant readout than the DHR123 assay. Finally, both assays 
suffer from the variability of neutrophil responses between donors. However, 
despite their limitations both assays provide a useful measure of neutrophil 




Commercially available monoclonal anti-PR3 and anti-MPO antibodies were 
used to set up ANCA assays and to provide preliminary data. As will be 
discussed, there were two major drawbacks to this approach. However, given 
the limited availability of consistently activating patient antibodies (discussed 
in the following section), and the time required to recruit patients, these 
monoclonal antibodies provided a useful tool to allow preliminary studies of 
the ANCA induced neutrophil respiratory burst.  
 
The first major drawback associated with the monoclonal antibodies used in 
this and the following chapter is that the Fc portions of the antibodies in 
question are mouse and not human. As discuss in chapter 1, data suggests 
that both the antigen binding region and the Fc portion of the ANCA molecule 
are important in ANCA signaling. Indeed, both FcγRIIa and FcγRIIIb have 
been shown to have a potential role in ANCA induced neutrophil activation in 
vitro. Consequently, it is important to note that while human FcγRIIa binds 
both human and mouse IgG1, human FcγRIIIb only binds human IgG [207]. 
Therefore it must be taken into account that Fc receptor signaling resulting 
from mouse IgG1 ligation likely differs from that induced by human IgG1 
ligation and, as a consequence, results gained by using monoclonal 
antibodies raised in mice may not accurately reflect what is happening with 
human antibodies. 
 
The second major disadvantage associated with the monoclonal antibodies 
used in this, and the following chapter, is with regards the antigenic targets of 
the antibodies. Firstly, the exact antigenic targets of the antibodies are 
unknown, and secondly, as only one anti-PR3 and one anti-MPO antibody 
was used, the results only hold true for these particular antibodies and not for 
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anti-PR3 and anti-MPO antibodies in general. What is known about these 
monoclonal antibodies will be discussed below. 
 
The monoclonal antibody to PR3 used, PR3G-2, was generated as part of a 
study designed to determine the antigenic targets of a number of established 
and newly developed monoclonal antibodies to PR3 [208]. It was produced 
from a hybridoma derived from mice immunised with a crude neutrophil 
granule extract. The antigen specificity of the antibody was established by 
four different methods including indirect immunofluorescence on ethanol-fixed 
neutrophils, Western blotting on a crude granule extract, flow cytometric 
analysis on isolated primed neutrophils, and antigen-specific direct and 
capture ELISA. In addition, and using a subclass antigen specific ELISA, the 
antibody isotype was confirmed to be IgG1. Further to this, biosensor 
technology was used to show that eight established and four newly generated 
monoclonal antibodies against PR3, including PR3G-2, recognised four 
separate epitopes on PR3. The antibodies tested in this study and their 
epitopes, designated Epitope 1-4, are shown in Table 3.8 (second column). In 
this study PR3G-2 was found to belong to the first epitope group. In a 
subsequent study, aimed at identifying the specific conformational surface 
epitopes recognised by a variety of monoclonal anti-PR3 monoclonal 
antibodies, this was taken a step further with PR3G-2 being shown to 
recognise a region of PR3 said to be “South East” of the substrate binding 
pocket of the molecule [209]. The antibodies tested in this study and their 
epitopes, designated Epitope 1, 3, 4 and 5 (the existance of the previously 
described Epitope 2 was not confirmed in this study while a new epitope, 
Epitope 5, was identified) are shown in the third and fourth columns of Table 
3.8. With regards patient derived PR3-ANCA, seven epitopes commonly 
bound by antibody from the sera of GPA patients have been identified [210]. 
Interestingly several of these epitopes were located in the catalytic region of 
the PR3 molecule. However, how these epitopes overlap with the antigenic 
target of PR3G-2 monoclonal antibody is unknown. Although there is no 
detailed comparison of this monoclonal antibody with patient derived anti-PR3 
IgG, it should be noted that published data has shown that PR3G-2 is capable 
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of activating isolated neutrophils to undergo respiratory burst in a manner 
similar to patient derived PR3-ANCA [81]. 
 
With regards the anti-MPO monoclonal antibody, the exact MPO binding site 
has unfortunately never been elucidated. The clone (266.6K2) used was 
developed in the nineties by IQ Products in collaboration with the University of 
Groningen, The Netherlands, with antibodies against the whole human MPO 
molecule being raised in mice. The isotype of this monoclonal antibody is 
IgG1. Although no information about the binding site is available, previous 
published data has shown that the antibody in question is capable of 
activating isolated neutrophils to undergo respiratory burst in a manner similar 




Antibody purification can be split into two main groups: precipitation methods 
and chromatographic methods. Used together these two groups can be 
effective in providing highly pure antibody solutions. Traditionally ammonium 
sulphate has been used to precipitate immunoglobulins out of plasma and 
thus produce an antibody preparation that can be further purified, using 
Protein G columns, to give a reasonably pure IgG solutions (Fig 3.6). This 
method of IgG purification is quite long, taking up to four days, and involves 
multiple precipitation and dialysis steps that may lead to loss of antibody. To 
overcome these limitations precipitation of fibrin from plasma using sodium 
chloride followed by Protein G purification was examined. This method 
resulted in antibody solutions similar in a) purity (Fig 3.7 A), b) ability to bind 
their antigen (Table 3.1), and, c) yield (Table 3.2), to those produced using the 
ammonium sulphate method. Furthermore, and for indeterminate reasons, 2 
of the 3 anti-MPO IgG solutions obtained using the sodium chloride 
precipitation method activated neutrophils to a greater extent than those 
obtained, in a side-by-side purification, using the ammonium sulphate 
precipitation method. In the case of 1 of these patient purified IgG samples 
the effect was striking. Although the sodium chloride precipitation method did 
not lead to greater antibody yields, it did halve the time required to produce a  
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binding to epitope  
[209] 
Approximate location of 
epitope [209] 
1 PR3G-2, 6A6, 
12.8, Hz1F12 
PR3G-2, 6A6, 12.8 
 
“South East” of the 
substrate binding 
pocket of PR3 
 
 
2 PR3G-4, PR3G-6, 
WGM3 
Unconfirmed as 







3 4A5, WGM2, 
PR3G-3 
4A5, WGM2,  
2E1, 1B10, 
MCPR3-3 
At the back of the PR3 




4 4A3, MCPR3-2 4A3, MCPR3-2, 
2E1, WGM2 
 
“North East” of the 
substrate binding 
pocket of PR3, 
adjacent to epitope 3 
 






At the binding site of 




Table 3.8 Monoclonal anti-PR3 antibodies and their antigenic targets as 
elucidated in two separate studies . Clone PR3G-2, the monoclonal antibody 
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pure IgG solution, while seemingly having no negative effects on the final 
antibody preparation. What is more, it may provide more effective antibody 
solutions, although overall the difference was not statistically significant in 
these experiments. Thus further work would be required to fully confirm, and 
possibly explain, if real, the reason for the difference in neutrophil respiratory 
burst activation potential of the same ANCA antibody purified using the two 
different precipitation methods. Interestingly, it is thought that neutrophil 
activation by ANCA occurs in an Fc dependent manner [71]. Therefore, and 
taking into account that there was no apparent precipitation method 
dependent difference seen in the antibodies ability to bind to its antigen (Table 
3.1), it can be speculated that a change may occur in the Fc receptor portion 
of the antibody as a result of the purification processes in question.  
 
Regardless of purification method, and as seen in Table 3.6 and 3.7, not all 
patient samples induce neutrophil respiratory burst and, of those that do, 
there is no discernible correlation between neutrophil activation potential and 
the severity of the patient’s disease. While donor variability accounts for 
inconsistencies in the ability of a single ANCA antibody solution to activate 
neutrophils day to day, this does not explain the fact that, of the ANCA 
antibodies tested, only 14% of anti-PR3 IgG solutions and 46% of anti-MPO 
IgG solutions induced notable levels of superoxide release (>10 nmol 02-/105 
neutrophils produced above control) as measured by the ferricytochrome C 
reduction assay. The DHR123 assay gave slightly better results with 
approximately 60% of both anti-PR3 and anti-MPO IgG solutions inducing 
notable levels of rhodamine 123 production (increase, over control IgG, in MFI 
of over 100). It should be noted that what constitutes notable reactive oxygen 
species production is arbitrary and is used only as a rough guide to individual 
ANCAs ability to activate neutrophils. Although few ANCA antibody solutions 
consistently failed to induce some ROS production relative to control IgG, a 
large proportion induced only very weak responses. There are many possible 
reasons for the varying ability of ANCA in activating neutrophils to undergo 
respiratory burst in vitro: 
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a) In vitro assays do not always accurately reflect what is happening in vivo. 
This is true for any cell-based assay; however, it may be a particular issue 
with regards neutrophil assays as these cells are thought to be particularly 
sensitive. It has been established that different methods of neutrophil 
isolatation lead to different expression of various neutrophil activation markers 
including CD11b, CD16 and CD32 [205]. Thus it is probable that isolated 
neutrophils behave differently to neutrophils in vivo. The development of a 
whole blood assay may help to overcome this issue and this will be further 
discussed in Chapter 4. 
 
b) It is possible that the use of whole IgG solutions leads to a number of 
problems resulting in decreased ANCA induced responses. Firstly, the 
percentage of IgG that is anti-PR3 or anti-MPO specific in any given sample is 
unknown. Therefore, it is possible that patient purified ANCA samples that 
induce strong neutrophil responses do so simply because they are composed 
of a higher proportion of anti-PR3 or anti-MPO IgG. Secondly, irrelevant IgG 
in the solutions may bind to Fc receptors required for ANCA activation; 
thereby blocking them, and thus inhibiting ANCA induce responses. Both of 
these issues could be overcome by affinity purifying the anti-PR3 and anti-
MPO antibodies. Finally, the IgG purified from patients may differ in regards to 
its subclass, epitope specificity and affinity; thereby leading to differences in 
its ability to interact with neutrophils. Of the four IgG subclasses found in 
humans, three are commonly associated with ANCA. These are IgG1, IgG3 
and IgG4. IgG3 is considered the most pathogenic [211], with levels shown to 
correlate with disease activity [212]. Furthermore, IgG3 has been suggested to 
be the predominate IgG subclass found in renal limited ANCA associated 
vasculitis [213] and in PR3-ANCA induced disease [214, 215]. However, other 
studies have suggested that it is IgG1 and IgG4 that predominate in PR3-
ANCA associated vasculitis [216] and ANCA associated vasculitis as whole 
[213, 214]. Although patient studies have not provided a clear answer, in vitro 
studies, using monoclonal mouse/human IgG1, IgG3 and IgG4 anti-PR3 
antibodies, have shown that these different IgG subclasses affect neutrophils 
in difference ways [217-219]. Indeed, while anti-PR3 antibodies of all three 
subclass were able to induce neutrophil adhesion, superoxide release and 
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degranulation [217-219], only IgG1 and IgG3 could induce IL-8 release [217, 
218]. Futhermore, IgG1 was shown to induce higher levels of degranulation 
[217], while IgG3 appeared to induce greater adhesion and IL-8 release [217, 
219]. With regards epitope specificity, it is interesting to note that there are 
currently no studies detailing the exact pathogenic potential of the antigenic 
target of anti-PR3 or anti-MPO antibodies. However, current data does 
suggest that different patients with GPA have PR3-ANCA that recognised 
different antigenic targets on PR3 [210]. Importantly, it is likely that this also 
holds true for MPA, with different patients having MPO-ANCA that recognises 
different MPO epitopes. Indeed, it has been suggested that this may 
contribute to the differences in disease, with regards severity and affected 
organs, seen among patients [210]. 
 
Thus it is possible that although a number of the patient antibodies tested 
were unable to induce significant reactive oxygen species production, they 
may be capable of inducing other neutrophil response, dependent on the the 
predominant IgG subclass present and their exact antigenic target. 
 
c) It is possible that the role of ANCA in disease pathogenesis is not related to 
its ability to activate the neutrophil respiratory burst. ANCA has also been 
shown to induce neutrophil degranulation [14, 16] as well as the release of 
proinflammatory cytokines [17] and it is possible that it is through these effects 
that ANCA mediates endothelial cell damage and thus disease. This is 
supported by a recent abstract [220] suggesting that respiratory burst deficient 
mice are not, as one would expect, protected from disease but in fact develop 
a more severe form of disease when compared with wildtype controls. If this is 
the case it may simply be coincidence that some ANCA are capable of 
inducing ROS production. 
 
d) There is ample in vivo evidence to suggest that ANCA are pathogenic. For 
the majority of patients ANCA levels correlate with disease activity, with the 
risk of relapse for patients persistently negative for ANCA being extremely low 
[8]. Furthermore, there was a recent report that the transplacental transfer of 
MPO-ANCA from a mother to a 33-week gestational age neonate resulted in 
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neonatal pulmonary haemorrhage and renal involvement, thus suggesting that 
anti-MPO antibodies are indeed pathogenic [221]. Finally, anti-MPO 
antibodies in mice result in a focal necrotising cresentic glomerulonephritis 
[92, 95]. While the in vivo evidence for ANCA pathogenicity is compelling, it is 
possible that this is not the whole story. In vitro, the ANCA induced neutrophil 
respiratory burst response requires the neutrophils to be primed with TNFα, 
and in the case of the ferricytochrome C reduction assay, cytochalasin B. 
While the need for TNFα can be explained by the hypothesis that 
proinflammatory stimulus in vivo is necessary for the translocation of ANCA 
antigens to the surface of neutrophils [14, 16], cytochalasin B is a cell-
permeable mycotoxin and therefore not native to humans. This, together with 
the fact that the majority of patient purified ANCA induces only weak 
neutrophil responses, suggests that there are other as yet unidentified factors 
involved in neutrophil activation in vivo and this may be an important avenue 
for future work. One such factor that has been suggested is the patient 
neutrophils themselves, with patients with active disease being shown to have 
higher neutrophil membrane ANCA antigen expression [16, 222, 223]. 
 
Despite these concerns, and taking into account the large body of published 
data showing that ANCA are pathogenic, the isolated ANCA capable of 
activating neutrophils to undergo respiratory burst were used to further study 
mechanisms of ANCA induced neutrophil activation. This will be discussed in 
the following chapter. 
 
IgG purification: Endotoxin contamination 
 
Endotoxin contamination is an important issue when purifying IgG solutions 
for use in both in vitro and in vivo experiments, as endotoxin has the potential 
to activate cells and thus lead to erroneous results. Therefore, throughout the 
purification process, every effort was made to ensure that all IgG preparations 
remained endotoxin free. Further to this, and where possible, only endotoxin 
free reagents, including endotoxin free 10 x PBS, tissue culture grade 
endotoxin free water and endotoxin free salts, were purchased, and every 
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effort was made to ensure that these remained endotoxin free, primarily 
through limited use and aseptic technique. Where large volumes of water 
were required, for example to make up 5 litres of PBS for dialysis, Millipore 
Ultrapure filtered water was used. In addition, all glassware was baked, over 
night, in a dry heat oven, and spinbar magnetic stirring fleas and dialysis 
membrane clips were stored in sodium hydroxide, in order to denature any 
contaminating endotoxin. Once purified, IgG preparations were immediately 
aliquoted and stored at -20ºC to prevent the possibly of endotoxin 
contamination in the time between purification and use. 
 
Despite these efforts, and as endotoxin was not tested for, it is impossible to 
state that all IgG preparations were in fact endotoxin free. However, control 
IgG, treated in the same manner as patient derived IgG, failed, once the 
assays were properly established, to activate neutrophils above unstimulated 
controls. Thus control IgG acted not only as a control for irrelevant IgG 
induced activation of neutrophils, but also as a control for neutrophil activation 
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4.1 Introduction 
 
Neutrophil activation by ANCAs is dependent on their ability to bind to their 
target antigens. For this to occur ANCA must be internalised by the 
neutrophils, or as evidence suggests (reviewed in Chapter 1), PR3 and MPO 
must be present on the cell surface. It is also possible that both may occur. In 
addition to this, the ability of ANCA to activate neutrophils in vitro is 
dependent on neutrophil priming, a process through which exposure to a 
priming agent, frequently a cytokine, increases the response of neutrophils to 
an activating stimulus. In the case of ANCA activation, priming is primarily 
thought to induce antigen translocation to the surface of the neutrophils, thus 
making it available to interact with the ANCA. However, it may also activate 
various molecules, such as NADPH oxidase, thus preparing the way for 
ANCA induced neutrophil activation [224]. TNFα is the most commonly used 
priming agent in in vitro ANCA assays, however, IL1, IL6, IL18, fMLP and C5a 
have also been used to prime for an ANCA induced neutrophil response [14, 
16, 88, 225].  
 
Granulocyte colony stimulating factor (GCSF) is a cytokine produced by a 
variety of cells types including neutrophils, monocytes, platelets and 
endothelial cells. It is a potent haematopoietic factor that stimulates 
granulopoiesis, as well as mobilising mature neutrophils from the bone 
marrow storage pool into the circulation [226]. The GCSF receptor is formed 
by a homodimer of the CD114 protein [227], and, like the other members of 
the haematopoietin superfamily, lacks intrinsic tyrosine kinase activity. Thus, 
the GCSF receptor, upon the binding of its ligand, recruits cytoplasmic 
tyrosine kinases, including members of the Janus kinase and Src families, 
and through these activates intracellular pathways such as the Janus 
kinase/signal transducer and activator of transcription (JAK/STAT) pathway, 
the phosphatidylinositol-3 kinase pathway and the mitogen-activated protein 
kinase (MAPK) pathway [228]. The GCSF receptor is highly expressed by 
neutrophils, and is also found on monocytes, eosinophils, some T- and B-cells 
lines and several non-haematopoietic cells including endothelial, placental 
and trophoblastic cells [227]. Interestingly, GCSF receptor expression has 
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been shown to be decreased in neutrophils during infection [228]. 
Furthermore, patients with chronic myelogenous leukaemia have been shown 
to express relatively low levels of the GCSF receptor when compared to 
healthy controls [229].  
 
There is evidence suggesting that, in addition to regulating neutrophil 
production, GCSF also induces functional changes [230]. Neutrophils treated 
with GCSF in vitro have been shown to have increased levels of adhesion 
molecules, enhanced chemotactic responses and greater phagocytic activity 
[231-235]. Furthermore, GCSF has been shown to increase neutrophil 
microbicidal activities [235] and antibody-mediated cellular cytotoxicity [236]. 
Finally, GCSF has been show to prime for a respiratory burst due to fMLP in 
some [231] but not all [237] studies. In addition to priming neutrophils in vitro, 
the administration of GCSF to both patients and healthy controls in vivo has 
been shown to enhance neutrophil phagocytosis, superoxide generation and 
bacterial killing [238]. Therefore, a possible role for GCSF in ANCA 
associated vasculitis was examined. The serum levels of GCSF in patients 
with active ANCA vasculitis were significantly higher that those of aged 
matched healthy controls (mean 38.9 vs 16.5 pg/ml, p<0.001) [239], while in 
an anti-MPO antibody transfer model of vasculitis, mice given GCSF had 
significantly greater disease compared to controls [239]. These data suggest 
that GCSF may play a role in exacerbating disease in ANCA vasculitis and in 
this chapter it is considered whether GCSF may prime neutrophils for a 
response to ANCA. 
 
Phosphoinositol 3-kinases (PI3Ks) are members of a conserved family of 
intracellular lipid kinases that play a key role in many signal transduction 
pathways. There are three classes of PI3Ks defined, each of which has a 
distinct role [240]. It is the Class I PI3Ks that are thought to be key 
components of the neutrophil signal transduction network [241]. Class I PI3Ks 
are further divided into two subfamilies based on the receptors to which they 
are coupled. Class IA PI3Ks are primarily activated through protein tyrosine 
kinase receptors [242], however there is evidence that they may also be 
activated by G protein coupled receptors (GPCR) [243]. Class IB PI3Ks are 
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activated by GPCRs [244]. Both classes produce phosphatidylinositol 3,4-
bisphosphate (PI[3,4]P2) and phosphatidylinositol (3,4,5)-triphosphate (PIP3), 
which are recognised by a variety of effector proteins and thus begin 
signalling cascades that culminate in various neutrophil responses including 
chemotaxis [83-85], phagocytosis [245], cells spreading [246] and the 
production of reactive oxygen species [247]. Class IA PI3Ks are composed of 
a homologous p85 family catalytic subunit and a p110α (PI3Kα), p110β 
(PI3Kβ) or p110δ (PI3Kδ) regulatory subunit [248], while class IB PI3Ks are 
heterodimers of a p110γ (PI3Kγ) catalytic subunit and a p101 or p84 
regulatory subunit [249]. The specific role of PI3Kα and PI3Kβ in neutrophils 
is just beginning to be elucidated.  A recent study has shown that PI3Kα 
inhibition significantly reduced reactive oxygen species production by 
neutrophils in response to both fMLP and TNFα [250]. Furthermore, a 
reduction in PI3Kα RNA and protein expression in healthy humans placed on 
a fish oil and borage oil supplemented diet, correlated with decreased ex vivo 
leukotriene B4 and IL1β production by neutrophils, thus suggesting a potential 
role for PI3Kα in proinflammatory cytokine production [251]. With regards 
PI3Kβ, a recent report indicates that in mouse neutrophils, PI3Kβ and PI3Kδ 
are necessary for neutrophil spreading and oxidase activation in response to 
Aspergillus fumigatus hyphae [252]. In addition, PI3Kβ has been shown to be 
essential for the FcγR-dependent activation of mouse neutrophils by immune 
complexes [253]. Furthermore, PI3Kβ-deficient mice were protected in an 
FcγR-dependent model of autoantibody-induced skin blistering and partially 
protected in an FcγR-dependent model of inflammatory arthritis [253]. The 
role of PI3Kδ in neutrophils is better understood with this isoform being shown 
to have roles in the generation of reactive oxygen species [250, 254, 255], the 
release of elastase from neutrophil granules [255] and in neutrophil 
chemotaxis [256-258]. Similarly, the role of PI3Kγ in neutrophil chemotaxis 
[83-85, 259, 260], cells spreading [246] and the production of reactive oxygen 
species [247, 254, 261, 262] has been well established. 
 
In vitro data using PI3K inhibitors [75, 76], together with data showing the 
importance of signalling molecules downstream of the PI3Ks [75, 76, 79], 
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have identified them as a possible key signalling molecules in ANCA 
associated vasculitis pathogenesis. The majority of research to date has been 
focused on the role of PI3Kγ. However, given the emerging roles of Class IA 
PI3Ks in neutrophil activation, a potential role for PI3Kβ/δ in ANCA induced 
neutrophil activation was examined in this chapter. 
 
In this chapter the expression of both PR3 and MPO on the surface of whole 
blood neutrophils and monocytes was examined. The development of a whole 
blood ANCA induced respiratory burst assay was briefly considered. A 
possible role for GCSF in priming neutrophils for an ANCA induced respiratory 
burst was demonstrated and, finally, PI3Kβ/δ was implicated in ANCA induced 




• To examine ANCA antigen expression on the surface of whole blood 
neutrophils and monocytes 
• To determine if GCSF plays a role in priming neutrophils for ANCA 
induced respiratory burst 
• To determine if PI3Kβ/δ may play a role in the ANCA induced 
respiratory burst 
 
4.3 Methods  
 
All blood and plasma samples, from both patients or healthy controls, were 
taken with informed consent and ethical approval (NRES committee London—
London Bridge 09/H084/72) 
 
4.3.1 Flow cytometry 
 
Flow cytometry was performed as described in Section 2.2.1 with some 
modifications. Briefly, human whole blood was not blocked as the presence of 
native antibody in the plasma made this step unnecessary. Whole blood was 
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stained immediately or incubated at 37°C in the presence of 2ng/ml TNFα or 
incubated at 37°C without further priming. Whole blood incubated at 37°C was 
cooled on ice for 5-10 minutes before being stained at room temperature. Red 
cells were lysed using BD FacsLyse as previously described. 
The antibodies used are shown in Table 4.1. Anti-PR3 FITC and the FITC 
isotype control were used at 2µg/ml. Anti-MPO APC and the APC isotype 
control where used at 4µg/ml. The anti-CD14 antibodies were both used at 
the recommended concentration (20µl/100µl of blood).  
 
Target Isotype Clone Fluorophore  Supplier Dilution 
PR3 Mouse IgG1, κ PR3G-2 FITC Hycult 1:50 
Control Mouse IgG1, κ MOPC-21 FITC Biolegend 1:250 
MPO Mouse IgG1, κ MPO-7 APC Dako 1:12.5 
Control Mouse IgG1, κ MOPC-21 APC Biolegend 1:50 
CD14 Mouse IgG2a, κ M5E2 PE BD 1:6 
CD14 Mouse IgG2a, κ M5E2 APC BD 1:6 
 
Table 4.1 Anti-human antibodies used for flow cytometry. All antibodies were 
obtained from commercial sources.  
 
4.3.2 Superoxide dismutase inhibitable ferricytochrome C reduction 
assay 
 
Neutrophils were isolated from either sodium citrate or lithium heparin anti- 
coagulated blood using Polymorphprep or Ficoll as described in Section 
2.2.6.1 and 2.2.6.2, respectively. The assay was performed as described in 
Section 2.2.7.1. For the PI3Kβ/δ inhibition experiments cells were primed with 
TNFα for 15 minutes at 37°C before being pre-incubated with various 
concentrations of TGX-221 (Cayman Chemicals, Michigan, USA) for 5 
minutes. The appropriate concentration of inhibitor was added, diluted in 
HBH, together with the appropriate stimuli to the wells of the 96 well plates 
before the addition of the cells. As the TGX-221 was dissolved in ethanol, an 
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equal concentration of ethanol was added both to the cells and to the wells 
that did not have inhibitor, to serve as a vehicle control. 
 
4.3.3 DHR123 assay 
 
Neutrophils were isolated from heparinised blood using Ficoll as described in 
Section 2.2.6.2, with assays being performed as described in Section 2.2.7.2. 
For the GCSF priming assays the rhodamine 123 production, and by 
extension the reactive oxygen species production, was determined as follows: 
The median fluorescent intensity (MFI) of the unprimed/GCSF primed control 
sample was subtracted from the MFI of the unprimed/GCSF primed ANCA 
stimulated sample. This was to compensate for any non-specific rhodamine-
123 production. This number was then divided by the MFI of the unprimed 
unstimulated cells. As the flow cytometer settings were not kept constant 
between donors, this was necessary to standardise the results and thus allow 
comparison.  
 
For whole blood assays, heparinised blood was taken and assays were 
carried out as follows: Whole blood was loaded with 70µg/ml DHR123 
together with 5µg/ml cytochalasin B and 2 mM sodium azide. This was 
incubated in the dark for 10 minutes at 37˚C. Blood was incubated with or 
without 2ng/ml TNFα for 30 minutes at 37˚C with gentle mixing at 5 minute 
intervals. 100µl of blood was added to each FACS tube and stimulated with 
5µg/ml monoclonal anti-PR3 or anti-MPO IgG for 1 hour at 37˚C. Control IgG 
was used as a negative control and fMLP as a positive control for cell 
activation. The reaction was stopped by incubation on ice for 5-10 minutes. 
The blood was then stained with CD14 APC at 20µl/100µl of blood to allow 
monocytes to be identified. Red cells were lysed using BD FACSLyse as 
previously described. The remaining cells were finally resuspended in a small 
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4.3.4 Determining the effect of GCSF on mouse neutrophil activation 
 
Mice were bled from the saphenous vein four days after injection with 30µg 
human pegylated GCSF (Neulasta®, from Amgen, Cambridge, UK) or PBS.  
They were then injected intraperitoneally with control PBS or with 10µg of 
LPS from E. coli, Serotype R515 (Enzo Life Sciences), and bled again from 
the saphenous vein 2 hours later. Flow cytometry was performed as 
described in Section 4.3.1 and using the antibodies shown in Table 4.2. 
 
Target Isotype Clone Fluorophore  Supplier Dilution 
Ly6G Rat (Lew) IgG2b, κ  IA8 Alexafluor700 BD 1:200 
CD11b Rat (Lew) IgG2b, κ M1/70 FITC BD 1:100 
CD11c Hamster IgG N418 PE BD 1:62.5 
CD62L Rat IgG2a, κ MEL-14 Pacific Blue Biolegend 1:80 
 
Table 4.2 Anti-mouse antibodies used for flow cytometry. All antibodies were 




Statistics were performed using Graphpad Prism software (Graphpad 
Software Inc, La Jolla, CA, USA). Data was analysed using paired t tests or 




I would like to thank Dr. Reena Popat  for her assistance in gathering the 
data, she kindly performed the experiments on 4 of the donors, presented in 
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4.4 Results: ANCA antigens are expressed on the surface of whole 
blood neutrophils and monocytes 
 
4.4.1 PR3 and MPO are present on the surface of whole blood 
neutrophils and monocytes 
 
Several studies have demonstrated, using flow cytometry, that PR3 is 
expressed on the surface of isolated neutrophils that have been primed with 
TNFα, and this was confirmed (Fig 4.1. A). Furthermore, the typical bimodal 
pattern of PR3 expression was present. Similarly, MPO has been shown to be 
expressed on the surface of TNFα primed neutrophils that have been isolated 
from whole blood, and this was also confirmed (Fig 4.1. B) As discussed in 
Chapter 3, however, neutrophils are thought to be particularly sensitive cells 
and it has been shown that different methods of neutrophil isolatation lead to 
different expression of various neutrophil activation markers. It is therefore 
possible that the isolation of neutrophils also changes their expression of 
membrane bound PR3 and MPO. In order to test this, blood was taken from a 
number of healthy volunteers and either stained immediately or after 
incubation at 37°C with or without 2ng/ml TNFα. As whole blood was used it 
was possible to examine PR3 and MPO expression on the surface of both 
neutrophils (Fig 4.2 and 4.3) and monocytes (Fig 4.4 and 4.5). Neutrophils 
were identified based on their forward and side scatter profile, while 
monocytes were identified as CD14 expressing cells. Whole blood, resting 
neutrophils, in this case defined as cells that had been stained as soon as the  
blood was taken, expressed PR3 on their membranes (Fig 4.2. B). Incubation 
at 37°C marginally increased the surface expression of PR3 (Fig 4.2. C), 
while priming with TNFα appeared to downregulate membrane PR3 
expression (Fig 4.2. D), both when compared to neutrophils incubated at 37°C 
(*p<0.05), and interestingly, with resting neutrophils (Fig 4.2 A). With regards 
to the whole blood monocytes, PR3 was expressed on the membranes of 
both resting (Fig 4.4. B), and primed, cells (Fig 4.4. C, D). Notably, priming 
with TNFα, and not incubation at 37°C alone, appeared to increase the levels 
of membrane bound PR3, although this did not quite significance (p<0.0629 
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using a paired t test, Fig 4.4. A). MPO was expressed on the surface of whole 
blood, resting neutrophils (Fig 4.3. B), and to a similar level, on neutrophils 
that had been incubated at 37°C for 30 minutes (Fig 4.3 C). Interestingly, the 
expression level of membrane MPO was significantly decreased following 
incubation with TNFα (p<0.01, Fig 4.3 A, B). Whole blood monocytes in 
contrast to neutrophils whether resting, incubated, or primed with TNFα, 
expressed only very low levels of membrane MPO (Fig 4.5 A-D). 
 
4.4.2. ANCA does not induce whole blood neutrophils to undergo 
respiratory burst 
 
Having identified PR3 and MPO on surface of whole blood neutrophils and 
monocytes, the next step was to determine if an ANCA induced whole blood 
respiratory burst assay could be established. Blood was taken from healthy 
volunteers and a whole blood DHR123 flow cytometry based assay was 
carried out either without (Fig 4.6 A, Fig 4.7 A) or with (Fig 4.6 B, Fig 4.7 B) 
TNFα priming as described in Section 4.3.3. Although both whole blood 
neutrophils (identified based on their forward and side scatter) (Fig 4.6) and 
monocytes (defined as CD14 positive cells) (Fig 4.7) underwent a respiratory 
burst in response to fMLP, neither cell type responded to anti-PR3 or anti-
MPO ANCA.  
 
4.5. Results: GCSF primes neutrophils for an anti-MPO IgG but not an 
anti-PR3 IgG induced respiratory burst  
 
4.5.1 Superoxide production by ANCA stimulated neutrophils is not 
increased by GCSF priming 
 
Neutrophils were isolated from sodium citrate anti-coagulated blood using 
Polymorphprep and the effect of priming with TNFα, GCSF or both together 
on ANCA induced superoxide release was examined using the 
ferricytochrome C reduction assay. Neutrophils were incubated at 37°C for 15 
minutes with or without 2ng/ml TNFα, 50ng/ml GCSF or both together before 
stimulation with either a commercial monoclonal anti-PR3 (Fig 4.8) or  
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Figure 4.1 PR3 and MPO expression on the surface of isolated neutrophils. 
Neutrophils were isolated from EDTA anti-coagulated whole blood, taken from 
a healthy volunteer, using Polymorphprep. (n=1) They were primed with 
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Figure 4.2 PR3 expression on the surface of whole blood neutrophils. EDTA 
anti-coagulated whole blood from heathly volunteers (n=4) was either stained 
immediately or incubated at 37˚C for 30 minutes with or without 2ng/ml TNFα. 
Red cells were lysed using BDFacsLyse. (A) Shows the results from 4 
separate experiments with the median of each group shown by the horizontal 
line, while (B-D) show representative graphs. Arbitrary units were obtained 
from the median fluorescence intensities (MFI) of the PR3 positive population 
minus the MFI of the negative isotype control population.  * p<0.05. Data were 
logarithmically transformed and analysed using a paired t test. 
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Figure 4.3 MPO expression on the surface of whole blood neutrophils. EDTA 
anti-coagulated whole blood from heathly volunteers (n=5) was either stained 
immediately or incubated at 37˚C for 30 minutes with or without 2ng/ml TNFα. 
Red cells were lysed using BDFacsLyse. (A) Shows the results from  between 
3 and 5  separate experiments with the median of each group shown by the 
horizontal line, while (B-D) show representative graphs. Arbitrary units were 
obtained from the median fluorescence intensities (MFI) of the MPO positive 
population minus the MFI of the negative isotype control population.  
** p< 0.01. Data was analysed using a paired t test.  
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Figure 4.4 PR3 expression on the surface of whole blood monocytes. EDTA 
anti-coagulated whole blood from heathly volunteers (n=4)  was either stained 
immediately or incubated at 37˚C for 30 minutes with or without 2ng/ml TNFα. 
Red cells were lysed using BDFacsLyse. (A) Shows the results from 4 
separate experiments with the median of each group shown by the horizontal 
line, while (B-D) show representative graphs. Arbitrary units were obtained 
from the median fluorescence intensities (MFI) of the PR3 positive population 
minus the MFI of the negative isotype control population.  
Data was analysed using a paired t test. 
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Figure 4.5 MPO expression on the surface of whole blood monocytes. . EDTA 
anti-coagulated whole blood from heathly volunteers (n=5)  was either stained 
immediately or incubated at 37˚C for 30 minutes with or without 2ng/ml TNFα. 
Red cells were lysed using BDFacsLyse. (A) Shows the results from between 
3 and 5 separate experiments with the median of each group shown by the 
horizontal line, while (B-D) show representative graphs. Arbitrary units were 
obtained from the median fluorescence intensities (MFI) of the MPO positive 
population minus the MFI of the negative isotype control population. Data 
were analysed using a paired t test. 
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Figure 4.6 Whole blood neutrophils are capable of undergoing respiratory 
burst in response to fMLP but not ANCA as measured by the conversion of 
DHR123 into fluorescent rhodamine-123. Heparinised whole blood was 
primed at 37˚C (A) without or (B) with 2ng/ml TNFα before stimulation with 
either fMLP or 5µg/ml human monoclonal anti-PR3 (n=1) or anti-MPO IgG 
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Figure 4.7 Whole blood monocytes are capable of undergoing respiratory 
burst in response to fMLP but not ANCA as measured by the conversion of 
DHR123 into fluorescent rhodamine-123. Heparinised whole blood was 
primed at 37˚C (A) without or (B) with 2ng/ml TNFα before stimulation with 
either fMLP or 5µg/ml monoclonal human anti-PR3 (n=1) or anti-MPO IgG 
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Figure 4.8 The role of GCSF and TNF in the priming of the ANCA induced 
superoxide release as measured by the superoxide dismutase inhibitable 
reduction of ferricytochrome C. Unprimed, TNFα primed, GCSF primed or 
TNFα and GCSF primed neutrophils isolated from sodium citrate anti-
coagulated blood using Polymorphprep were stimulated with 5µg/ml of 
monoclonal human anti-PR3 IgG (n=1) or a relevant control. (A) Shows the 
results from 3 separate experiments with the median of each group shown by 
the horizontal line. Arbitrary units were obtained by subtracting the amount of 
O2-  produced following the stimulation of neutrophils with the isotype control 
from the amount of O2-  produced following stimulation of neutrophils with the 
anti-PR3 antibodies. (B) Shows a representative graph. Data was analysed 
using a repeated measures ANOVA with a Dunnett’s post test and are 
presented as mean values ± SEM of triplicate wells. 
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anti-MPO (Fig 4.9) antibody. An IgG isotype control was included to discount 
non-specific superoxide production. TNFα primed neutrophils consistently 
produced greater amounts of superoxide in response to anti-PR3 IgG than 
either unprimed or GCSF primed cells, although this did not reach statistical 
significance (Fig 4.8. A). There was no synergistic effect of TNFα and GCSF 
observed. In fact the neutrophils of 2 of the 3 donors produced slightly less 
superoxide when compared to those primed with TNFα alone, although the 
difference was minimal. Similarly, anti-MPO IgG stimulated neutrophils that 
had been primed with TNFα induced significantly more superoxide than those 
that were unprimed (p<0.01) or primed with GCSF (p<0.05). Again, there was 
no synergistic effect of TNFα and GCSF observed (Fig 4.9. A). Interestingly, 
the GCSF primed neutrophils of 2 out of 3 donors produced more superoxide 
than the unprimed neutrophils when stimulated with anti-MPO IgG. 
 
4.5.2 GCSF primes neutrophils for an anti-MPO IgG but not an anti-PR3 
IgG induced respiratory burst  
 
For the DHR123 assay neutrophils were isolated from heparinised whole 
blood using the Ficoll method described in Section 2.2.6.2. Isolated 
neutrophils were incubated at 37°C for 15 minutes with or without 50ng/ml  
GCSF, or 2ng/ml TNFα, before stimulation with either a commercial 
monoclonal anti-PR3 (Fig 4.10) or anti-MPO (Fig 4.11) antibody. Of the 8 
donors assessed only 3 showed an increase in anti-PR3 IgG induced 
rhodamine 123 production as a result of GCSF priming, while all showed an 
increase in response to TNFα (Fig 4.10).  In contrast, 5 out of 8 donors 
assessed had a noticeable increase in anti-MPO IgG induced rhodamine-123 
production as a result of GCSF priming. Overall there was a significant 
increase in intracellular reactive oxygen species production as a result of 
priming the neutrophils with GCSF before stimulation with anti-MPO IgG 
(p<0.05, Fig 4.11). Once again neutrophils from all donors showed elevated 
rhodamine 123 production in response to TNFα. The data for all 8 donors is 
shown in Figure 4.10 A, and a representative histogram is shown in Figure 
4.11 B. To determine whether the effect of GCSF priming on the ANCA  
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Figure 4.9 The role of GCSF and TNF in the priming of the ANCA induced 
superoxide release as measured by the superoxide dismutase inhibitable 
reduction of ferricytochrome C. Unprimed, TNFα primed, GCSF primed or 
TNFα and GCSF primed neutrophils isolated from sodium citrate anti-
coagulated blood using Polymorphprep were stimulated with 10µg/ml of 
monoclonal human anti-MPO IgG (n=1) or a relevant control. (A) Shows the 
results from 3 separate experiments with the median of each group shown by 
the horizontal line. Arbitrary units were obtained by subtracting the amount of 
O2-  produced following the stimulation of neutrophils with the isotype control 
from the amount of O2-  produced following stimulation of neutrophils with the 
anti-PR3 antibodies. (B) Shows a representative graph. **p<0.01. Data was 
analysed using a repeated measures ANOVA with a Dunnett’s post test and 
are presented as mean values ± SEM of triplicate wells. 
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Figure 4.10 The role of GCSF and TNF in the priming of the ANCA induced 
respiratory burst as measured by the conversion of DHR123 into fluorescent 
rhodamine-123. Unprimed, GCSF primed and TNFα primed neutrophils 
isolated from heparinised blood using Ficoll and red cell lysis were stimulated 
with 5µg/ml of monoclonal human anti-PR3 IgG (n=1) or a relevant control. 
(A) Shows the results from 8 separate experiments with the median of each 
group shown by the horizontal line, while (B) shows a representative graph. 
Arbitrary units were obtained from the median fluorescence intensities (MFI) 
as indicated in the figure, with data normalised for the MFI of unstained 
unstimulated cells in each experiment. Data was analysed using a paired t 
test. 
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Figure 4.11 The role of GCSF and TNF in the priming of the ANCA induced 
respiratory burst as measured by the conversion of DHR123 into fluorescent 
rhodamine-123. Unprimed, GCSF primed and TNFα primed neutrophils 
isolated from heparinised blood using Ficoll and red cell lysis were stimulated 
with 1.25 µg/ml of monoclonal human anti-MPO IgG or a relevant control. (A) 
Shows the results from 8 separate experiments with the median of each group 
shown by the horizontal line, while (B) shows a representative graph. Arbitrary 
units were obtained from the median fluorescence intensities (MFI) as 
indicated in the figure, with data normalised for the MFI of unstained 
unstimulated cells in each experiment. *p<0.05. Data was analysed using a 
paired t test. 
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induced response was limited to the specific monoclonal antibodies used, IgG 
purified from anti-PR3 and anti-MPO ANCA positive patients was also tested. 
Figure 4.12 shows the result of 8 separate ANCAs, 4 purified from anti-PR3 
ANCA positive patients and 4 purified from anti-MPO ANCA positive patients. 
Data is taken from 2 donors. Patient ANCA induced greater rhodamine-123 
production in neutrophils primed either with TNFα or the combination of TNFα 
and GCSF, although there was no synergistic effect observed. In Figures 4.12 
A and C, which show data from the same donor, none of the ANCA used 
induced a greater response when added to GCSF primed neutrophils as 
compared to unprimed neutrophils. Conversely, using a different donor, all 
ANCA induced greater rhodamine 123 production, although in most cases the 
difference was very small and no statistical significance was reached. There 
was no difference seen between anti-PR3 antibodies and anti-MPO 
antibodies in these experiments. 
 
4.5.3 GCSF priming does not alter the surface expression of PR3 or MPO 
 
Neutrophils were isolated from heparinised whole blood using the Ficoll 
method described in Section 2.2.6.2. Isolated neutrophils were then prepared 
in the same manner as those used in the respiratory burst assays examining 
GCSF priming; that is they were incubated at 37°C for 15 minutes with or 
without 50ng/ml GCSF, or 2ng/ml TNFα, before staining with commercial anti-
PR3 and anti-MPO antibodies designed for flow cytometry. The neutrophil 
donors in for this experiment were chosen based on their strong response to 
GCSF priming in the experiments described in the previous section.  
GCSF priming had no effect on the surface expression of either PR3 or MPO 
under these conditions (Fig 4.13 A-B). In contrast, and for 3 out of 3 donors, 
TNFα priming led to the upregulation of both enzymes on the surface of the 
isolated neutrophils (Fig 4.13 B). Of note, once again, PR3 displayed a 
bimodal pattern of expression (Fig 4.13 A). 
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Figure 4.12 The role of GCSF and TNF in the priming of the ANCA induced 
respiratory burst as measured by the conversion DHR123 into fluorescent 
rhodamine-123. Unprimed, TNFα primed, GCSF primed or TNFα and GCSF 
primed neutrophils isolated from heparinised blood using Ficoll and red cell 
lysis were stimulated with 200µg/ml human ANCA.(n=8). V14, V16, V18 and 
V21 refer to separate patient derived anti-PR3. antibodies V20, V33, V41 and 
V45 refer to patient derived anti-MPO antibodies. Plots on the right are 
representative. (A, C) show data from the same donor on different days. (B) 
shows data from a separate donor. Arbitrary units were obtained from the 
median fluorescence intensities (MFI) as indicated in the figure, with data 
normalised for the MFI of unstained unstimulated cells in each experiment. 
The dot plots show the median activation (horizontal line). 
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Figure 4.13 The effect of GCSF on the expression of ANCA antigens. 
Neutrophils were isolated from heparinised blood, drawn from healthy 
volunteers (n=3), using Ficoll and red cell lysis. They were unprimed, GCSF 
primed or TNFα primed before being stained for (A) PR3 or (B) MPO surface 
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4.5.4 GCSF primes mouse neutrophils in vivo 
 
In addition to priming human neutrophils in vitro, the ability of GCSF to prime 
mouse neutriphils in vivo was also examined. Wildtype mice were divided into 
4 groups, as indicated in Figure 4.14. Each group was either treated with 
30µg of human pegylated GCSF, or a PBS control. After 4 days the mice 
given either 10µg LPS, or a PBS control. Two hours later the mice were bled 
and the expression of CD11b, CD11c and CD62L on their neutrophils was 
assessed. LPS but not GCSF treatment was shown to upregulate CD11b 
expression on mouse neutrophils (Fig 4.14 A). Importantly, there was no 
synergistic effect observed as a result of treatment with both GCSF and LPS.  
In contrast, CD11c was upregulated in mice given GCSF, either alone or in 
combination with LPS, but not in mice given LPS alone (Fig 4.14 B). Indeed, 
in mice given only LPS, CD11c levels were no different from that seen in 
control-treated mice, showing that this upregulation was due to the effect of 
GCSF. Finally, GCSF and LPS, both individually and in combination, led to 
to the shedding of CD62L from the surface of mouse neutrophils (Fig 4.14 C) 
 
4.6 Results: PI3Kβ/δ  blockade inhibits both ANCA and fMLP induced 
superoxide release as measured by the superoxide dismutase 
inhibitable reduction of ferricytochrome C 
 
Neutrophils were isolated from heparinised blood drawn from healthy 
volunteers and using Ficoll as described. They were treated with 1000nM 
TGX-221, a PI3Kβ/δ  inhibitor, and stimulated with one of the following: 5µg/ml 
human monoclonal anti-PR3 IgG, 10µg/ml human monoclonal anti-MPO IgG, 
10µg/ml human IgG isotype control or 5µg/ml fMLP. It should be noted here 
that the viability of the cells treated with TGX-221 was not assessed at any 
point, and this will be discussed in the following section. TGX-221, at 1000nM, 
completely abolished superoxide release in response to anti-PR3 IgG (Fig 
4.15 A) and anti-MPO IgG (Fig 4.15 B). The fMLP induced response was 
partially inhibited at this concentration of TGX-221 (Fig 4.15 C). To determine 
whether the effect of TGX-221 on the ANCA induced superoxide release was  
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Figure 4.14 The effect of GCSF on mouse neutrophils in vivo. Mice were 
treated with PBS or GCSF for 4 days and then given either LPS or PBS, with 
blood taken 2 hours later. The 4 groups, each containing 4 mice, were treated 
as is indicated in the figure. Following treated the mice were culled and the 
expression of (A) CD11b, (B) CD11c and (C) CD62L on their neutrophils was 
assessed. Expression levels were obtained after gating on Ly6G+ cells. Data 
from individual mice, with the median of each group shown by the horizontal 
line, and a representative flow cytometry plot for each marker is shown. * 
p<0.05, **p<0.01, ***p<0.001. Data was analysed using a one-way ANOVA 
with a Tukey’s multiple comparison post test. 
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Figure 4.15 TGX-221 inhibits both ANCA and fMLP induced superoxide 
release as measured by the superoxide dismutase inhibitable reduction of 
ferricytochrome C. TNFα primed neutrophils were isolated from a healthy 
volunteer using Ficoll. They were treated with 1000nM TGX-221 or the same 
dilution of ethanol as the vehicle control before, and during, stimulation with 
either 5µg/ml human monoclonal anti-PR3 IgG, 10µg/ml human monoclonal 
anti-MPO IgG (n=1), a relevant IgG control or 5µg/ml fMLP. Data are 
presented as mean values ± SEM of triplicate wells. 
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limited to the specific monoclonal antibodies used, IgG purifed from anti-MPO 
ANCA positive patients was also tested. IgG purified from healthy voluteers 
was used as a negative control. Although only 1 of the 3 patient purified IgG 
samples activated the neutrophils to any great extent, it was clear that TGX-
221 inhibited the ANCA induced response nonetheless (Fig 4.16). Finally, a 
dose response experiment was performed using 5 concentrations of TGX-
221, ranging from 100nM to 1000nM (Fig 4.17). Anti-MPO IgG induced 
superoxide release was completely abrogated when TGX-221 was used at 
concentrations of 500nM and higher (Fig 4.17 A). At a concentration of 
250nM, TGX-221 partially inhibited the ANCA induced response. Interestingly, 
100nM TGX-221 changed the kinetics of the reaction, slowing down the 
response but not affecting the overall yield of the superoxide released after 2 
hours of anti-MPO IgG stimulation. fMLP induced superoxide release was 
inhibited to some degree by all concentrations of TGX-221, although the 
response was never fully abolished (Fig 4.17 B).   
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Figure 4.16 TGX-221 inhibits the patient ANCA induced superoxide release 
as measured by the superoxide dismutase inhibitable reduction of 
ferricytochrome C. TNFα primed neutrophils were isolated from a healthy 
volunteer using Ficoll. They were treated with 1000nM TGX-221 or ethanol, 
as the vehicle control, before, and during, stimulation with 200µg/ml human 
polyclonal anti-MPO IgG (n=3) or a relevant IgG control (n=1). Data are 
presented as mean values ± SEM of triplicate wells. 
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Figure 4.17 TGX-221 inhibition of ANCA induced superoxide release as 
measured by the superoxide dismutase inhibitable reduction of 
ferricytochrome C is dose dependent. TNFα primed neutrophils were isolated 
from a healthy volunteer using Ficoll. They were treated with various 
concentrations of TGX-221, or ethanol as the vehicle control, before and 
during stimulation with (A) 10µg/ml monoclonal human anti-MPO IgG  (n=1) 
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4.7 Discussion 
 
PR3 and MPO expression 
 
The vast majority of research on the membrane expression of ANCA 
antigens, PR3 and MPO, has been carried out using isolated cells. Some of 
the problems inherent to this approach have been discussed in Section 3.6 of 
the previous chapter. Thus, to avoid artefacts associated with cell isolation 
methods, and to allow both neutrophil and monocyte PR3 and MPO 
expression to be assessed simultaneously, experiments were carried out 
using whole blood. Using this system PR3 and MPO were found to be present 
on the surface of both resting neutrophils (Fig 4.2 and 4.4) and monocytes 
(Fig 4.3 and 4.5). This is in contrast to a previous study which showed that 
apoptotic neutrophils, and neutrophils primed by 4 and 8 hour incubation at 
37°C, but not unstimulated cells, expressed both PR3 and MPO on their 
membrane [263]. However, it is in agreement with a later study showing that 
whole blood, resting neutrophils from patients with GPA, and to a lesser 
extent neutrophils from healthy controls, expressed PR3 on their membrane 
surface [264]. Although it cannot be directly compared, as the staining was 
not done in parallel, it is interesting to note that neutrophils from the same 
donor had a bimodal expression of PR3 when these cells were isolated (Fig 
4.1), but not when they were examined in whole blood (Fig 4.2). The 
significance of this was not established but is discussed briefly below. What is 
perhaps most surprising however, is the fact that priming with TNFα did not 
increase surface expression of either PR3 or MPO on neutrophils. On the 
contrary, priming appeared to lead to a significant decrease in their 
expression (Fig 4.2 A and Fig 4.3 A, respectively). This is in direct contrast to 
what is observed using isolated neutrophils, where TNFα is frequently used to 
upregulate ANCA antigens and thus increase ANCA induced neutrophil 
activation [14, 67, 68]. This suggests that the isolation of neutrophils has 
profound effects on their function, and thus, in vitro ANCA assays may not 
accurately reflect the behaviour of these cells and, by extension, ANCA in 
vivo. Finally, in the case of monocytes, membrane MPO was present, 
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although almost undetectable, and unchanged by priming (Fig 4.5). In 
contrast, reasonably high levels of membrane PR3 were found to be 
expressed by monocytes, and this expression was upregulated in cells that 
had been primed with TNFα, although this did not reach statistical 
significance (p<0.0629, Fig 4.3). This is consistent with a report that 
monocytes, isolated together with lymphocytes and identified based on their 
forward and side scatter characteristics, expressed PR3 on their surface when 
primed with TNFα for 30 minutes [265].  
 
The role of monocytes in ANCA associated vasculits has not been studied to 
any great extent. While they express both PR3 and MPO, unlike neutrophils, 
they have not been shown to be essential for disease pathogenesis. 
Using a passive transfer model of disease (Discussed in Chapter 1) mice that 
were depleted of neutrophils were completely protected from anti-MPO IgG 
induced NCGN. Under the conditions of this model, monocyte activity was 
insufficient to cause disease [22]. It is important to note, however, that this is a 
MPO dependent model of disease, and, as results have shown, MPO is only 
weakly expressed by monocytes. Although the data on MPO expression 
relates to human cells, mouse MPO is very similar to human MPO and it is 
likely, though unconfirmed here, that this holds true for mouse monocytes. 
Interestingly, the majority of data showing a potential role for monocytes in 
ANCA associated vasculitis have come from studies of GPA and using anti-
PR3 antibodies. For example, monocytes have been shown to be present in 
the granulomas and glomerular crescents of patients with GPA [266]. 
Furthermore, increased monocyte activation, as measured by increased 
neopterin and IL6 production, together with increased surface expression of 
CD11b and CD64, has been shown to correlate with disease activity in GPA 
[267]. Finally, in vitro, it has been shown that anti-PR3 antibodies can activate 
monocytes, inducing the release of monocyte chemoattractant protein (MCP)-
1 [268], IL8 [265, 269], TNFα, IL1β, IL6 and thromboxane A2 [269]. These 
studies, together with a lack of corresponding data for MPA and anti-MPO 
antibodies, and the strong expression of PR3 but not MPO on the surface of 
monocytes, suggests that these cells might play an important role the 
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pathogenesis of anti-PR3 ANCA but not anti-MPO ANCA associated 
vasculitis. 
 
Despite the presence of PR3 and MPO on the surface of whole blood 
neutrophils, an ANCA induced whole blood respiratory burst assay could not 
be established. As previously mentioned, the role of TNFα in potentiating the 
ANCA induced respiratory burst is generally attributed to its ability to 
translocate PR3 and MPO from the granules of neutrophils to their cell 
membranes. However, data in whole blood suggests that TNFα actually 
downregulates neutrophil ANCA antigen surface expression (Fig 4.2, 4.4). 
Despite the emphasis on ANCA expression, it is important to note that there is 
also some evidence that TNFα can play a role in the assembly of the NADPH 
oxidase system, an enzyme system that is necessary for the neutrophil 
respiratory burst response [270]. Furthermore, a recent study has suggested 
that TNFα primes neutrophils for ANCA induced activation, at least partially, 
through the redistribution and subsequent colocalisation of gp91phox, an 
important component of the NADPH oxidase system, together with β2-
integrins and FcγRIIa on the cell surface [271]. Consequently the whole blood 
respiratory burst assay was performed both with and without TNFα priming. 
While, in a limited study, TNFα appeared to increased, but was not essential 
for, the response to fMLP in both neutrophils and monocytes, it clearly had no 
effect on the response to either anti-PR3 or anti-MPO IgG (Fig 4.6-4.7). There 
are a number of reasons why isolated neutrophils, but not whole blood 
neutrophils, might undergo oxidative burst in response to ANCA. As 
discussed in chapter 1, data suggests that both the antigen binding region 
and the Fc portion of the ANCA molecule are important in ANCA signaling. It 
is therefore possible that antibodies, present in the plasma component of the 
whole blood and binding transiently to whole blood neutrophil Fc receptors, 
are preventing the Fc region of the ANCA molecules binding to the neutrophils 
and thereby activing them. It is also possible that the process of isolating 
neutrophils primes them for an ANCA induced response. It is unclear what 
this might mean for in vivo ANCA induced neutrophil activation, however, as 
discussed in Chapter 3 there are various intrinsic issues with in vitro 
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respiratory burst assays as models of ANCA induced neutrophil activation. 
Alternatively, or perhaps concomitantly, other plasma factors may inhibit 
ANCA induced neutrophil activation. Antiprotease α1-antitrypsin (A1AT), a 
physiological inhibitor of PR3 found in plasma, is an example of one such 
factor. A number of clinical studies have shown a correlation between A1AT 
deficiency and GPA [272-275]. Furthermore, the addition of A1AT to TNFα 
primed neutrophils, isolated from healthy controls and stimulated with anti-
PR3 antibodies, led to a 47% decrease in the production of reactive oxygen 
species. For neutrophils isolated from GPA patients, the decrease upon A1AT 
addition was greater, at 56% [276]. A1AT is thought to bind to PR3 and thus 
prevent its interaction with ANCA. Therefore, it would be expected that PR3 
expression on the surface of cells in whole blood would be undetectable using 
flow cytometry. However, this is not the case. It has already been noted that 
neutrophils from the same donor had a bimodal expression of PR3 when 
these cells were isolated (Fig 4.1) but not when they were examined in whole 
blood (Fig 4.2). It is possible that this is due to A1AT binding preferentially to 
the mPR3high population of neutrophils, leaving the mPR3low population to be 
bound by the anti-PR3 antibody used for flow cytometry. This is, however, 
unconfirmed. Furthermore, it should not affect the ability of ANCA to induce 
intracellular reactive oxygen species production in whole blood neutrophils, as 
the mPR3 pheonotype was shown to be irrelevant when using a DHR123 
assay [50, 56]. It has been shown that activated neutrophils and neutrophil 
products, such as H2O2, can inactivate A1AT in vitro [277, 278]. In addition, 
the adhesion of neutrophils to endothelial cells was enough to overcome 
A1AT inhibition [279]. Therefore, while A1AT may inhibit neutrophil activation 
as a result of ANCA stimulation in vitro it is unlikely to be able to protect 
against anti-PR3 antibodies in vivo. 
 
The role of GCSF in priming ANCA induced oxidative burst 
 
The ability of GCSF to stimulate granulopoiesis has led to its use in treating 
neutropenia in patients, allowing the rapid production and mobilization of 
neutrophils into their circulation. As discussed in Chapter 1, the passive 
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transfer model of ANCA associated vasculitis is very mild when compared to 
human disease. One possible reason for this is the relatively small population 
of neutrophils, the key effector cell in ANCA vasculitis, found in mice. 
Neutrophils comprise approximately 50-70% of the leukocytes in human 
blood, however, they account for only 10-25% of circulating mouse leukocytes 
[280]. Therefore, in the hopes of establishing a more severe model of ANCA 
vasculitis, mice were treated with human GCSF together with LPS and anti-
MPO antibodies. Despite only a modest increase in neutrophil numbers, there 
was a very significant increase in disease severity in mice treated with GCSF 
[239]. In addition to mobilising neutrophils from the bone marrow, several 
studies have shown that GCSF primes neutrophils both in vitro and in vivo 
(Discussed in Section 4.1). Further to this, GCSF signalling has been shown 
to activate, PI3K [281] and Akt [282], two signalling molecules thought to be 
essential for ANCA induced activation of neutrophils [75, 76]. Consequently, a 
possible role for GCSF in priming ANCA induced neutrophil activation was 
examined using both the ferricytochrome C reduction assay and the DHR123 
assay. GCSF did not appear to prime neutrophils for superoxide release in 
response to stimulation with an anti-PR3 monoclonal antibody (Fig 4.8). 
However, it was noted that the GCSF primed neutrophils of all 3 donors tested 
produced more superoxide than the unprimed neutrophils when stimulated 
with monoclonal anti-MPO IgG (Fig 4.9). Although this did not reach statistical 
significance, it suggested that a difference might be seen with a larger number 
of donors. Believing that the difference might be small, yet physiologically 
significant, it was decided to switch to the DHR123 assay, as it is more 
sensitive than the ferricytochrome C reduction assay, and therefore might be 
better able to distinguish an effect. Indeed, it was found using this assay that 
neutrophils stimulated with monoclonal anti-MPO IgG produced significantly 
more reactive oxygen species when first primed with GCSF (Fig 4.11). In 
contrast, GCSF did not increase the response to monoclonal anti-PR3 IgG 
(Fig 4.10). Why this GCSF priming effect appears to be specific to anti-MPO 
antibodies is unclear. Previous studies have shown that, unlike TNFα, GCSF 
priming does not alter the expression of PR3 or MPO on the surface of 
neutrophils [237, 283], and this was confirmed under the same conditions 
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used for the respiratory burst assays (Fig 4.13). Interestingly, the TNFα 
induced translocation of ANCA antigens to the surface of isolated neutrophils 
has been shown to be p38 MAPK dependent [76]. Furthermore, it was found 
that ERK, while activated by TNFα, had no role in TNFα induced ANCA 
antigen translocation. Therefore, the inability of GCSF to induce PR3 and 
MPO expression on the surface of isolated neutrophils is consistent with the 
fact that GCSF has been shown to selectively activate ERK, but not p38 
MAPK, in neutrophils [284]. If GCSF priming is not affecting MPO expression, 
and the signalling molecules known to be both activated by GCSF and 
thought to play important roles in ANCA vasculitis (PI3K and Akt) are common 
to both anti-PR3 and anti-MPO induced neutrophil activation, then the reason 
for the anti-MPO IgG specific GCSF priming response remains to be seen.  
 
The role of GCSF in priming for an anti-MPO ANCA induced response was 
established using a single monoclonal antibody and was not confirmed using 
patient samples. This is perhaps unsurprising given that the patient derived 
ANCA was tested on only 2 donors and, of these, only 1 showed any 
response (Fig 4.12). The decision to preferentially use the monoclonal 
antibody was based on the fact that patient derived antibodies are, as 
discussed in Section 3.6 of the previous chapter, unreliable in their ability to 
activate neutrophils and, due to the use of whole IgG solutions, less clear in 
their results. 
 
GCSF primes neutrophils in vivo  
 
Using an anti-MPO antibody transfer model of vasculitis, it was shown that 
mice given GCSF, in addition to LPS, had significantly greater disease 
compared to controls [239]. This was likely due, at least in part, to an increase 
in the number of mouse neutrophils, combined with the ability of GCSF to 
prime these cells for an anti-MPO antibody induced respiratory burst. 
However, it is also likely that the ability of GCSF to modulate neutrophil 
adhesion molecules played an equally important role in exacerbating disease 
in these mice. Indeed, it has been shown here that GCSF treatment, both 
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alone and in combination with LPS, serves to increase the expression of 
CD11c while simultaneously downregulating CD62L (Fig 4.14 B-C). CD11c is 
a member of the CD18 family of integrins, expressed primarily by 
monocytes/macrophages, NK cells, DCs and neutrophils. Importantly, TNFα 
primed neutrophils have been shown to bind to fibrinogen in a CD11c 
dependent manner [285]. Furthermore, that CD11c, but not CD11b, appeared 
to be increased by GCSF treatment in vivo (Fig 4.14 A-B), suggests that it is 
the former rather than the latter that has an important role in neutrophil 
adhesion in the context of ANCA induced disease. Indeed, in a recent study 
using intravital microscopy, it was shown that, in the context of LPS 
stimulation, blocking LFA1 but not CD11b prevented the anti-MPO triggered 
recruitment of neutrophils to glomeruli [25]. CD62L is involved in neutrophil 
rolling [286] and is characteristically downregulated in response to cell 
activation [287], likely in preparation for the switch from rolling to firm 
adhesion and subsequent neutrophil transmigration. Therefore, taken 
together, these data suggest that GCSF treatment leads to the conversion of 
neutrophil rolling to firm adhesion, via the induction of CD62L shedding and 
CD11c upregulation, and in this manner further contributes to anti-MPO IgG 
induced disease. 
 
PI3Kβ/δ  plays a role in ANCA induced superoxide production? 
 
TGX-221 is a potent Class IA PI3K specific inhibitor. The IC50 of TGX-221 for 
each Class I PI3K isotype, as determined in three separate studies, is shown 
in Table 4.3. Using the ferricytochrome C reduction assay, it has been shown 
that TGX-221 is capable of inhibiting, though not abolishing, the fMLP induced 
release of superoxide by isolated neutrophils (Fig 4.15, 4.17). In addition, it 
has been shown that 1000nM of TGX-221 completely abrogates superoxide 
release by anti-PR3 and anti-MPO monoclonal IgG (Fig 4.15), and polyclonal 
patient derived anti-MPO IgG (Fig 4.16). Furthermore, it has been 
demonstrated that TGX-221 inhibits monoclonal anti-MPO IgG and fMLP 
induced respiratory burst activation in a dose-dependent manner (Fig 4.17).  
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When used at 1000nM, TGX-221 inhibits both PI3Kβ and PI3Kδ. The extent 
to which it also inhibits PI3Kα at this concentration is less certain, as out of 3 
separate studies, 1 has reported an IC50 of 784nM for TGX-221 against 
PI3Kα, while 2 have reported an IC50 of >1000nM (Table 4.3). However, 
taking into account that 500nM TGX-221 completely abolished the anti-MPO 
induced respiratory burst (Figure 4.17A), it is likely that PI3Kα does not play a 
major role, relative to PI3Kβ and PI3Kδ, in the ANCA induced release of 
reactive oxygen species by neutrophils. Similarly, based on the results shown 
in Figure 4.17B, it is likely that Class IA PI3Ks, particularly PI3Kβ and/or 
PI3Kδ, play prominent roles in the fMLP induced neutrophil respiratory burst. 
Importantly, however, not even the highest concentration of TGX-221 
completely abrogated superoxide generation by treated neutrophils. This 
result is fits with previous studies showing that fMLP activates neutrophils 
through both PI3Kδ, which is inhibited here, and PI3Kγ, which is not [254].   
 
Interestingly, neither 100nM nor 250nM of TGX-221 abolished the ANCA 
induced respiratory burst, although at 100nM TGX-221 did change the 
kinetics of the response. Indeed, 100nM TGX-221, while not sufficient to 
affect the overall yield of superoxide released after 2 hours of anti-MPO IgG 
stimulation, did appear to slow down the response, with superoxide release 
starting at a later time point and increasing rapidly. At 250nM, TGX-221 
almost halved the amount of superoxide generated (51 nmol O2-/105 
neutrophils without inhibitor vs 26 nmol O2-/105 neutrophils with 250nM TGX-
221, following 2 hours ANCA stimulation). The exact reason for this is unclear 
and would require further study to be elucidated. However, as the IC50 of 
TGX-221 against PI3Kδ is in the range of 65-211nM (Table 4.3), it is possible 
that superoxide generation in the presense of both 100nM and 250nM TGX-
221 is the result of remaining PI3Kδ activity.  
 
It is important to note that the effect of TXG-221 on neutrophil viability was not 
tested. It is therefore possible that the results shown are the due to neutrophil 
death and not specific inhibition of PI3Ks. However, as 10µM TGX-221 (10 
times the highest concentration used here) was found to have no toxic effects 
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on bone marrow derived macrophages, following incubation of up to 40 hours 
[288], it is unlikely that the results shown are due to TGX-211 cell toxicity.  
 
Taken together, and presuming that TGX-221 is not affecting neutrophil 
viability, these data suggest that Class IA PI3Ks, particularly, PI3Kβ/δ play an 
important role in the ANCA induced respiratory burst, and by extension may 
be important for the pathogenesis of ANCA associated vasculitis.  
 
To date, the majority of research on PI3Ks in ANCA associated vasculitis has 
focused on PI3Kγ, which, as discussed in Chapter 1, was shown to have an 
important role in disease pathogenesis. Indeed, the data presented here are 
in direct contrast to a previous study by Ben-Smith et al., in which ANCA 
stimulation failed to activate the PI3Kα, PI3Kβ and PI3Kδ catalytic subunit 
p85, and thus suggested that Class IA PI3Ks do not have a role in ANCA 
signalling [75]. However, it is likely that this discrepancy is due to the timing of 
the assays involved. In the study by Ben-Smith et al., p85 activation was 
examined following 30 seconds, 1 minute and 15 minutes of ANCA 
stimulation. This is significant as there was little superoxide production, either 
with out without TGX-221, seen in the first 30 minutes following the addition of 
ANCA to the neutrophils in the ferricytochrome C reduction assays presented 
in Figures 4.15-4.17. Thus, it is possible, although it cannot be confirmed 
without further study, that p85 activation does not occur within the first 15 
minutes of ANCA stimulation. Consequently, its activation, likely between 15 
and 30 minutes post ANCA addition, was missed by Ben-Smith et al.. 
Interestingly, it has been shown that fMLP induces biphasic activation of the 
PI3K pathway in human neutrophils, with the first phase largely dependent on 
PI3Kγ activation, and the second phase largely dependent on PI3Kδ 
activation [254]. Further to this, a separate study has shown that PI3Kγ is 
essential for early fMLP induced reactive oxygen species generation, but is 
dispensable for the late response to fMLP [250]. In the same study it was 
suggested that that Class IA PI3Ks might be activated by PI3Kγ, via Ras in 
the early phase and Src in the late phase. Thus, it is possible that a similar 
response occurs in ANCA induced neutrophil activation, with PI3Kγ being 
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important for early ANCA responses, and for the activation of PI3Kβ and/or 
PI3Kδ, which are in turn essential for late ANCA responses. Consequently, it 
is possible that both Class IA and Class IB PI3Ks are potential therapeutic 
targets for the treatment of ANCA associated vasculitis.   
 
α β δ γ  
784 10 65 3240 [254] 
>1000 9 211 - [289] 
5000 5 100 >10000 [290] 
 
Table 4.3 The IC50’s (nM) of TGX-221 for the four class I PI3K isoforms as 
determined by three separate studies.  
Chapter 5 Establishing a humanised mouse model 	  
	   170 
5.1 Introduction 
 
It has been long established that findings in mice do not always translate to 
humans. Furthermore, there exist a number of pathogens that simply do not 
infect small laboratory animals. Therefore humanised mice, in this case mice 
that possess human immune cells, represent an important tool for the in vivo 
study of human leukocytes, and their roles in both host defence and 
autoimmunity. As discussed in Chapter 1, there are numerous issues with 
regards the current animal models of ANCA associated vasculitis that make 
the prospect of a humanised mouse model attractive. This will be further 
discussed in Chapter 7.  
 
Despite, or perhaps because of, the continuous efforts to improve the 
currently available models, the development of humanised mice remains 
complicated by the fact that there is no consensus on how it should be 
approached. Factors that must be considered when developing these models 
include the following: a number of different human cell types can be used to 
engraft mice, IL2rγ-/- mice are available on a number of background strains, 
mice can be engrafted both as adults and neonates, and there are numerous 
routes of injection that can be used [129]. To date there have been few 
studies on the engraftment of humanised mice that have directly compared 
these factors. Although some investigators use peripheral blood leukocytes to 
reconstitute mice, human hematopoietic stem cells (HSCs) have been shown 
to provide better engraftment, and present less risk of the mice developing 
graft vs host disease. HSCs can be derived from peripheral blood, bone 
marrow, foetal tissue and umbilical cord blood (UCB). They are capable of 
differentiating into cells of both the lymphoid and myeloid lineage, depending 
on the presence or absence of various hematopoietic factors, and are self-
renewing, thus allow for long term engraftment [134]. The majority of 
investigators use CD34+ HSCs derived from UCB to develop humanised mice, 
and indeed it has been established that HSCs from newborn/foetal sources 
have greater potential than those from adult sources [291, 292]. 
Consequently, CD34+ stem cells derived from UCB were chosen to 
repopulate immunodeficient mice with human immune cells in this study. 
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The engraftment levels of three strains of immunodeficient mice, all with the 
IL2rγ-/- mutation, were compared after adoptive transfer of human CD34+ cells 
derived from UCB [128]. In addition, this study examined engraftment in both 
adult and neonatal mice. The three strains used were as follows: NOD-scid 
IL2rγ-/-, NOD-Rag1-/-IL2rγ-/-, BALB/c-Rag1-/-. Both NOD strains supported 
higher levels of engraftment than the BALB/c strain, and this was independent 
of age. However, despite not quite reaching statistical significance, it was 
observed that NOD-scid IL2rγ-/- mice engrafted as neonates tended to have 
greater human leukocyte reconstitution when compared to mice engrafted as 
adults. Interestingly, the main difference seen between neonatal and adult 
engrafted mice was with regards to their ability to reconstitute lymphocytes. 
While neonatal mice supported significantly increased T cell development 
when compared with their adult counterparts, B cell engraftment was higher in 
adult engrafted mice as compared to mice engrafted as newborns. The 
development of myeloid lineage cells was not compared. There are many 
advantages to working with adult mice over neonates. Perhaps most 
importantly, there is much more leeway with regards timing. Mouse breeding 
is often unreliable and, as a consequence, it can be difficult to plan 
experiments with newborn mice. Indeed, there is an ever-present risk that 
UCB stem cells may become available at time when there are no litters to 
engraft, or conversely, newborn mice may be available at time when there are 
no UCB stem cells. In contrast, adult mice are generally engrafted between 6 
and 12 weeks, and thus there is generally sufficient time to procure stem cells 
and carefully plan out experiments. Therefore, few stem cells or mice will go 
to waste. In addition, newborn mice may not survive to adulthood. Female 
mice have been known to reject litters and the risk of this is increased when 
the newborns have been handled. Taking both this, and the fact that T cell 
development is unlikely to be important for a potential humanised mouse 
passive transfer model of ANCA vasculitis, adult NOD-scid IL2γ-/- mice were 
chosen for use in this study. 
 
In this chapter the passive transfer of human neutrophils into NOD-scid IL2γ-/- 
mice was considered, various methods of CD34+ cell isolation from UCB were 
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tested, purified cells were transferred into conditioned NOD-scid IL2rγ-/- mice 




• To repopulate conditioned NOD-scid IL2γ-/- mice with human 
leukocytes using human haematopoietic stem cells 




5.3.1 Passive transfer of neutrophils  
 
Neutrophils were isolated from healthy volunteers using Polymorphprep as 
described in Section 2.2.6.1. Approximately 1x107 neutrophils in 200µl PBS 
were injected into adult NOD-scid IL2γ-/- mice via the lateral tail vein. Mice 
were bled from the saphenous vein 10 and 60 minutes post transfer and 
whole blood was stained for the presence of human neutrophils using human 
CD45 and human CD66b antibodies. A small volume of blood was used to 
perform whole blood counts using Turk's solution. Flow cytometry was 
performed as described in Section 5.3.2. Absolute numbers of neutrophils 
were calculated from flow cytometry data and total leukocyte numbers.  
 
5.3.2 Flow cytometry  
 
Flow cytometry was performed as described in Section 2.2.1. The antibodies 
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Target Isotype Clone Fluorophore  Supplier Dilution  
CD3 Mouse IgG2a, κ BW264/56 APC Miltenyi 1:11 
CD19 Mouse IgG1,κ HIB19 FITC BD 1:6 
CD34 Mouse IgG2a, κ AC136 PE Miltenyi 1:11 
CD45 Mouse IgG1, κ HI30 V450 BD 1:101 
CD45 Mouse IgG1, κ HI30 PE-Cy7 BD 1:101 
CD66b Mouse IgM, κ G10F5 FITC BD 1:11 
 
Table 5.1 Anti-human antibodies used for flow cytometry. All antibodies were 
obtained from commercial sources. 
 
Target Isotype Clone Fluorophore  Supplier Dilution 
CD45 Rat (LOU) IgG2b, κ 30-F11 PE BD 1:500 
 
Table 5.2 Anti-mouse antibodies used for flow cytometry. All antibodies were 
obtained from commercial sources. 
 
5.3.3 CD34+ isolation from frozen cord blood 
 
Frozen UCB was defrosted as described in Section 2.2.10.1. UCB cells were 
resuspended in MACS buffer (PBS with 0.5% BSA and 2mM EDTA) and 
CD34+ cells were purified using the Miltenyi MACS separation system as 
described in Section 2.2.10.3, with any changes made to this protocol being 
listed in Table 5.3. The yield and purity of the resulting cell suspension was 
determined using flow cytometry. Staining was carried out for CD34+ cells and 
CD3+ contaminating T cells. 
 
5.3.4 CD34+ isolation from fresh cord blood 
 
CD3+ cells were depleted from fresh cord blood as described in Section 
2.2.10.2. For some batches of cord blood, the yield and purity of the resulting 
cell suspension was determined using flow cytometry before the cells were 
either injected into mice or cryopreserved in 90% FCS and 10% DMSO. For 
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other batches the cells were resuspended in MACS buffer (PBS with 0.5% 
BSA and 2mM EDTA) and CD34+ cells were purified using the Miltenyi MACS 
separation system as described in Section 2.2.10.3 or resuspended in PBS 
containing 2% FCS and 1mM EDTA with CD34+ cells being purified using 
StemCell Technolies EasySep separation system (Section 2.2.10. 4). 
 
5.3.5 Engraftment of NOD-scid IL2γ -/- mice 
 
Humanised mice were generated as described in Section 2.2.11. Briefly, mice 
were engrafted by injecting 1x105 human cord blood CD34+ stem cells (either 
purified as described in Section 2.2.10 or purchased from Lonza, Slough, 
Berkshire, UK) into 6-12 week old NOD-scid IL2γ-/- mice approximately 4 
hours post irradiation at 2.4Gy with a Cs-source irradiator.  
 
5.3.5 Characterisation of humanised mice 
 
Reconstitution of human cells in the peripheral blood, bone marrow and 
spleen of engrafted mice was assessed using flow cytometry at least 8 weeks 
post adoptive transfer of stem cells. Mouse blood and tissue was collected as 
described in Section 2.2.13.1.The percentage of mouse and human CD45+ 
cells was first examined. By gating on the human CD45+ cell population 





Statistics were performed using Graphpad Prism software (Graphpad 
Software Inc, La Jolla, CA, USA). Student t tests or one-way/repeated 
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5.4 Results: Passively transferred human neutrophils rapidly disappear 
from the mouse circulation  
 
Isolated human neutrophils were injected into immunodeficient  
NOD-scid IL2γ-/- mice via the lateral tail vein. The percentage and total 
number of human neutrophils remaining in the circulation of injected mice was 
then tested at 10 and 60 minutes post passive transfer. After approximately 
10 minutes the percentage of human neutrophils remaining in the peripheral 
blood of these mice was on average 6.98%, with a standard deviation of 
1.89%. After 60 minutes this had decreased to give an average of 2.38%, with 
a 1.25% standard deviation. A representative flow cytometry plot is shown in 
Figure 5.1. The flow cytometry data together with total leukocyte counts was 
used to determine the approximate number of human neutrophils remaining in 
circulation. Approximately 1x107 neutrophils were injected into each mouse 
and Table 5.3 shows the total number of neutrophils/ml in the peripheral blood 
of mice 10 and 60 minutes post transfer. At 10 minutes there were, on 
average, approximately 1.15x105 neutrophils/ml remaining and this had 
decrease to 3.9x104 neutrophils/ml after 60 minutes. 
 
5.5 Results: Isolating viable haematopoietic stem cells from umbilical 
cord blood 
 
5.5.1 CD34+ cells could not be purified for injection into mice from frozen 
umbilical cord blood 
 
Non-clinical standard, frozen UCB was obtained from The Anthony Nolan 
Trust. It was defrosted at 37°C and CD34+ cells were purified using the 
Miltenyi magnetic cell (MACS) separation system. Flow cytometry, staining for 
both CD34+ and CD3+ cells, was used to determine the purity of the cell 
preparations. Figure 5.2 shows a representative plot from the purification of 
one batch of UCB. A small population of CD34+ cells could be seen in the 
untreated blood, together with a large population of CD3+ T cells.  After CD34+  
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Figure 5.1 Representative plot showing the percent of human CD45+CD66b+ 
neutrophils in the circulation of NOD-scid IL2γ-/- mice  (n=4) 10 and 60 
minutes post adoptive transfer of 1x107 human neutrophils isolated from 
healthy controls. 
 
Mouse Total no. of circulating human 
neutrophils 10 minutes post transfer 
(cells/ml) 
Total no. of circulating human 
neutrophils 60 minutes post transfer 
(cells/ml) 
1 85.400  77,400  
2 85,000  17,100  
3 173,300  43,350  
4 117,300  21,200  
Average 115,250 39,763 
 
Table 5.3 The total number of human CD66b+ neutrophils remaining in the 
circulation of NOD-scid IL2γ-/- mice (n=4) 10 and 60 minutes post adoptive 
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Figure 5.2 Representative flow cytometry data showing CD34+ cell purification 
using the Miltenyi MACS seperation system from cryopreserved human cord 
blood obtained from The Anthony Nolan Trust. Data is from Donor 100640 
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cell purification, using MACS separation involving two separate isolation 
steps, the cell suspension contained approximately 75.6% CD34+ cells and 
8.9% contaminating CD3+ T cells. The flow through, containing the cells that 
were not magnetically labelled and thus passed straight through the 
separation column, was also examined to ensure no CD34+ cells that could be 
collected by an extra purification step remained. As can be seen, no CD34+ 
cells were present in the flow through. Table 5.4 summarises the various 
attempts to purify CD34+ cells from frozen cord blood. Of the 5 attempts to 
isolate CD34 + cells from frozen UCB, sufficient purity (>95% CD34+ cells) 
combined with a sufficiently low percent of CD3+ T cell contamination (<1%) 
was achieved only once, and in this case the yield was very low (4x105 cells 
total, enough to engraft a maximum of 4 mice). 
 
5.5.2 CD3+ cells were successfully depleted from fresh umbilical cord 
blood 
 
Non-clinical standard, fresh UCB was obtained from the National Blood 
Service, Oxford and Collindale. In order to produce a cell suspension 
containing CD34+ cells that could safely be injected into mice, CD34+ cell 
isolation using the Miltenyi MACS separation system was compared to CD3+ 
cell depletion using RosetteSep followed by CD34+ cell purification using the 
EasySep system. As can be seen in Figure 5.3, MACS separation alone did 
not provide a sufficiently pure (comprising >95% CD34+ cells and <1% CD3+ 
cells) cell suspension. RosetteSep, on the other hand, effectively depleted all 
CD3+ T cells from the UCB, and when this was followed by CD34+ cell 
purification using EasySep, a cell suspension with 84% CD34+ cells and less 
than 1% CD3+ T cells was achieved. Furthermore, the yield was acceptable 
(2.1x106 cells total, enough to engraft approximately 20 mice) (Table 5.5). As 
T cell contamination, and subsequent graft vs host disease, is the biggest 
concern with regards to injecting mice with whole UBC cells it was decided 
that CD3 depleted UCB cells would be sufficient to engraft mice as suggests 
by both Brehm et al. [128] and Lang et al. [293]. Table 5.5 summarises the 
fresh UCB batches processed. 
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CD3+   
cells 
(%) 
Notes on protocol 
100640 2 2x106 75.6 
 








100672 8 7x105 55.3 13.8 2 x through column, 
EDTA in MACS 
buffer replaced with 
ACD/A 
 
100730 1.75 4x105 98.1 0.35 3 x through column, 
returned to EDTA for 
MACS buffer 
 
100720 3.5 2x105 94 2.2 3 x through column 
 
Table 5.4 List of CD34+ cell purifications using the Miltenyi MACS seperation 
system from cryopreserved human cord blood obtained from The Anthony 
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Figure 5.3 Comparing CD34+ cell isolation using (A) the Miltenyi MACS cell 
seperation system with (B) CD3+ cell depletion using RosetteSep followed by 
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166 7.76 2.4x106 76.8 
 





166 7.76 2.1x106 84 <1 RosetteSep CD3+ cell 
depletion followed by 
EasySep CD34+ cell 
purification 
 















478G 7.31 2.32x108 0.8 <1 RosetteSep CD3+ cell 
depletion 
 
Table 5.5 List of fresh human cord blood obtained from NBS, Oxford and 
Colindale. All donor identification numbers begin G180 105 127 with the 
exception of the donor 478G the sole cord blood received from Colindale NBS 
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5.6 Results: Generating humanised mice 
 
5.6.1 Humanised mice possess similar levels of human cells at 8 and 12 
weeks post engraftment 
 
The majority of studies using humanised mice assess engraftment 12 weeks 
post transfer of HSCs. To determine whether this was the earliest time point 
at which engrafted mice possessed human cells, irradiated NOD-scid IL2γ-/- 
mice were injected intravenously with either human CD3+ cell depleted UCB 
cells (Fig 5.4) or isolated CD34+ stem cells obtained from Lonza (Fig 5.5), and 
assessed using flow cytometry, 4, 8 and 12 weeks later. Mice engrafted with 
CD3 depleted UCB had low levels of human CD45+ cells in their circulation at 
all time points tested (Fig 5.4). Importantly the average percentage of human 
CD45+ cells more than doubled between 4 and 8 weeks post engraftment 
(Mean 2.45% vs 5.59%). Although this was not a statistically significant 
increase it is very suggestive. In contrast, there was little change in the level 
of human cells between 8 and 12 weeks post engraftment (Mean 5.59% vs 
4.94%). Mice that received isolated CD34+ stem cells possessed relatively 
high levels, when compared to the CD3 depleted UCB cell engrafted mice, of 
human CD45+ leukocytes in their circulation at all time points tested. These 
mice had significantly more human CD45+ cells in their peripheral blood at 8 
weeks post engraftment when compared to their levels at 4 weeks post 
engraftment (Mean 27.04% vs 7.54%). Consistent with CD3 depleted UCB 
cell engrafted mice, there was little difference seen in the percentage of 
human cells between 8 and 12 weeks post engraftment (mean 27.04% vs 
26.02%). 
 
5.6.2 NOD-scid IL2γ -/- mice engrafted with CD34+ stem cells (from Lonza) 
had enhanced leukocyte reconstitution when compared with mice 
engrafted with CD3 depleted umbilical cord blood cells  
 
Table 5.6 shows a summary of mice engrafted during this project. It includes 
the number of mice in each group, the cells used to reconstitute them and the 
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Figure 5.4 Time course of peripheral blood engraftment of human (h)CD45+ 
cells using CD3+ cells depleted cord blood cells. (A) Combined data from 
Group 2 (n=5 at weeks 4 and 8, n=3 at week 12) and Group 5.1 (n=10 at 
weeks 4 and 8, n=9 at week 12) with the median of each group shown by the 
horizontal line. (B) Representative plots from a single mouse from Group 2. 
mCD45 refers to mouse CD45+ cells. See Table 5.6 for further information on 
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Figure 5.5 Time course of peripheral blood engraftment of human (h)CD45+ 
cells using CD34+ cells obtained from Lonza. (A) Combined data from Group 
1 (n=8 at week 4 and n=7 at weeks 8 and 12) and Group 5.1 (n=10 at weeks 
4 and 8, n=0 at week 12) with the median of each group shown by the 
horizontal line.. (B) Representative plots from a single mouse from Group 1. 
mCD45 refers to mouse CD45+ cells. See Table 5.6 for further information on 
groups of mice shown. *p<0.05, **p<0.01. Data was analysed using a one-
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No. of mice 
engrafted/No. of 
mice surviving to 
end point 
CD34 positive cells used 
 
Mean engraftment 
(% human CD45+ 
cells)  
1 8/7 Purchased from Lonza, 
Lot 091254A 
22.8 ± 20.5 
 
2 6/3 CD3 positive cell depleted 
cord blood from donor 182 
16.7 ± 9.09 
 
3 7/6 CD3 positive cell depleted 
cord blood from donor 205 
0.8 ± 1.06 
Week 8 
4 7/7 CD3 positive cell depleted 
cord blood from donor 231 
1.4 ± 2.51 
Week 5 
5.1 12/10 Purchased from Lonza, 
Lot OF3018 
22.9 ± 12.4 
Week 9 
5.2 10/10 CD3 positive cell depleted 
cord blood from donor 231 
4.14 ± 4.37 
Week 9 
6 9/8 CD3 positive cell depleted 
cord blood from donor 478G 
15.4 ± 16 
 
7 10/7 Purchased from Lonza, 
Lot 080026B  
15.1±5.38 
 




















12 18/13 Purchased from Lonza, 
Lot IF3299 
0.53 ± 0.77 
 




14 10/8 Purchased from Lonza, 
Lot OF4444 
51.8 ± 10 
 
 
Table 5.6 Humanised mice generated. All engraftment data is from peripheral 
blood 12 weeks post engraftment unless otherwise stated. All mice received 
approximately 1x105 CD34+ cells with the exception of those in Group 12 who 
received 5x104 cells (Due to a low availability of CD34+ cells at the time of 
engraftment). All CD34+ cells purchased from Lonza were derived from cord 
blood with the exception of Lot 080026B, which were bone marrow derived. 
Mean is given as ± standard deviation. 
 
Chapter 5 Establishing a humanised mouse model 	  
	   186 
average percentage of human CD45+ cells in their peripheral blood 12 weeks 
(unless otherwise stated) post adoptive transfer of human CD34+ HSCs. It is 
clear from these data that mice engrafted with isolated CD34+ cells obtained 
from Lonza had a higher level of human CD45+ cell reconstitution than mice 
engrafted with CD3 depleted UCB cells. This was confirmed by the 
comparison of two groups of mice engrafted side-by-side, with one group 
receiving CD34+ Lonza cells and one group receiving CD3 depleted UCB cells 
(Fig 5.6). The mice were assessed together at 9 weeks post engraftment. The 
mice that received Lonza cells had significantly higher levels of human 
leukocyte engraftment as measured by the percentage of human CD45+ cells 
present in their peripheral blood.  
 
5.6.3 NOD-scid IL2γ -/- mice reconstituted with CD34+ stem cells had 
human T and B cells in their bone marrow, spleen and peripheral blood 
12 weeks post engraftment 
 
Humanised mice reconstituted with isolated human CD34+ cells (Group 1 
Table 5.6) were sacrificed 12 weeks post engraftment and their bone marrow 
and spleens were harvested for analysis. Concurrently, blood was collected 
from the axillary vessels under terminal anaesthesia. Human CD45+ cells 
were present in the bone marrow, spleens and circulation of all mice tested 
(Fig 5.7). Furthermore, there were considerably more human leukocytes 
present in the bone marrow and spleen of these mice than in the blood (Mean 
26.07% vs 59.81% vs 49.62%) (Fig 5.7 A). Having demonstrated that human 
CD45+ cells repopulate conditioned NOD-scid IL2γ-/- mice that have received 
human HSCs, it was decided to further identify the human cells present. The 
majority of human CD45+ cells found in these mice were CD19+ B cells (Fig 
5.8). They accounted for on average 75.4%, 87.7% and 60.32% of the human 
cells in the bone marrow, spleen and blood, respectively. Notably, there were 
more B cells found in the found in the spleen than in the bone marrow or 
peripheral blood and in the bone marrow than in the blood (Fig 5.8 A). 
Together with B cells, CD3+ T cells were found to be present in the spleen 
Chapter 5 Establishing a humanised mouse model 	  
	   187 
 
 
Figure 5.6 Comparison of two groups of mice engrafted side-by-side with one 
group receiving CD34+ Lonza cells and one group receiving CD3 depleted 
UCB cells. The mice where from group 5.1 (n=10) and 5.2 (n=10) 
respectively. See table 5.6 for more information. The mice were assessed 
together at 9 weeks post engraftment. (A) Percentage of human CD45+ cells 
in the peripheral blood of these mice. with the median values of each group 
shown by the horizontal line. (B) Representative plots. ****p<0.0001. Data 
was analysed using an unpaired t test.  
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Figure 5.7 Engraftment of human (h)CD45
+
 cells. (A) Combined data from 
Group 1 (n=7) with the median of each group shown by the horizontal line. (B) 
Representative plots from single mouse from Group 1. mCD45 refers to 
mouse CD45
+
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Figure 5.8 Engraftment of human (h)CD19+ cells as a percent of human 
CD45+ cells. (A) Data from Group 1 (n=7) with the median of the groups 
shown by the horizotal line. (B) Representative plots from a single mouse 
from Group 1. mCD45 refers to mouse CD45+ cells. See Table 5.6 for further 
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and blood but not, to any great extent, the bone marrow of mice tested (Fig 
5.9). On average, humanised mice had 0.49%, 4.71% and 9.95% T cells in 
their bone marrow, spleen and blood, respectively. There were far more T 
cells found in the spleen and blood of mice compared to the bone marrow (Fig 
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Figure 5.9 Engraftment of human (h)CD3+ cells as a percent of human CD45+ 
cells. (A) Data from Group 1 (n=7) with the median of the groups shown by 
the horizotal line.  (B) Representative plots from a single mouse from Group 1. 
mCD45 refers to mouse CD45+ cells. See Table 5.4 for further information on 
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5.7 Discussion 
 
Passive transfer of human neutrophils  
 
The failure to develop a murine model of anti-PR3 induced ANCA associated 
vasculitis has largely been attributed to differences between murine and 
human PR3, the most important of which is thought to be the former’s 
inaccessibility to circulating anti-PR3 antibodies. Thus the development of a 
mouse model with human neutrophils present in the peripheral blood would 
provide a potential tool for the study of anti-PR3 antibodies in vivo. To 
investigate what would perhaps be the simplest way of achieving such a goal, 
human neutrophils were passively transferred directly into the circulation of 
mice. Isolated human neutrophils injected into the lateral tail vein of 
immunodeficient mice were rapidly cleared from the circulation (Fig 5.1). 
Although the whereabouts of the infused neutrophils was not investigated, it is 
likely that they were cleared from the circulation by the bone marrow, liver and 
spleen. Indeed, following the intravenous injection of radiolabelled neutrophils 
into mice, high levels of radioactivity were detected in these organs [294]. 
Furthermore it was demonstrated that, in mice, each of these organs was 
responsible for approximately 30% of neutrophil clearance from the peripheral 
blood under homeostatic conditions [295]. Further to this, radiolabelled 
neutrophils infused into human volunteers, both with and without sepsis, were 
revealed to be cleared from the circulation by the bone marrow, liver and 
spleen over the 24 hour period post passive transfer [296].  
 
It is not only their rapid clearance from the circulation that makes the passive 
transfer of human neutrophils into mice unsuitable for their study in vivo. 
Indeed, in addition to this neutrophils are very short-lived cells with a half-life 
of only 6-8 hours. Therefore, even if they were not cleared rapidly, human 
neutrophils would disappear from mouse circulation within a relatively short 
space of time. Consequently, to overcome this, mice would require daily 
injections of neutrophils if longer studies were to be performed. Thus, instead 
of a passive transfer model, a mouse model that constantly generates, and 
replaces, human neutrophils is required. 
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Humanised mice 
 
Human immune cells are present in mice reconstituted with human HSCs for 
up to twelve months [127, 149]. The lack of human progenitor renewal, itself 
due to the lack of a maintence pool of human HSCs, may be responsible for 
the eventual disappearance of human cells from these mice [148]. As human 
cells are present for an extended period of time, humanised mice may provide 
an effective tool to study human neutrophils in vivo and this will be discussed 
at length in the following chapter. In this chapter, the generation of mice with 
human lymphocytes present in their bone marrow, spleen and circulation was 
investigated.  
 
As discussed in Section 5.1, human UCB was chosen to repopulate irradiated 
NOD-scid IL2γ-/- mice with human cells. Thus, establishing a source of human 
HSCs was the first step in the generation of humanised mice. As procuring 
cord blood samples directly from women is both difficult, and time consuming, 
it was decided to purchase non-clinical grade UCB samples from The Anthony 
Nolan Trust and the National Blood Service, Oxford and Collindale. Initially, 
cryopreserved UCB was obtained from The Anthony Nolan Trust. The use of 
frozen UCB allowed greater control over the timing of sample processing. 
Using the Miltenyi MACS separation system, CD34+ HSCs were purified from 
frozen UCB. However, the cell suspensions obtained from this were thought 
to be insufficiently pure (Table 5.4). That is they appeared to contain more 
than 1% CD3+ T cells, and thus, if injected into mice would likely induce graft 
vs host disease. In hindsight, it is possible that a proportion of the CD3+ cells 
were actually dead. Indeed, dead cells may bind non-specifically to MACS 
microbeads (Manufacturers Protocol). However, as no dead cell stain was 
used, it is difficult to be completely certain of the viability of the CD3+ cells 
identified in Figure 5.2 and Table 5.4. Thus, believing that CD34+ cells 
suitable for injection into mice could not be isolated from frozen cord blood, 
fresh cord blood was obtained from the National Blood Service. In the initial 
experiment UCB from a single donor was divided into two equal parts. One 
part was used to test CD34+ cell separation using the MACS system, while 
the other half was used to test CD3+ cell depletion using RosetteSep followed 
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by magnetic CD34+ cell selection using EasySep (Fig 5.3). Contaminating 
CD3+ T cells (>1% of the total cell suspension) remained after MACS 
separation; however, they were completely absent after treatment with 
RosetteSep CD3 depletion cocktail. CD34+ cell selection using EasySep was 
then used to give a cell suspension comprising approximately 84% CD34+ 
cells. It has been suggested that T cell depleted cord blood may be more 
efficient than isolated CD34+ cells when it comes to repopulating conditioned 
NOD-scid IL2γ-/- mice with human immune cells [128, 293]. Therefore, and 
taking into account the time and expense required to isolate CD34+ cells, it 
was decided that CD3+ cell depleted UCB cells would be used to engraft 
mice. At approximately the same time, though not in parallel, it was decided 
that CD34+ cells derived from UCB would be purchased from Lonza and used 
to generate humanised mice.  Both CD3 depleted UCB cells (Fig 5.4) and 
CD34+ cells from Lonza (Fig 5.5) gave rise to human CD45+ cells in the 
peripheral blood of irradiated NOD-scid IL2γ-/- mice as early as 4 weeks post 
engraftment. Mice engrafted with the CD3+ cell depleted UCB cells did not 
see a significant increase in their percentage of human CD45+ cells over time 
(Fig 5.3). In contrast, mice engrafted using the enriched CD34+ stem cells 
showed a significant increase in their human leukocyte levels at 8 weeks 
compared to 4 weeks post engraftment. These levels then stayed fairly 
constant between 8 and 12 weeks post engraftment (Fig 5.4). Importantly, the 
mice that were reconstituted using enriched CD34+ cells showed enhanced 
engraftment compared to their counterparts that received CD3+ cell depleted 
UCB cells, although this was not formally compared in this experiment. In 
order to confirm this observation, two groups of mice were engrafted side-by-
side; with one group receiving CD34+ Lonza cells and one group receiving 
CD3 depleted UCB cells (Fig 5.6). The mice were then assessed together at 9 
weeks post engraftment. The results showed that mice reconstituted with 
enriched CD34+ cells from Lonza had significantly higher levels of human 
leukocytes in their circulation compared to mice reconstituted with CD3+ cell 
depleted UCB cells. The reason for this is unclear, however, it may be related 
to the age of the cord blood (It was a minimum of 24 hours before isolation of 
CD34+ cells could be performed). Regardless, it was decided that for future 
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experiments, isolated CD34+ cells purchased from Lonza would be used for 
the generation of humanised mice. 
 
Due to differing levels of engraftment, human cells of the lymphoid lineage 
have been more extensively studied than cells of the myeloid lineage in 
humanised mice (Discussed in detail in Chapter 1). As a consequence of this, 
early attempts to characterise the humanised mice in this study focused on 
the identification of human CD19+ B cells and human CD3+ T cells. 
Mice were exsanguinated at 12 weeks post engraftment and their bone 
marrow and spleens were harvested for analysis. Human CD45+ cells were 
identified in the bone marrow, spleen and peripheral blood of all mice tested 
(Fig 5.7). Consistent with their roles in leukocyte production and storage, the 
bone marrow and the spleen of all mice tested contained a large numbers of 
CD45+ cells. Furthermore, the majority of human CD45+ cells found, in the 
bone marrow, spleen and peripheral blood, were CD19+ B cells (Fig 5.8). 
CD3+ T cells were found to be present in the spleen and blood but not the 
bone marrow of mice tested. As T cells are generated in the thymus and not 
the bone marrow the lack of T cells in the bone marrow of these mice was 
unsurprising. In fact, it was the presence of T cells in both the spleen and the 
peripheral blood of these mice that was surprising.  Indeed, previous study 
has shown that NOD-scid IL2γ-/- mice engrafted with HSC as adults do not 
support engraftment of human T cells [128]. The reason for this discrepancy is 
unclear, however, as the mice were healthy and the percentage of human T 
cells was still relatively low it seems unlikely to be due to T cell contamination 
of the CD34+ cell preparation used to engraft the mice. 
 
It has been shown that human leukocytes, primarily lymphocytes, are 
reconstituted in adult irradiated NOD-scid IL2γ-/- mice engrafted with enriched 
CD34+ stem cells. The reconstitution of human myeloid cells, with a particular 
focus on neutrophils, will be discussed in the following chapters.  
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6.1 Introduction 
 
Neutrophils are one of the most important cells in the host defence against 
pathogens. They are the first leukocytes to be mobilised in response to 
infection and they serve to launch the immune response [297]. Importantly, 
neutropenia leads to sepsis and death [298]. Although they are essential for 
our survival, neutrophils can also cause unwanted inflammation and 
pathology during systemic infection or autoimmune disease. Therefore, an 
understanding of neutrophil biology in health and disease is a priority in 
medical research. Unfortunately neutrophils are short-lived cells that are 
easily activated and thus are difficult to study in vitro (Discussed in Chapter 3 
and Chapter 4). To further complicate matters significant differences in human 
and mouse neutrophils have been found. For example, there are important 
differences in the roles and structure of key molecules such as serine 
proteases [299]. Indeed, as mention in Chapter 1, and discussed further in 
Chapter 7, it is likely that it is the differences between human and mouse PR3 
that prevents the development of a mouse model of anti-PR3 ANCA 
associated vasculitis. Therefore, the development of humanised mice with 
functional human neutrophils may be an important step in advancing our 
ability to study these cells. 
 
Up until this point, neutrophils in humanised mouse models have received 
relatively little attention. In one report, human neutrophils, defined as 
CD66b+CD10+ cells, were identified in humanised mice using the zymosan 
induced air pouch model of inflammation [300]. Another report identified 
neutrophils, defined as CD15+CD14- cells, in the bone marrow and spleen of 
human HSC engrafted mice [301]. Neutrophils were also identified in the bone 
marrow of the thrombopoeitin knockin mice, as CD33+CD66hi cells [302]. In a 
more recent study, the differentiation of human myeloid subsets was studied 
in NOD-scid IL2γ-/- mice engrafted as neonates [165]. Granulocytes identified 
in the bone marrow and spleen of these mice included CD15+CD33lowHLA-
DR- neutrophils, CD117-CD123+CD203c+ basophils and 
CD117+CD123+CD203c+HLA-DR- mast cells. 
Chapter 6 Humanised mice have functional human neutrophils 	  
	   197 
It is important to note that in each of these studies neutrophils were identified 
based on their expression of a different set of surface markers. Indeed, this is 
an important issue as the majority of neutrophil surface markers are also 
expressed by other granulocytes. Consequently, care must be taken when 
attempting to identify neutrophils in humanised mice.  
 
CD66b is a single chain GPI-linked member of the carcinoembryonic antigen 
(CEA) family of Ig domain containing glycoproteins [303]. It is expressed 
exclusively on granulocytes (neutrophils, eosinophils and basophils) where it 
is thought to mediate cell-cell adhesion. Indeed, the cross-linking of CD66b 
with monoclonal antibodies can stimulate the adhesion of neutrophils to 
endothelial cells in an integrin dependent manner [304]. Furthermore, CD66b 
molecules have been shown to be involved in regulating the adhesion and 
activation of eosinophils [305].  
 
CD16 (FcγRIII) is a low affinity IgG receptor and is a member of the same 
family as CD64 (FcγRI) and CD32 (FcγRII). There are two CD16 isotypes: 
CD16a is a transmembrane molecule with a distinct cytoplasmic domain 
found on monocytes/macrophages, NK cells, mast cells, T cells and T- and B- 
cell progenitors, while CD16b is a GPI linked molecule thought to be found 
exclusively on neutrophils [306, 307]. While CD66b is expressed by 
granulocytes (not including mast cells), neutrophils are the only one of these 
cells widely believed to also express CD16. Indeed, the presence of CD16 on 
neutrophils, and its usual absence on eosinophils and basophils, is the basis 
of the use of CD16-negative selection for the separation of these cells from 
neutrophils [308, 309]. Therefore, cells that express both CD66b and CD16 
can be defined as neutrophils. Finally, CD16 appears late during neutrophil 
development and thus can be used as a rough marker of neutrophil 
maturation [307]. 
   
In this chapter the reconstitution of functional human neutrophils in humanised 
mice was examined. Human GCSF was used to mobilise neutrophils from the 
Chapter 6 Humanised mice have functional human neutrophils 	  
	   198 
bone marrow into the peripheral blood and the response of these neutrophils 




• To identify human neutrophils in a humanised mouse model  
• To expand the population of human neutrophils  
• To investigate the functional responses, both in vivo and in vitro, of 




6.3.1 Engraftment of NOD-scid IL2γ -/- mice 
 
Humanised mice were generated as described in Section 2.2.11. Briefly, mice 
were engrafted by injecting 1x105 human cord blood CD34+ stem cells, 
purchased from Lonza, into 6-12 week old NOD-scid IL2γ-/- mice 
approximately 4 hours post irradiation at 2.4Gy with a Cs-source irradiator.  
 
6.3.2 Flow cytometry 
 
Mouse blood and tissue was collected as described in Section 2.2.13.1 and 
flow cytometry was performed as described in Section 2.2.1. The antibodies 
used are shown in Table 6.1 and 6.2. Absolute numbers of human and mouse 
cells were calculated from whole blood counts, performed as described in 
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Target Isotype Clone Fluorophore  Supplier Dilution  
CD11b Mouse IgG1, κ ICRF44 APC BD 1:6 
CD16 Mouse IgG1, κ 3G8 APC BD 1:20 
CD16 Mouse IgG1, κ 3G8 PerCP-Cy5.5 BD 1:20 
CD45 Mouse IgG1, κ HI30 V450 BD 1:101 
CD62L Mouse IgG1, κ DREG-56 PerCP-Cy5.5 Biolegend 1:6 
CD63 Mouse IgG1, κ H5C6 PE BD 1:6 
CD66b Mouse IgM, κ G10F5 FITC BD 1:12 
CD66b Mouse IgM, κ G10F5 PE Biolegend 1:12 
CD66b Mouse IgM, κ G10F5 PerCP-Cy5.5 Biolegend 1:20 
PR3 Mouse IgG1, κ PR3G-2 FITC Hycult 1:50 
Control Mouse IgG1, κ MOPC-21 FITC Biolegend 1:250 
MPO Mouse IgG1, κ MPO-7 APC Dako 1:12.5 
Control Mouse IgG1, κ MOPC-21 APC Biolegend 1:50 
 
Table 6.1 Anti-human antibodies used for flow cytometry. All antibodies were 
obtained from commercial sources. 
 
Target Isotype Clone Fluorophore  Supplier Dilution 
CD45 Rat (LOU) IgG2b, κ 30-F11 FITC BD 1:250 
Ly-6G Rat (LEW) IgG2b, κ IA8 AlexaFluor 700 BD 1:200 
 
Table 6.2 Anti-mouse antibodies used for flow cytometry. All antibodies were 
obtained from commercial sources. 
 
6.3.3 Expansion of human neutrophils in vivo 
 
Mice were bled from the saphenous vein between 2 and 6 months post 
engraftment and given 50µg human pegylated GCSF (Neulasta ®, from 
Amgen, Cambridge, UK) subcutaneously. Five days later the mice were bled 
again from the saphenous vein their engraftment levels were assessed using 
flow cytometry. 
Chapter 6 Humanised mice have functional human neutrophils 	  
	   200 
6.3.4 Measuring activation of human neutrophils in vivo 
 
Mice were bled via the saphenous vein and then treated with 50µg human 
pegylated GCSF (Neulasta ®, from Amgen, Cambridge, UK). 5 days later 
they were rebled and then given 10µg highly purified LPS from E.coli, 
Serotype R515 (Enzo Life Sciences, Exeter, UK) intraperitoneally. Two hours 
later the mice were bled from the axillary vessels under terminal anaesthesia 
and their lungs were either harvested for flow cytometric analysis as 
described in Section 2.2.13 or collected for histological analysis as described 
in Section 2.2.16. All blood was taken into lithium heparin tubes. Total 
leukocyte counts were obtained as described in Section 2.2.2.  
 
6.3.5 Immunofluorescence staining 
 
Frozen lung sections were cut and stained as described in Section 2.2.17 
using the antibodies shown in Table 6.3. 
 
Target Isotype Clone Fluorophore  Supplier Dilution 
Human 
CD66b 
IgG1 80H3 NA Serotec 1:100 
Mouse 
IgG 
Goat IgG Fc 
fragment specific 




Table 6.3 Antibodies used for immunofluorescence staining. All antibodies 
were obtained from commercial sources. 
 
6.3.6 Neutrophil functional assays 
 
Respiratory burst assays were carried as described in Section 2.2.7. Due to 
the significant spectral overlap between A) rhodamine 123 and FITC and B) 
rhodamine 123 and PE, human CD45-V450 and human CD66b-PerCP-Cy5.5 
were used flow cytometry (See Table 6.1). Degranulation assays were carried 
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out as described in Section 2.2.8. Neutrophils were identified as human 
CD45+CD66b+ cells for both assays.  
 
6.3.7 Staining for human PR3 and MPO 
 
Immunostaining was performed as described in Section 2.2.14. Flow 
cytometry was carried out as described in Section 6.3.2. For flow cytometry 




Statistics were performed using Graphpad Prism software (Graphpad 
Software Inc, La Jolla, CA, USA). Where two data sets from the same mouse 
were compared a paired t test was used, and for more than two data sets 
from the same mouse a repeated measures ANOVA with Dunnett’s post test 
was used. For data from different mice an unpaired t test was used.  
 
6.4 Results: Human neutrophils are mobilised in peripheral blood of 
humanised mice in response to human GCSF 
 
6.4.1 Treatment with human GCSF increases the number of human 
neutrophils present in the peripheral blood of humanised mice 
 
As established in the previous chapter, NOD-scid IL2γ-/- mice reconstituted 
with human CD34+ UCB HSCs purchased from Lonza had high levels of 
human CD45+ cells present in both their peripheral blood and bone marrow. 
To determine the percentage of these human cells that comprised human 
CD66b+ granulocytes, humanised mice were sacrificed at 12 weeks post 
engraftment and their blood and bone marrow cells were assessed using flow 
cytometry. On average 60.33% of the leukocytes present in their peripheral 
blood of the humanised mice were of human origin (Fig 6.1 A). Of these 
human CD45+ cells less than 0.4%, on average, were also positive for human 
CD66b (Fig 6.1 B). Notably, significantly more human leukocytes were found 
in the bone marrow than in the peripheral blood of these mice (Mean 75.34%). 
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Figure 6.1 Reconstitution of human granulocytes in the peripheral blood and 
bone marrow of humanised mice. (A) Engraftment of human (h)CD45+ cells. 
(B-C) Engraftment of hCD66b+ granulocytes as a percent of human CD45+ 
cells. (B) Data for all mice, with the median of each group indicated by the 
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More importantly, however, human CD66b+ granulocytes represented a 
significantly higher percentage of the human CD45+ cells in this compartment 
(Mean 6.62% of the human CD45+ cells) (Figure 6.1 B). Representative flow 
cytometry plots show the staining for human CD45+CD66b+ cells (Fig 6.1 C).  
Humanised mice at least 8 weeks post engraftment were injected, 
subcutaneously, with 50µg human pegylated GCSF in order to determine if 
these bone marrow human granulocytes could be mobilised into the 
peripheral blood (Fig 6.2). A human CD16 antibody was included in the 
staining to allow the identification of mature human neutrophils. Before GCSF 
treatment human CD66b+CD16+ neutrophils accounted for less that 1% of the 
human CD45+ cells present in the peripheral blood of these mice (Mean 
0.17%). This represented an average of 1.76x103 total human neutrophils per 
mouse (Fig 6.2 A). The same mice were then assessed 5 days post GCSF 
and were to found have significantly more human neutrophils present in their 
peripheral blood. On average, 2.29% of human CD45+ cells were also positive 
for human CD66b and CD16 post GCSF. This represented a new average of 
16.28x103 total human neutrophils per mouse. Representative flow cytometry 
plots show the staining for human CD45+CD66b+CD16+ cells pre and post 
GCSF (Fig 6.2 B). This data was reanalysed to exclude the CD16 marker and 
thus show the effect of GCSF on the total human granulocyte population (Fig 
6.3). Before GCSF treatment human CD66b+ granulocytes accounted for 
approximately 0.25% of the human CD45+ cells present in the peripheral 
blood of these mice. This represented an average of 3.04x103 total human 
granulocytes per mouse (Fig 6.3 A). On average, 2.57% of human CD45+ 
cells were also positive for human CD66b post GCSF. This represented an 
average of 18.57x103 total human granulocytes per mouse. Representative 
flow cytometry plots show the staining for human CD45+CD66b+ cells pre and 
post GCSF (Fig 6.3 C). As can be inferred from a comparison of these two 
figures, and is confirmed in Table 6.4, the majority of human granulocytes 
(Mean±SEM 86.14±1.97%) in the peripheral blood of mice post GCSF are in 
fact positive for both CD66b and CD16 and thus can be characterised as 
mature neutrophils. Consequently, neutrophils will be defined as CD66b+ cells 
in the rest of this chapter. 
Chapter 6 Humanised mice have functional human neutrophils 	  
	   204 
6.4.2 Human GCSF cross-reacts with mouse cells 
 
The number of human and mouse CD45+ cells were assessed both before 
and after GCSF administration (Fig 6.4). While GCSF treatment led to a 
dramatic decline in the percentage of human CD45+ cells that comprised the 
leukocytes in the peripheral blood of these mice, it has no affect on the 
absolute number of human cells present (Mean 1.18x106 human CD45+ cells 
before GCSF vs 1.32x106 human CD45+ cells post GCSF) (Fig 6.4 A). In 
contrast, both the percentage and absolute numbers of mouse CD45+ cells 
were significantly higher post GCSF treatment (Fig 6.4 B). Representative 
flow cytometry plots show the staining for human and mouse CD45+ cells both 
before and after GCSF (Fig 6.4 C). An expansion in the number of peripheral 
blood mouse neutrophils in response to human GCSF was thought to be 
responsible for the increase in mouse CD45+ cells. To investigate this, the 
total number of mouse CD45+ leukocytes and Ly6G+ neutrophils present in 
peripheral blood of humanised mice was assessed before and after GCSF 
treatment (Fig 6.5). The absolute numbers of mouse CD45+ cells was 
significantly higher post GCSF administration (Fig 6.5 A). Importantly, this was 
mirrored by a similarly significant increase in the number of mouse Ly6G+ 
neutrophils (Fig 6.5 B). Representative flow cytometry plots show the staining 
for mouse CD45+Ly6G+ cells, which was used to determine absolute numbers 
of mouse neutrophils both before and after GCSF (Fig 6.5 C) 
 
6.5 Results: Human neutrophils present in the peripheral blood of 
humanised mice undergo functional responses in vivo 
 
6.5.1 Human neutrophils respond to GCSF and LPS in vivo by 
augmenting their expression of activation markers  
 
In order to establish if human neutrophils respond to inflammatory stimuli in 
an appropriate manner in vivo, the level of expression of four neutrophil  
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Figure 6.2 Human CD66b+CD16+ mature neutrophils in the peripheral blood of 
mice (n=11) before and after 5 days of GCSF administration. (A) Data are 
shown as a percent of human CD45+ cells and as absolute numbers , with (B) 
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Figure 6.3 CD66b+ granulocytes in the peripheral blood of mice (n=11) before 
and after 5 days of GCSF administration. (A) Data are shown as a percent of 
human CD45+ cells and as absolute numbers, with (B) representative FACs 
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Mouse 
 









neutrophils as a 
percent of CD66b+ 
granulocytes 
1 17.70 13.38 75.58 
2 8.34 6.76 81.13 
3 7.68 6.65 86.67 
4 17.43 13.71 78.68 
5 17.56 14.16 80.64 
6 6.05 5.39 89.03 
7 23.18 11.18 84.91 
8 41.81 39.34 94.10 
9 13.18 12.99 95.21 
10 24.18 21.51 88.96 
11 36.72 34.03 92.66 
Mean±SEM 18.57±3.49 16.28±3.35 86.14±1.97 
 
Table 6.4 Total number of granulocytes, defined as CD66b+ cells, and mature 
neutrophils, defined as CD66b+CD16+ cells, in the peripheral blood of 
humanised mice post 5 day treatment with human GCSF. The percent of 
human granulocytes comprising neutrophils reconstituted in these mice is 
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Figure 6.4 The effect of GCSF on (A) human and (B) mouse CD45+ 
leukocytes in the peripheral blood of humanised mice (n=11) before and after 
5 days of GCSF treatment. Data are shown as a percent of total leukocytes 
and as absolute numbers, with (C) showing representative FACs plots.**** 




Chapter 6 Humanised mice have functional human neutrophils 	  
	   209 
 
 
Figure 6.5 The increase in the number of mouse CD45+ cells in humanised 
mice (n=7) in response to GCSF correlates with an increase in the number of 
mouse Ly6G+ neutrophils. (A) Absolute numbers of mouse CD45 positive 
cells (B) Absolute numbers of mouse Ly6G+ neutrophils (C) Representative 
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activation markers was measured, using flow cytometry, before and after 5 
days of GCSF treatment, and 2 hours post subsequent LPS or PBS 
administration. It should be noted that flow cytometer settings were kept 
constant for this study, and although the pre and post GCSF samples were 
collected on different days, activation marker expression was analysed at the 
same time using Flowjo software. Furthermore, gates on the human 
CD45+CD66b+ cells were synchronised, thus ensuring there were identical 
gates in place for samples taken both before and after stimulation.   
 
In addition to being a granulocyte marker, CD66b is upregulated in both 
primed and activated neutrophils. Therefore, CD66b expression in human 
CD45+CD66b+ cells before and after GCSF administration was assessed. As 
shown in Figure 6.6 A, CD66b was significantly upregulated post GCSF 
treatment. Importantly, the administration of LPS, but not PBS, resulted in a 
further and significant increase in the surface expression of CD66b (Fig 6.6 
B). Concurrently, human CD11b expression was assessed and found to be 
significantly increased post GCSF (Fig 6.7 A). Subsequent LPS, but not PBS, 
administration resulted in a further, though not statistically significant, 
upregulation in CD11b expression (Fig 6.7 B). In addition to this, CD62L was 
found to be significantly downregulated in human neutrophils post GCSF 
treatment (Fig 6.8A). Notably, the administration of LPS, but not PBS, resulted 
in a further, and significant, shedding of CD62L by human neutrophils (Fig 6.8 
B). Finally, the expression of human CD63 was examined and found to be 
significantly increased post GCSF (Fig 6.9 A). Surface bound CD63 
expression was higher on the neutrophils of mice that had received LPS than 
on the neutrophils of mice that had received PBS (Fig 6.9 B).  
 
6.5.2 Human neutrophils sequester in the lungs of humanised mice in 
response to LPS 
 
The ability of human neutrophils to migrate to the lungs of humanised mice in 
response to LPS was investigated. Neutrophils were identified by human 
CD66b immunofluorescence staining of lung tissue taken at the end of the  
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Figure 6.6 CD66b expression in peripheral blood neutrophils before and after 
(A) GCSF in all mice (n=7), and then either after subsequent (B) PBS (n=3) or 
LPS (n=4). Data for individual mice are shown on the left, with the median of 
each group indicated by the horizontal line, and representative histograms are 
shown on the right. *p<0.05, ***p<0.001. Data shown in (A) was analysed 
using a paired t test, while data shown in (B) was analysed using an unpaired 
t test. 
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Figure 6.7 CD11b expression in peripheral blood neutrophils before and after 
(A) GCSF in all mice (n=7), and then either after subsequent (B) PBS (n=3) or 
LPS (n=4). Data for individual mice are shown on the left, with the median of 
each group indicated by the horizontal line, and representative histograms are 
shown on the right. **p<0.01. Data shown in (A) was analysed using a paired t 
test, while data shown in (B) was analysed using an unpaired t test. 
 
Chapter 6 Humanised mice have functional human neutrophils 	  
	   213 
 
 
Figure 6.8 CD62L expression in peripheral blood neutrophils before and after 
(A) GCSF in all mice (n=7), and then either after subsequent (B) PBS (n=3) or 
LPS (n=4). Data for individual mice are shown on the left, with the median of 
each group indicated by the horizontal line, and representative histograms are 
shown on the right. *p<0.05. Data shown in (A) was analysed using a paired t 
test, while data shown in (B) was analysed using an unpaired t test. 
 
Chapter 6 Humanised mice have functional human neutrophils 	  
	   214 
 
 
Figure 6.9 CD63 expression in peripheral blood neutrophils before and after 
(A) GCSF in all mice (n=7), and then either after subsequent (B) PBS (n=3) or 
LPS (n=4). Data for individual mice are shown on the left, with the median of 
each group indicated by the horizontal line, and representative histograms are 
shown on the right. *p<0.05, **p<0.01. Data shown in (A) was analysed using 
a paired t test, while data shown in (B) was analysed using an unpaired t test. 
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Figure 6.10 CD66b+ human neutrophils in the lungs of mice 5 days post 
GCSF treatment and 2 hours post PBS (n=3) or LPS (n=4) administration. (A) 
Average number of human neutrophils per high powered field (B) 
Representative lung tissue showing immunofluorescence staining for CD66b. 
(C-D) Total number of peripheral blood neutrophils 5 days post GCSF (C) and 
2 hours after subsequent LPS or PBS administration (D). ****p<0.0001. Data 
was analysed using an unpaired t test. The dot plots show the median values 
of the populations (horizontal line). 
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experiment described in Section 6.5.1. Neutrophil numbers and representative 
histology are shown in Figure 6.10 A-B. There were significantly more  
neutrophils seen in the lungs of mice receiving LPS compared to those given 
PBS (Fig 6.10 A). Furthermore, neutrophils were seen in the alveolar 
capillaries and were not located in the air spaces (Fig 6.10 B). When the total 
number of peripheral blood human neutrophils were compared in these two 
groups there was no difference observed either post GCSF pre LPS/PBS (Fig 
6.10 C) or post GCSF and LPS/PBS (Fig 6.10 D). Finally, the activation status 
of human neutrophils, as measured by expression of CD66b, CD11b, CD62L 
and CD63, found in collagenase-digested lungs were assessed using flow 
cytometry (Fig 6.11). Lung neutrophils taken from mice that had received LPS 
expressed significantly more human CD66b than their counterparts taken 
from PBS treated mice (Fig 6.11 A). There was no difference in the 
expression of hCD11b (Fig 6.11 B), hCD62L (Fig 6.11 C) or hCD63 (Fig 6.11 
D). 
 
6.6 Results: Peripheral blood human neutrophils from humanised mice 
undergo respiratory burst and degranulate in response to fMLP and 
E.coli in vitro 
 
The ability of human neutrophils generated by humanised mice to exhibit 
functional responses in vitro was examined. In order to avoid the 
complications and potential artifacts of neutrophil isolation whole blood assays 
were chosen for this purpose. It must be noted that all mice received human 
pegylated GCSF 5 days before the assays were performed. Whole blood 
human neutrophils from humanised mice underwent respiratory burst, as 
measured by the generation of rhodamine 123, in response to both fMLP and 
opsonised E.coli (Fig 6.12). While there was an increase in rhodamine 123 
production in response to fMLP in 3 out of 4 mice, overall this did not reach 
statistical significance (p=0.07). In contrast, the human neutrophils from all 
mice produced more rhodamine 123 when stimulated with opsonised E.coli 
and this was statistically significant. Degranulation was measured by the 
upregulation of human CD63, CD66b and CD11b on the surface of human 
whole blood neutrophils. As shown in Figure 6.13, there was a significant  
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Figure 6.11 Phenotype of human CD45+CD66b+ neutrophils obtained from 
digested lung tissue showing expression of CD66b, CD11b, CD62L and CD63 
in the same PBS (n=3) or LPS (n=4) treated mice from figure 6.10. *p<0.05. 
Data was analysed using an unpaired t test. The dot plots show the median 
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Figure 6.12 A respiratory burst shown by rhodamine 123 generation in 
response to fMLP or E.coli in a whole blood assay. All mice (n=4) had 
received GCSF 5 days prior to obtaining blood for the assays, and all data 
shown was obtained after gating on hCD45+hCD66+ cells. (A) Shows data for 
each individual mouse, with the median indicated by the horizontal line and 
(B) shows representative histograms. **p<0.01. Data was analysed using a 






Chapter 6 Humanised mice have functional human neutrophils 	  
	   219 
 
 
Figure 6.13 Expression of CD63 in response to fMLP or E.coli in a whole 
blood assay. All mice (n=4) had received GCSF 5 days prior to obtaining 
blood for the assays, and all data shown was obtained after gating on 
hCD45+hCD66+ cells. (A) Shows data for each individual mouse, with the 
median indicated by the horizontal line and (B) shows representative 
histograms. *p<0.05, ** p<0.01. Data was analysed using a repeated 
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increase in human CD63 in response to both fMLP and opsonised E.coli, 
though it was more marked for fMLP. Similarly, there was a significant 
increase in the surface expression of human CD66b in response to fMLP (Fig 
6.14). However, CD66b expression was unchanged following stimulation with 
opsonised E.coli. Furthermore, while there was an increase in CD11b 
expression on the surface of human neutrophils in response to fMLP in 3 out 
of 4 mice, overall this did not reach statistical significance (p=0.059) (Fig 
6.15). Finally, opsonised E.coli did not appear to induce human CD11b 
upregulation. 
 
6.7 Results: Human neutrophils derived from the bone marrow of 
humanised mice express the ANCA antigens PR3 and MPO 
 
The expression of human PR3 and MPO by human neutrophils generated by 
humanised mice was investigated. Bone marrow cells from HSC engrafted 
mice that had not received GCSF were fixed in ethanol and 
immunofluorescent staining for human PR3 and MPO was performed. 
Neutrophils were identified based on their morphology with the help of 
Hoeshst dye, which stains nuclei blue. Representative immunofluorescent 
staining demonstrating the present of human neutrophils expressing both PR3 
and MPO is shown in Figure 6.16 A. In addition to this, flow cytometry was 
performed, gating on hCD45+CD66b+ cells, in order to confirm the presence of 
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Figure 6.14 Expression of CD66b in response to fMLP or E.coli in a whole 
blood assay. All mice (n=4) had received GCSF 5 days prior to obtaining 
blood for the assays, and all data shown was obtained after gating on 
hCD45+hCD66+ cells. (A) Shows data for each individual mouse, with the 
median indicated by the horizontal line and (B) shows representative 
histograms.  ** p<0.01. Data was analysed using a repeated measures 
ANOVA with a Dunnett’s post test. 
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Figure 6.15 Expression of CD11b in response to fMLP or E.coli in a whole 
blood assay. All mice (n=4) had received GCSF 5 days prior to obtaining 
blood for the assays, and all data shown was obtained after gating on 
hCD45+hCD66+ cells. (A) Shows data for each individual mouse, with the 
median indicated by the horizontal line and (B) shows representative 
histograms. Data was analysed using a repeated measures ANOVA with a 
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Figure 6.16 Human PR3 and MPO expression in bone marrow derived human 
CD66b+ neutrophils in humanised mice. (A) Ethanol fixed bone marrow 
derived neutrophils showing immunofluorescence staining for human PR3 and 
MPO (Green). Hoechst dye (Blue) was used to stain the nuclei of the cells. 
Images are representative of 3 separate experiments (B) Human PR3 and 
MPO on the surface of human neutrophils as measured by flow cytometry and 
with gating on hCD45+CD66b+ cells (n=1) 
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6.8 Discussion 
 
The role of GCSF in mobilising human neutrophils generated in 
humanised mice from the bone marrow into the circulation 
 
Human granulocyte reconstitution in humanised mice is poor. While human 
granulocytes accounted for, on average, 6.62% of human cells in the bone 
marrow of humanised mice, they constituted, on average, only 0.4% of the 
human cells present in the peripheral blood (Fig 6.1). The relatively low 
frequency of human granulocytes both in the bone marrow and in the 
circulation is most likely due to an inadequate cytokine environment. Previous 
strategies to improve myeloid engraftment in humanised mice have included 
the transient expression of human cytokines through injection of viral vectors, 
the construction of transgenic mice with human transgenes, and the 
generation of knockin mice expressing human homologues of murine genes 
(Discussed in Chapter 1). The role of GCSF in neutrophil differentiation, 
mobilisation and activation has previously been discussed (Chapter 4). Since 
neutrophils are short-lived cells that develop rapidly when required, and long 
acting human GCSF is readily available, the more straightforward approach of 
direct injection of the cytokine protein was chosen for the purpose of 
expanding the population of peripheral blood neutrophils. In addition to being 
relatively easy from a technical standpoint, using this approach ensured that 
all mice had similar levels of cytokine, which may not be the case with the use 
of viral vectors for cytokine gene expression. As demonstrated, this strategy 
led to a dramatic increase in the number of peripheral blood circulating 
neutrophils, defined as CD45+CD66b+CD16+ cells (Fig 6.2). It must be noted 
here that there was a decrease in the fluorescent intensity of the CD16 
staining, however, this is agreement with previously published data [310]. 
These results correspond with those of a recent study in which it was 
demonstrated that humanised mouse bone marrow derived human 
CD45+CD33+ cells, which comprise neutrophils, monocytes and DCs, 
expressed the GCSF receptor [165]. In addition, it was shown that GCSF 
induced STAT3 and STAT5 phosphorylation in these cells in vitro. This is an 
important finding as STAT3 is thought to be essential for GCSF mediated 
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granulopoeisis, while STAT5 plays a role in the proliferation and survival of 
mature neutrophils. Finally, it was shown in this study that humanised mice 
treated with recombinant human GCSF for 5 days had an increase in the 
frequency of human CD45+CD15+CD33low neutrophils present in their 
circulation. Thus, this study together with the data shown here confirm that 
human bone marrow derived neutrophils generated in humanised mice are 
mobilised from the bone marrow into the peripheral blood in a similar manner 
to normal human neutrophils. 
 
In addition to mobilising human granulocytes from the bone marrow of 
humanised mice into their circulation (Fig 6.2, 6.3), human GCSF also led to 
an increase in both the percentage and absolute number of mouse cells 
composing the population of leukocytes in the humanised mouse peripheral 
blood (Fig 6.4). This resulted in a corresponding decrease in the percentage 
of human CD45+ cells, while leaving their total number largely unaffected. 
Given that human and mouse GCSF are approximately 76% identical at the 
amino acid level, and that the two proteins show species cross reactivity [311-
313] it was theorised that the increase in the number of mouse cells was due 
to the mobilisation of mouse neutrophils from the bone marrow into the 
peripheral blood in response to GCSF. This was confirmed by the addition of 
an antibody against mouse neutrophil marker Ly6G in the analysis of a 
different group of mice that had received GCSF for 5 days (Fig 6.5). In this 
group, the increase in the number of mouse CD45+ cells was closely mirror by 
an increase in the number of mouse Ly6G+ cells present in the mouse 
peripheral blood. 
 
GCSF and LPS induce humananised mouse human neutrophil activation 
in vivo  
 
Technical difficulties, such as compensation issues and the instability of 
tandem conjugate fluorescent antibodies, arise when performing multicolour 
flow cytometry involving more than six colours. Consequently, and taking into 
account the importance of examining a wide range of neutrophil activation 
markers, it was decided to determine if, for the purpose of this study, CD66b 
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alone could be used to identify neutrophils. To achieve this, the data from the 
initial GCSF induced neutrophil mobilisation experiments (Fig 6.2) were 
reanalysed to exclude the CD16 marker (Fig 6.3). This allowed the number of 
human neutrophils (CD45+CD66b+CD16+) present in the peripheral blood post 
GCSF to be expressed as a percentage of the total number of granulocytes 
(CD45+CD66b+)(Table 6.4). As can be seen the vast majority of CD66b+ cells 
were also CD16+  (Mean±SEM 86.14±1.97%) and thus the majority of 
granulocytes present in the peripheral blood post GCSF were in fact 
neutrophils. Furthermore, if it is taken into account that CD16 is only present 
on neutrophils during the last stages of development [307] then it is also 
possible that some of the CD66b+CD16- cells are in fact immature neutrophils. 
Given both the normally small percentage of eosinophils (1-4%) and basophils 
(0.5-1%) present in the human circulation, and the low frequency of human 
basophils (0.1%) [165] found in the bone marrow and spleen of humanised 
mice, this is likely. Therefore, CD66b was used to identify neutrophils when 
investigating their ability to respond to stimuli in vivo and in vitro. 
 
Neutrophils possess a wide array of activation markers, four of which were 
investigated using flow cytometry in the course of this study. Due to its 
abundance in the intracellular stores of neutrophils and its upregulation in 
response a variety of inflammatory stimuli, CD66b is not only a surface 
marker but also an activation marker for neutrophils [307]. Similarly, CD63 is 
present in the azurophilic granules of neutrophils and is translocated to the 
surface of activated cells [314]. Finally, both CD62L (L selectin) and CD11b 
are involved in neutrophil adhesion. CD62L, like other selectins, mediates the 
initial attachment of leukocytes to endothelial cells [286]. It is characteristically 
downregulated, or shed, in response to cell activation [287]. CD11b is a  β2-
integrin that associates with CD18 to form Mac-1. Mac-1 mediates the firm 
adhesion of neutrophils to endothelial cells and is involved in the 
transmigration of neutrophils to sites of inflammation [287]. It is present in the 
membranes of secretory, gelatinase and specific granules of neutrophils [315] 
and is characteristically upregulated in activated cells.  
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For the study of neutrophil activation in response to GCSF in vivo, flow 
cytometer settings were kept constant and the expression of activation 
markers both before and after stimulation was analysed together using Flowjo 
software. Gates on the human CD45+CD66b+ cells were synchronised, thus 
ensuring there were identical gates in place for samples taken both before 
and after stimulation. All mice in this study received GCSF for 5 days. They 
were then divided into two groups with some given LPS and some PBS as a 
control. The expression of activation markers between the LPS and the PBS 
groups was compared 2 hours post administration with samples both run and 
analysed together. CD66b, CD11b and CD63 showed increased expression 
post GCSF (Fig 6.6. 6.7 and 6.9 respectively). Concurrently, CD62L 
expression was downregulated (Fig 6.8). This is entirely consistent with 
previous findings for these markers in humans [316, 317]. Furthermore, 
subsequent LPS but not PBS administration resulted in a significant increase 
in CD66b and CD63 expression and with further shedding of CD62L (Fig 6.6. 
6.8 and 6.9, respectively). There was an upregulation in CD11b in response to 
LPS, however, when compared to PBS treated mice this was not statistically 
significant (Fig 6.7). It is possible that total CD11b expression, as measured 
here, was a poorly chosen marker of humanised mouse human neutrophil 
activation. Indeed, it has been shown in vivo that conformational activation of 
CD11b on mouse neutrophils can occur in the absence of total CD11b 
upregulation [318]. In addition, it was shown that, if present, the upregulation 
of total CD11b on mouse neutrophils in vivo is both mild and short lived. In 
contrast, a subpopulation of neutrophils was found to persistently express 
increased levels of the CD11b activation epitope CBRM1/5. Thus, it is likely 
that CD11b mobilisation from intracellular reservoirs and CD11b activation 
can be regulated independently by neutrophils in vivo, and that CBRM1/5 
expression is a more sensitive marker of circulating neutrophil activation than 
total CD11b expression [318]. Despite this, taken together these results 
demonstrate that human neutrophils reconstituted by humanised mice are 
activated in vivo in a manner similar to normal human neutrophils.  
 
Gram-negative sepsis is a major cause of mortality. Regardless of the source 
of sepsis a prominent pulmonary neutrophil influx often occurs and this lung 
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injury may be the major cause of death [319]. Consequently, the ability of 
neutrophils to traffic to the lungs in response to LPS was examined. There 
were significantly more neutrophils found in the lungs of mice receiving LPS 
than in those receiving PBS. Furthermore, the neutrophils were located in the 
alveolar capillaries and not found in the air spaces (Fig 6.10). Importantly, 
when the total numbers of peripheral blood neutrophils were compared, there 
was no difference found between mice receiving LPS or PBS. This confirms 
that neutrophils had migrated to the lung in response to LPS and the 
difference in numbers did not reflect differences in peripheral blood numbers. 
The mechanisms of neutrophil sequestration in the lung in response to sepsis 
are not fully understood although current data obtained in fully murine models 
suggests that stimulation of TLR4 on endothelial cells plays a key role [320], 
and that it may be selectin and β2 integrin independent [320, 321]. This fits 
with the data showing that human neutrophils, taken from the lungs of mice 
that had received LPS, expressed similar levels of CD11b, CD62L and CD63, 
as those that received PBS (Fig 6.11 B-D). Interestingly, there was 
significantly more CD66b expressed on the human neutrophils taken from the 
lungs of LPS treated mice than on their counterparts taken from PBS treated 
mice (Fig 6.11 A). Given the already established role of CD66b in neutrophil-
endothelial cell adhesion [304], this perhaps suggests a role for CD66b in 
neutrophil sequestration in the lung in response to LPS. Although, it must also 
be noted that there was an increase in CD66b levels in peripheral blood 
neutrophils of LPS treated mice, and so the neutrophils in the lungs could 
merely be representative of those in the circulation. In addition, it must also be 
taken into account that peripheral blood neutrophils from mice that had 
received LPS expressed higher levels of CD11b and CD63 together with 
lower levels of CD62L. Therefore, it is possible that these cells are 
preferentially trapped in the lungs and that CD11b, CD63 and CD62L are 
important despite previous reports in fully murine systems [320, 321].  
 
Human neutrophils reconstituted by humanised mice undergo 
respiratory burst and degranulation in vitro 
 
The role of neutrophils in host defence, and in tissue damage, is based on 
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their ability to, upon activation, a) produce highly toxic reactive oxygen 
species and b) to release proteolytic enzymes from intracellular storage 
granules. Therefore, using whole blood neutrophils from mice treated with 
GCSF for 5 days, the ability of human neutrophils generated by humanised 
mice to undergo respiratory burst and degranulation was examined.  
Human neutrophils stimulated with fMLP and opsonised E.coli produced 
intracellular reactive oxygen species as measure by the production of 
rhodamine 123 (Fig 6.12). The respiratory burst in response to opsonised 
E.coli was more robust than the response to fMLP. This is perhaps 
unsurprising given that E.coli is a strong particulate stimulus while fMLP is a 
low soluble stimulus. 
 
Degranulation is frequently measured by the release of granular contents 
such as MPO, lysozyme and neutrophil elastase. This approach, however, 
would require the purification of human neutrophils from humanised mouse 
bone marrow or blood. Fortunately, degranulation can also be measured by 
the selective upregulation of granule membrane molecules such as CD63 
(azurophilic granules), CD66b (secondary granules) and CD11b (secretory, 
gelatinase and specific granules) [314, 322]. This is made possible by the fact 
that the granule membrane containing these markers fuses with the plasma 
membrane thus leading to an increase in their surface expression [314]. Using 
this, degranulation can be measured by flow cytometry, and thus human 
neutrophil specific degranulation can be examined without the need to isolate 
the cells. Humanised mouse human neutrophils underwent degranulation in 
response to both fMLP and opsonised E.coli. There was a significant increase 
in human CD63 in response to both fMLP and E.coli (Fig 6.13). Similarly, 
there was a significant increase in the surface expression of human CD66b in 
response to fMLP, although there was no response to E.coli (Fig 6.14). 
Finally, while there was an increase in CD11b expression on the surface of 
human neutrophils in response to fMLP in 3 out of 4 mice, overall this did not 
quite reach statistical significance (p=0.059) (Fig 6.15).  
 
Neutrophils release their granules in the following order: secretory vesicles > 
tertiary granules > secondary granules > azurophilic granules [323]. Therefore 
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it would be expected that if E.coli induces the upregulation of CD63, the result 
of the release of azurophilic granules, then it must also induce the 
upregulation of CD66b and CD11b, indicating the release of secondary and 
tertiary granules, and secretory vesicles. However, this was not observed. 
The likely reason for this discrepancy is the variability of CD66b and CD11b 
expression on the surface of humanised mouse human neutrophils, combined 
with small mouse cohorts. CD63 expression on the surface of humanised 
mouse human neutrophils is relatively low and, furthermore, there is very little 
variability in CD63 expression between mice (Fig 6.13). Thus even a small 
increase in expression appears to be statistically significant. In contrast, 
CD66b and CD11b appear to be highly expressed on the surface of 
humanised mouse human neutrophils and, importantly, the levels of 
expression of these two molecules vary between mice (Fig 6.14 and Fig 6.15, 
respectively). Thus, although there may be an increase in the expression of 
CD66b and CD11b in response to E.coli, it does not reach statistical 
significant due to the variance. It is likely, had more mice been available, that 
a larger sample size would have overcome this variability and led to statistical 
significance being achieved. Similarly, the variability of CD11b expression 
between mice may explain why the increase in CD11b expression, in contrast 
to the increase in CD66b and CD63 expression, in response to fMLP was not 
found to be statistically significant.  
 
Despite these technical issues, together these data indicate that human 
neutrophils in the peripheral blood of humanised mice are capable of 
undergoing respiratory burst and degranulation in response to inflammatory 
stimuli.  
 
Human PR3 and MPO expression by human neutrophils reconstituted by 
humanised mice 
 
The ultimate goal in establishing a humanised mouse model with functional 
human neutrophils present in the peripheral blood is to allow the development 
of an in vivo model of anti-PR3 induced ANCA associated vasculitis. 
Therefore, the expression of human PR3, and to a lesser extent human MPO, 
Chapter 6 Humanised mice have functional human neutrophils 	  
	   231 
by human neutrophils generated by humanised mice is of the upmost 
importance. To investigate the expression of human PR3 and MPO, 
immunofluorescent staining of ethanol fixed humanised mouse bone marrow 
neutrophils was performed. The ethanol fixation and subsequent staining of 
neutrophils for PR3 and MPO produces characteristic staining patterns. 
Antibodies against PR3 produce a diffusely cytoplasmic, internuclear staining 
pattern (c-ANCA) while antibodies against MPO generally produce a 
perinuclear staining pattern with some nuclear extension (p-ANCA). These 
patterns are artefacts of the ethanol fixation process and are related to the 
charge of the protein in question [324, 325]. Using human monoclonal 
antibodies, PR3 and MPO were found to be present in a small percentage of 
humanised mouse neutrophils (Fig 6.16 A). Furthermore, the antibody against 
human PR3 produced a perinuclear staining pattern. The staining pattern 
produced by the anti-MPO antibody was somewhat indistinct, however, it did 
appear to be cytoplasmic with some nuclear extension. It must be noted that 
human neutrophils were identified based on their reactivity with antibodies 
specific for human proteins. Therefore, as there may have been some cross 
reactivity with the mouse proteins, the presence of PR3 and MPO on human 
neutrophils was confirmed using flow cytometry. PR3 and MPO were both 
found to be expressed on the surface of TNFα primed human neutrophils 
(CD45+CD66b+ cells) in humanised mouse bone marrow (Fig 6.16 B).   
These data, together with the data showing that humanised mouse human 
neutrophils respond to inflammatory stimuli both in vivo and in vitro, suggest 
these cells have all the components required to induce disease when 
activated by human anti-PR3 and/or anti-MPO antibodies in vivo. This will be 
discussed in the following chapter. 
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7.1 Introduction 
 
Attempts to develop models of anti-PR3 ANCA induced vasculitis, and thus 
provide evidence of a pathogenic role for anti-PR3 antibodies in disease 
development, have remained largely unsuccessful (Discussed in depth in 
Chapter 1). One possible reason for this is that murine PR3 is functionally 
more similar to both human and mouse neutrophil elastase than to human 
PR3 [104]. Consequently, human anti-PR3 antibodies do not recognise 
mouse PR3. Furthermore, PR3 is unlikely to be present on the surface of 
mouse neutrophils, and thus, likely remains unavailable to circulating anti-PR3 
antibodies, whether of mouse or human origin. Evidence suggests that this is 
in fact the case, as PR3 is undetectable on the surface of freshly isolated 
mouse neutrophils [101]. Interestingly, in the same study PR3 was detected 
on the surface of peritoneal exodate neutrophils. This, however, is likely to be 
an artefact and a consequence of the activating effects of the isolation method 
used, which involved the mice receiving 1ml of a 9% sterile casein solution via 
intraperitoneal injection. Peritoneal cells were then isolated 3 hours later by 
peritoneal gavage. Thus the lack of circulating neutrophils expressing PR3 
must be overcome if a mouse model of anti-PR3 associated vasculitis is to be 
established. One possible approach to this issue is to use the humanised 
mouse model described in the previous chapter. In addition to having 
circulating, functional, and already primed human neutrophils present in their 
peripheral blood, these mice express PR3, which is recognised by human 
anti-PR3 antibodies, on the human neutrophils they reconstitute. Thus, this 
model not only provides the opportunity to establish a role of anti-PR3 
antibodies in disease induction, but it also provides the possibility of directly 
demonstrating a role for human anti-PR3 antibodies derived from patients in 
the pathogenesis of ANCA associated vasculitis.  
 
As discussed in Chapter 1, the passive transfer of anti-MPO antibodies raised 
in MPO-/- mice results in the development of a mild necrotising cresentic 
glomerulonephritis in wildtype mice. In addition, LPS was shown to 
exacerbate disease in this model. Therefore, in this chapter, the ability of 
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patient derived anti-MPO and anti-PR3 antibodies passively transferred into 
humanised mice, that had also been administered human GCSF and LPS, to 




• To induce cresentic glomerulonephritis and/or pulmonary haemorrhage 





All plasma samples, from both patients and healthy controls, were taken with 
informed consent and ethical approval (NRES committee London—London 
Bridge 09/H084/72). 
 
7.3.1 Generation of humanised mice   
 
Humanised mice were generated as described in Section 2.2.11. Briefly, mice 
were engrafted by injecting 1x105 human cord blood CD34 positive stem cells, 
purchased from Lonza, into 6-12 week old NOD-scid IL2γ-/- mice 
approximately 4 hours post irradiation at 2.4Gy with a Cs-source irradiator.  
 
7.3.2 Antibody purification 
 
Human IgG from either healthy controls or ANCA positive patients was 
purified using ammonium sulphate precipitation followed by Protein G 
antibody purification as described in Section 2.2.3.1. IgG was stored at at -
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7.3.3 PR3/MPO capture ELISA 
 
ELISAs for antibodies against PR3 and MPO were carried out using the 
Weislab Capture PR3 and MPO ELISA Kits as described in Section 2.2.5. 
Purified antibody was diluted in PBS to give a final concentration of 20µg/ml 
per test. Serum was diluted 1:100 in PBS before testing. 
 
7.3.4 Flow cytometry 
 
Mouse blood was collected either from the saphenous vein of conscious mice 
or from the axillary vessels of mice under terminal anaesthesia as described 
in Section 2.2.13.1. Flow cytometry was performed as described in Section 
2.2.1. The antibodies used are shown in Table 7.1 and 7.2. Absolute numbers 
of human and mouse cells were calculated from whole blood counts, 
performed as described in Section 2.2.2, and flow cytometry data. 
 
Target Isotype Clone Fluorophore  Supplier Dilution  
CD14 Mouse IgG2a, κ M5E2 APC BD 1:6  
CD16 Mouse IgG1, κ 3G8 PerCP-Cy5.5 BD 1:20 
CD45 Mouse IgG1, κ HI30 V450 BD 1:101 
CD66b Mouse IgM, κ G10F5 PE Biolegend 1:12 
 
Table 7.1 Anti-human antibodies used for flow cytometry. All antibodies were 
obtained from commercial sources. 
 
Target Isotype Clone Fluorophore  Supplier Dilution 
CD45 Rat (LOU) IgG2b, κ 30-F11 FITC BD 1:250 
 
Table 7.2 Anti-mouse antibodies used for flow cytometry. All antibodies were 
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7.3.5 Inducing disease 
 
Two separate experiments were carried in the hope of inducing disease in 
humanised mice. In both cases, humanised mice between 8 and 12 weeks 
post engraftment were matched based on the absolute number of human 
neutrophils and monocytes present in their peripheral blood. In the first 
experiment (Section 7.4) mice were treated as follows:   
 
Day 0-Engrafted mice received 6µg GCSF subcutaneously, 10µg LPS 
intraperitoneally and 4mg IgG (either control of patient derived ANCA) via the 
lateral tail vein 
 
Day 1 and 2-Mice received 6µg GCSF subcutaneously 
 
Day 3-Mice received 6µg GCSF subcutaneously and 10µg LPS 
intraperitoneally 
 
Day 4 and 5-Mice received 6µg GCSF subcutaneously 
 
Day 6-Mice received 6µg GCSF subcutaneously and were placed in 
metabolic cages overnight for urine collection 
 
Day 7-  
1. Mice were exsanguinated and their blood collected into heparin tubes 
for flow cytometric analysis and into eppendorfs for serum collection 
2. Their kidneys and lungs were harvested for histological analysis 
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While in the second experiment (Section 7.5) mice were treated as follows: 
 
Day 0-Engrafted mice received 50µg pegylated GCSF subcutaneously, 10µg 
LPS intraperitoneally and 4mg IgG (either control of patient derived ANCA) via 
the lateral tail vein 
 
Day 3-Mice received 10µg LPS intraperitoneally 
 
Day 6-Mice were placed in metabolic cages overnight for urine collection 
 
Day 7-  
1. Mice were exsanguinated and their blood collected into heparin tubes 
for flow cytometric analysis and into eppendorfs for serum collection 
2. Their kidneys and lungs were harvested for histological analysis 
 
7.3.6 Albuminuria measurement 
 
Mice were housed in metabolic cages for 24 hours for urine collections. The 
urine albumin concentration was measure by ELISA using a mouse albumin 
ELISA quantisation set from Bethyl Laboratories as described in Section 
2.2.18. Urine albumin was then calculated by multiplying the concentration of 
albumin in each sample, as measured by ELISA (µg/ml), by the volume of 
urine collected over the 24-hour period.  
 
7.3.7 Urine creatinine measurement 
 
Urine creatinine was measured with the help of Dr N Dalton and Dr C Turner 
in the Department of Paediatric Biochemistry at St. Thomas' Hospital by mass 
spectrometry as described in Section 2.2.19. 
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7.3.8 Histology 
 
Kidney and lungs were collected and histology performed as described in 
Section 2.2.16. All of the PAS stained sections of lungs and kidneys from both 
of the experiments described here were reviewed by Prof Terry Cook 
(Imperial College), an expert clinical and experimental renal pathologist, who 




Statistics were performed using Graphpad Prism software (Graphpad 
Software Inc, La Jolla, CA, USA). Paired t tests, as indicated, were used to 
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7.4 Results: Neither human anti-PR3 nor anti-MPO antibodies induced 
disease in the humanised mouse model 
  
Mice were engrafted as previously described with CD34+ cells either derived 
from human bone marrow or human UCB. In either case the CD34+ cells were 
purchased from Lonza. Between 8 and 12 weeks later mice were divided into 
three groups based primarily on the total number of human CD45+ leukocytes 
(Fig 7.1 A), CD45+CD66b+ neutrophils (Fig 7.1 B) and CD45+CD14+ 
monocytes (Fig 7.1 C) present in their peripheral blood. The first group would 
go on to receive control IgG, the second group would go on to receive anti-
PR3 IgG and the final group would go on to receive anti-MPO IgG as 
indicated in Figure 7.1. IgG from 6 individual patients, 3 positive for anti-PR3 
ANCA and 3 positive for anti-MPO ANCA, was chosen based on the severity 
of disease present in the patient from which they were derived (Table 7.3) and 
on their ability to bind to MPO and PR3 as measure by ELISA (Fig 7.2). Due 
to the variability of the neutrophil respiratory burst induced by patient derived 
ANCA, combined with technical difficulties experienced in performing these 
assays during this period (Discussed in Chapter 3), the ability of these ANCA 
to activate neutrophils in vitro was not taken into account. Control IgG was 
derived from a healthy volunteer (L2) and as shown in Figure 7.2 did not bind 
to either PR3 or MPO.  
 
Table 7.4 shows a summary of the mice used in this experiment including the 
IgG administered, the mouse group number (which refers to the source of 
CD34+ cells used for engraftment and can be cross referenced with Table 5.6) 
and the percentage of human leukocytes, neutrophils and monocytes present 
in their circulation. There were 7 groups of mice all together, a control group 
containing 5 mice and one group comprising 3 mice for each of the patient 
ANCA samples tested. Each mouse received 6µg GCSF (Neupogen®) 
together with 4m IgG and 10µg LPS. They were boosted daily with 6µg GCSF 
and received a single boost of 10µg LPS 3 days after the first. On day 6 mice 
were place in metabolic cages for 24 hour, to allow urine collection, and 
following this the mice were culled and their kidneys and lungs were  
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Figure 7.1 Engraftment of human cells. Total number of human (A) CD45+ 
leukocytes (B) CD66b+ neutrophils  and (C) CD14+ monocytes in the 
peripheral blood of humanised mice (n=5 for control mice, n=10 for anti-PR3 
treated mice and n=10 for anti-MPO treated mice) are shown on the left. 
Representative flow cytometry plots used to calculate total numbers are 
shown on the right. The dot plots show the median population (horizontal 
line). 
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V3* 12 31 No Chest/ns/ent/skin 1±1 56 
V5* 12 32 Yes Eyes/ns/abdo 1±1 195 
V8* 12 14 Yes No 5±2 32 
 V7**  12  20  No  Chest/ent 15±3 9 
 V26**  12  22  Yes  Ent/chest 9±1 0 
 V30**  12  18   No  Chest 18±1 6020 	  
Table 7.3 Information on ANCA used in an attempt to induce disease. 
ANCA was derived from patients that had evidence of active renal 
involvement, which was confirmed by renal biopsy in most cases. Clinical 
evidence of other tissue involvement (ent-ear, nose or throat, ns-nervous 
system, abdo-abdomen) is also indicated. BVAS-Birmingham Vasculitis 
Activity Score. * anti-PR3 ANCA, **anti-MPO ANCA. V26 was from a patient 




Figure 7.2 PR3 and MPO Capture ELISA results showing the binding of 
antibody used in an attempt to induce disease. Antibody was tested at a 
concentration of 20µg/ml. The median binding is shown (horizontal line). 
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L2 7 13.2 0.83 3 
L2 7 8.09 0.22 4.83 
L2 8.1 52.4 0.5 1.73 
L2 8.1 33.2 1.05 5.81 
L2 8.2 15 0.29 2.08 
V3 8.2 68.9 0.76 1.44 
V3 8.2 7.54 0.7 2.49 
V3 8.2 64 0.38 1.65 
V5 8.1 56.3 1.66 4.09 
V5 8.1 68.4 2.13 5.38 
V5 8.2 8.72 0.25 1 
V7 7 24.2 0.62 2.73 
V7 7 13.1 0.79 3.04 
V7 8.1 39 0.39 1.95 
V8 7 14.1 2.09 4.9 
V8 7 20.3 2.34 5.81 
V8 7 12.6 0.2 1.84 
V26 8.1 6.8 0.23 2.38 
V26 8.1 47. 0.19 1.35 
V26 8.2 17.5 0.42 1.74 
V30 8.1 46.7 0.55 2.01 
V30 8.1 40.4 6.03 13.3 
V30 8.1 40.5 4.55 13.3 
 
Table 7.4 Summary of ANCA and mice used in the experiment to induce 
disease in humanised mice. Each mouse received 4mg of IgG intravenously. 
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harvested. There were no histological signs of disease in either the kidneys or 
the lungs of mice receiving anti-PR3 or anti-MPO IgG (Fig 7.3). Furthermore, 
there was no difference in the levels of albumin over 24 hours in the urine of 
mice receiving patient derived ANCA when compared with those receiving 
control antibody (Fig 7.4 A). As there was some doubt about the urine 
collection, due to an issue with the metabolic cages the urine:creatinine ratio 
was measured and found to be similar in all mice regardless of whether they 
received anti-PR3, anti-MPO or control IgG (Fig 7.4 B). In addition, there was 
no haematuria detected in any of the mice tested. The presence of anti-PR3 
and anti-MPO IgG in the circulation of the relevant mice at the end point of the 
experiment was confirmed, for the majority of mice, using a PR3 and a MPO 
capture ELISA (Fig 7.5). 
 
7.5 Results: Human anti-PR3 antibodies did not induce disease in the 
humanised mouse model 
 
For the first experiment IgG from patients positive for either anti-MPO or anti-
PR3 was transferred into humanised mice. As none of the anti-PR3 nor anti-
MPO IgG preparations used appeared to induce disease, IgG from two further 
anti-PR3 positive patients, with particularly severe disease, was used in a 
second attempt to assess the pathogenicity of patient ANCA. Mice were 
engrafted as previously described with CD34+ cells from human UCB 
obtained from Lonza. Approximately 12 weeks later they were divided into 
three groups based primarily on the total number of human CD45+ leukocytes 
(Fig 7.6 A), CD45+CD66b+ neutrophils (Fig 7.6 B) and CD45+CD14+ 
monocytes (Fig 7.6 C) present in their circulation. The first group would go on 
to receive control IgG while the second and third groups would go on to 
receive anti-PR3 IgG derived from two individual patients (V14 and V31) as 
indicated. Patient IgG was chosen based on the severity of disease present in 
the patient from which they were derived, and in the case of V31 on the 
patients high anti-PR3 titres (Table 7.5). Due to the variability of the neutrophil 
respiratory burst induced by patient derived ANCA, combined with technical 
difficulties experienced in performing these assays during this period  
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Figure 7.3 PAS staining of (A) a kidney section and (B) a lung section 
showing no abnormalities. Magnification is x 400 on a BX51 fluorescent 
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Figure 7.4 Functional readouts from mice receiving purified control (n=5), anti-
PR3 (n=9) or anti-MPO antibody (n=10). (A) Albuminuria over the 24 hour 
period 6 days post human control antibody or ANCA administration to 
engrafted NOD-scid IL2γ-/- mice treated with GCSF and LPS. (B) Urine 
albumin:creatinine ratios over the 24 hour period 7 days post human control 
antibody or ANCA administration to engrafted NOD-scid IL2γ-/- mice treated 
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Figure 7.5 MPO and PR3 Capture ELISA results showing the binding of 
antibody remaining in mouse (n=5 for control antibody treated mice, n=9 for 
anti-PR3 treated muce and n=10 for anti-MPO treated mice) serum 7 days 
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Figure 7.6 Engraftment of human cells. Total number of human (A) CD45+ 
leukocytes (B) CD66b+ neutrophils  and (C) CD14+ monocytes in the 
peripheral blood of humanised mice (n=5 for control mice, n=5 for anti-PR3 
treated mice and n=5 for anti-MPO treated mice) are shown on the left. 
Representative flow cytometry plots used to calculate total numbers are 
shown on the right. The dot plots show the median population (horizontal 
line). 
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(Discussed in Chapter 3), the ability of these ANCA to activate neutrophils in 
vitro was not taken into account. However, in hindsight V14 consistently 
induced a strong neutrophil respiratory burst as measured by rhodamine 123 
production. Control IgG was the combination of IgG derived from 2 healthy 
volunteers (L1 + 2). Table 7.6 shows a summary of the mice used in this 
experiment including the IgG administered, the mouse group number (which 
refers to the source of CD34+ cells used for engraftment and can cross 
referenced with Table 5.6) and the percentage of human leukocytes, 
neutrophils and monocytes present in their circulation. There were 3 groups of 
mice, one control group and two test groups, each comprising 5 mice. Each 
mouse received 50µg pegylayed GCSF (Neulasta®), this was in contrast to 
the previous experiment in which the mice received 6µg GCSF (Neupogen®) 
daily from day 0-6, together with 10mg IgG (more than twice that given in the 
previous experiment) and 10µg LPS. They received a single boost of 10µg 
LPS 3 days after the first. On day 6 mice were place in metabolic cages for 24 
hour, to allow urine collection, and the following day they were culled and their 
kidney and lungs were harvested. There were no histological signs of disease 
in either the kidneys or the lungs of mice receiving anti-PR3 IgG (Not shown, 
See figure 7.3 for representative histology). Furthermore, there was no 
difference in the levels of albumin over 24 hours in the urine of mice receiving 
patient derived ANCA when compared with those receiving control antibody 
(Fig 7.7). In addition, only 1 of the 10 mice receiving anti-PR3 antibody, and 
none of the mice receiving control antibody, had haematuria. 
 
In this second experiment flow cytometry was performed in order to confirm 
the presence of human cells, particularly mature neutrophils, in these 
humanised mice both before and 7 days after treatment with GCSF, LPS and 
human IgG (Fig 7.8-7.10). As expected, based on the results from Chapter 6, 
in which GCSF treatment led to a significant increase in the number of mouse 
neutrophils and a concurrent decrease in the percentage of human cells, 
there was a significant decrease in the percentage of human CD45+ cells in 
the peripheral blood of mice treated with GCSF, LPS and human IgG. 
Surprisingly, however, this corresponded with a significant decline in the total  
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V14 12 21 Yes Ent 0 2719 
V31 12 15 Yes No No data No data 
Table 7.5 Information on ANCA used in an attempt to induce disease. 
ANCA was derived from patients that had evidence of active renal 
involvement, which was confirmed by renal biopsy in most cases. Clinical 
evidence of other tissue involvement (ent-ear, nose or throat) is also 
indicated. BVAS-Birmingham Vasculitis Activity Score.  
 









L1 + 2 9 75.9 0.61 8.51 
L1 + 2 9 43 2.08 5.09 
L1 + 2 9 50.3 0.25 2.96 
L1 + 2 9 61.5 0.19 2.07 
L1 + 2 9 63.2 0.57 2.62 
V14 9 69.5 1.87 9.45 
V14 9 41.1 0.43 2.47 
V14 9 65.1 0.6 7.31 
V14 9 54.3 0.41 9.98 
V14 9 58.7 0.19 4.18 
V31 9 76.5 0.88 14.1 
V31 9 66.4 0.92 8.49 
V31 9 72.6 0.48 7.12 
V31 9 68.6 0.63 5.65 
V31 9 49.5 1.33 13.7 
Table 7.6 Summary of ANCA and mice used in the experiment to induce 
disease in humanised mice. Each mouse received 10mg of IgG intravenously. 
For data on mouse groups used refer to Table 5.6. 
Chapter 7 The passive transfer of ANCA does not induce disease in 
humanised mice 	  
	   249 
number of human CD45+ cells in the circulation (Fig 7.8 A). In contrast, both 
the percentage and absolute number of mouse CD45+ cells was significantly 
increased 7 days after GCSF, LPS and IgG administration (7.8 B). 
Representative flow cytometry plots show the staining for human and mouse 
CD45+ cells (Fig 7.8 C). Of the human CD45+ cells present in the peripheral 
blood of these mice before GCSF, LPS and human IgG treatment, on average 
0.87% were mature human neutrophils, defined as CD66b+CD16+ cells. Post 
treatment this had increased; with human neutrophils accounting for, on 
average, 2.64% of the human CD45+ cell population (Fig 7.9 A). 
Representative flow cytometry plots show the staining for human 
CD45+CD66b+CD16+ cells (Fig 7.9 B). Interestingly, two separate populations 
of human neutrophils could be identified both before and after GCSF, LPS 
and human IgG administration. These were a CD66b+CD16dim  population and 
a CD66b+CD16+ population. Concurrently, the percentage and absolute 
number of human monocytes, defined as human CD45+CD14+ cells, were 
significantly higher 7 days post GCSF, LPS and human IgG (Fig 7.10). 
Importantly, as shown in Figure 7.10 B, these monocytes could be divided into 
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Figure 7.7 Albuminuria over the 24 hour period 6 days post human control 
antibody (n=5) or ANCA (n=10) administration to engrafted NOD-scid IL2γ-/- 
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Figure 7.8 Human cell engraftment pre and post disease induction. Mice 
(n=15) were bled from the saphenous vein and given 50µg pegylated GCSF 
subcutaneously, 10µg LPS intraperitoneally and 10mg human IgG 
intravenously. They received a second dose of LPS 3 days later. On day 7 
they were culled and bled via the axillary vessels. (A) Human and (B) mouse 
CD45+ leukocytes are shown as a percent of the total leukocytes and as 
absolute numbers. (C) Shows representative FACs plots.***p<0.001, 
****p<0.0001. Data was analysed using a paired t test. 
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Figure 7.9 Human CD45+CD66b+CD16+ cells in humanised mice (n=15) pre 
and post disease induction. Mice were bled from the saphenous vein and 
given 50µg pegylated GCSF subcutaneously, 10µg LPS intraperitoneally and 
10mg human IgG intravenously. They received a second dose of LPS 3 days 
later. On day 7 they were culled and bled via the axillary vessels. (A) Data 
from each individual mouse (B) Representative FACs plots. *p<0.05.  
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Figure 7.10 Human CD45+CD14+CD16+ cells in humanised (n=15) mice pre 
and post disease induction. Mice were bled from the saphenous vein and 
given 50µg pegylated GCSF subcutaneously, 10µg LPS intraperitoneally and 
10mg human IgG intravenously. They received a second dose of LPS 3 days 
later. On day 7 they were culled and bled via the axillary vessels. (A) Data for 
individual mice (B) Representative FACs plots. Multiple populations of 
monocytes can be identified as indicated. *p<0.05. **** p<0.0001. Data was 
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7.6 Discussion 
 
A humanised mouse model of ANCA associated vasculitis 
 
Despite two separate attempts, the passive transfer of patient derived ANCA 
failed to induce pathological changes in the kidneys or lungs of humanised 
mice. Consistent with this, anti-PR3 and anti-MPO antibodies also failed to 
induce proteinuria or haematuria. Mice in these experiments were matched 
based primarily on their reconstitution of human neutrophils, however, the 
overall engraftment of human cells and the number of human monocytes 
present was also taken into account (Fig 7.1 and 7.6). As established in 
Chapter 4, it is possible that monocytes play a role in the pathogenesis of 
anti-PR3, if not anti-MPO, induced ANCA associated vasculitis. In order to 
increase the chances of inducing disease and to provide a proinflammatory 
environment, which is thought to be required for the pathogenesis of ANCA 
associated vasculitis (Chapter 1), all humanised mice in these experiments 
were administered GCSF and LPS, alongside either human anti-PR3, anti-
MPO or control IgG. In the previous chapter human GCSF was shown to 
expand, and partially activate, the population of human neutrophils found in 
humanised mice, while LPS was shown to further activate these human 
neutrophils and maximise their recruitment to the lungs. In addition, GCSF 
has been shown to prime human neutrophils for activation by anti-MPO 
antibodies (Fig 4.11).  Furthermore, GCSF acting in synergy with LPS has 
been shown to exacerbate disease in wildtype mice receiving anti-MPO 
antibodies via passive transfer [239]. Indeed, LPS itself has been shown to 
activate endothelial cells [93, 94] and, through its induction of TNFα 
production, exacerbate disease in the passive transfer model of anti-MPO 
induced glomeronephritis [23]. Thus, although the humanised mice appeared 
to have all the components necessary to support disease induction by the 
passive transfer of anti-PR3 or anti-MPO antibodies, a humanised mouse 
model of ANCA-associated vasculitis could not be established. This in 
contrast to a recent study by Little et al., in which patient derived anti-PR3 IgG 
induced mild pathology, including focal pulmonary haemorrhage and mild 
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renal abnormalities, together with proteinuria and hematuria in a humanised 
mouse model [326]. There are numerous possible reasons for the failure of 
the model described here and the relatively mild disease found in the Little et 
al. model: 
 
a) The number of human neutrophils present in the circulation of the 
humanised mouse model may be limiting. Relatively speaking, there are very 
few human neutrophils reconstituted by these mice. While there are >1.5x106 
neutrophils/ml found in healthy humans, there are on average only 1.62x104 
human neutrophils/ml in the peripheral blood of humanised mice post GCSF 
(data from Table 6.4).  Thus, as neutrophils are the key effector cells in 
disease pathogenesis, their relative lack may be responsible for the absence 
of disease in this model.  
 
The main difference between the humanised mouse model described here 
and that employed by Little et al. is the source of the HSCs used to 
reconstitute the NOD-scid IL2γ-/- mice. While human UCB CD34+ cells were 
used in this study, Little et al., engrafted mice using mobilised CD34+ human 
bone marrow derived HSCs. It has been shown previously that HSCs from 
newborn/foetal sources have greater potential for repopulating 
immunodeficient mice than those from adult sources [291, 292]. However, this 
was with regards to overall human engraftment and focused primarily on the 
reconstitution of lymphoid lineage cells. Therefore it is possible, though it 
cannot be confirmed as the absolute number of cells were not provided in the 
Little et al. study, that mice engrafted with bone marrow derived HSCs 
reconstituted a higher number of human neutrophils than those engrafted with 
UCB HSCs. If this is the case it may help explain why disease, though mild, 
was present in the humanised mice used in the Little et al. study. 
 
b) Although human neutrophils from UCB CD34+ cell engrafted mice were 
shown to be capable of responding to opsonised E.coli and fMLP in vitro (Fig 
6.12-6.15), there is no evidence that these cells can be activated by anti-PR3 
or anti-MPO antibodies, despite data showing that both PR3 and MPO are 
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indeed expressed by these cells (Fig 6.16). This lack of data is primarily due 
to technical difficulties involved the use of ANCA assays. As discussed in 
Chapter 4, there is currently no whole blood assay that can be performed to 
assess the ability of ANCA to activate neutrophils and therefore neutrophils 
must be isolated for ANCA activation studies. There are several reasons why 
this might present difficulties with regards to humanised mice. As noted 
above, human neutrophils in humanised mice are relatively rare and thus 
isolating sufficient numbers would be difficult. In addition, the donor 
dependent variability of neutrophils seen with healthy human volunteers is 
likely to translate to humanised mice. Taking both of these issues into 
account, a large number of humanised mice would be required to properly test 
human neutrophil responses to ANCA. Thus, due to the limited number of 
humanised mice, a consequence of the time and expense required to 
generate them, this study was not feasible in the time allotted. Finally, 
neutrophils are sensitive cells and are activated by cell separation to some 
extent regardless of the method used, meaning that results in vitro might not 
accurately reflect the situation in vitro (Discussed in Chapter 3).  
 
c) Due to the variability of the neutrophil respiratory burst induced by patient 
derived ANCA, combined with technical difficulties experienced in performing 
these assays during this period (Discussed in Chapter 3), the ability of ANCA 
to activate neutrophils in vitro was not taken into account when choosing 
patient IgG to induce disease. However, it must be noted that both V14 and 
V30 were later found to consistently induce a strong neutrophil respiratory 
burst as measured by rhodamine-123 production, if not by superoxide 
production (Table 7.5). Despite this, mice receiving IgG for patient V14 had no 
signs of disease. In contrast, Little et al., specifically chose to inject mice with 
anti-PR3 antibodies that had been shown to induce a strong respiratory burst 
and degranulation response in neutrophils isolated from human volunteers. It 
is therefore possible that the ability of ANCA to activate neutrophils in the 
humanised model is dependent on the anti-PR3 and anti-MPO antibodies 
used. Indeed this would be consistent with the variability found between 
ANCA derived from different patients to induce neutrophil activation in vitro. If 
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this is the case it is likely that the testing a larger number of patient derived 
ANCAs would lead to the development of disease in some mice. This 
potentially raises questions as to whether patient derived ANCA is in itself 
pathogenic. If this were the case then it would be expected that all ANCA 
would be capable of inducing disease. Having said that however, and as 
discussed in Chapter 3, it is possible that it is simply the use of whole IgG 
solutions that is the problem. ELISA results are insufficient to quantify the 
percentage of anti-PR3 or anti-MPO specific antibodies in a whole IgG 
solution. Therefore, it is impossible to be sure how much ANCA each mouse 
is actually receiving. In addition, it is possible that ANCA purified from patients 
may differ in regards to its subclass, epitope specificity and affinity, leading to 
differences in its ability to interact with neutrophils and thus induce disease in 
these mice. 
 
d) Concern has been raised with regards to the ability of human cells 
generated in mice to transmigrate to sites of inflammation, and once there to 
adequately adhere to mouse endothelial cells. The data from Chapter 4 
suggests that this is not an issue for human neutrophils, at least not with 
regards to their ability to respond to LPS by migrating to the lungs where they 
can bind to vasculature. Despite this, there are numerous interactions that 
may be required for disease pathogenesis that cannot occur in the mouse 
system due to a lack of cross reactivity between mice and human proteins, 
combined with the limited number of human cells available to compensate for 
this.  
 
e) Although humanised mouse neutrophils have been shown to respond as 
normal human neutrophils thus far, they have not been fully phenotyped or 
tested. Therefore, it is possible that there are yet undiscovered defects in 
these cells, perhaps with regards signalling, that prevents them functioning as 
proper human neutrophils. 
 
It is likely that no single point discussed is wholly responsible for the absence 
of disease in the model shown here, and for the relatively mild disease 
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observed in the model established by Little et al, but instead it is due to a 
combination of these issues. 
 
It should be noted here that while it is possible that some strains of mice might 
be resistant to NCGN, previous results showning robust disease in NOD-scid 
mice [103] suggest that this is not a problem for associated with mice of this 
background strain. 
 
Human neutrophil and monocyte subpopulations generated by 
humanised mice 
 
Flow cytometry confirmed that human cells, including neutrophils and 
monocytes, remained in the circulation of humanised mice 7 days after 
treatment with GCSF, LPS and human IgG (Fig 7.8-7.10). Indeed, post 
treatment the number of human neutrophils and monocytes had increased, 
although, unexpectedly the absolute number of human leukocytes had 
declined (Fig 7.8). The decrease in the number of human CD45+ cells in the 
peripheral blood 7 days post GCSF, LPS and human IgG administration 
cannot be fully explained, however, it is possible that the loss of cell numbers 
in due to LPS induced apoptosis of lymphocytes [327, 328], which account for 
the majority of human cells present in the peripheral blood of engrafted mice. 
Interestingly, two separate populations of human neutrophils could be 
identified after GCSF, LPS and human IgG administration. These were a 
CD66b+CD16dim  population and a CD66b+CD16+ population (Fig 7.9). The 
importance of this is unknown, however, it is likely that the CD16dim population 
represents less mature neutrophils that have been recently released into the 
circulation from the bone marrow. This is supported by the fact that this 
population is not present before GCSF, LPS and human IgG administration 
[329]. Alternatively they are neutrophils that are undergoing apoptosis and 
have thus downregulated their CD16 expression [330].  
 
Perhaps more importantly however, at least with regards to understanding the 
engraftment of humanised mice, monocytes could be divided into three 
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subpopulations: CD14dimCD16+, CD14+CD16+ and CD14+CD16dim/- (Fig 7.10). 
This is in keeping with human monocyte populations where these subsets 
have been identified and studied with each one demonstrating a specific 
function. CD14dimCD16+ monocytes do not produce TNFα or IL1β in response 
to LPS but instead have been shown to patrol blood vessels where they 
respond specifically to viruses and nucleic acids [331]. CD14+CD16+ 
monocytes are often referred to as proinflammatory monocytes and express 
high levels of CX4CR1, low levels of CCR2 and are the main producers of 
TNFα and IL1β in response to LPS. Finally, CD14+CD16dim/- monocytes, the 
largest of the subsets, express low levels of CX4CR1, high levels of CCR2 
and produce IL10 in preference to TNFα in response to LPS [332]. Notably, 
with regards ANCA associated vasculitis, there was no difference in the 
relative proportions of monocyte subsets observed between patients and 
healthy controls, although there was an increase in the percentage of 
monocytes expressing TLR4 [333].
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This chapter detailed the development of the neutrophil assays and ANCA 
purifications that would be used throughout this project. Using both 
commercial monoclonal, and patient purified polyclonal, anti-PR3 and anti-
MPO antibodies, two respiratory burst assays to measure the ANCA-induced 
activation of neutrophils were established. These assays had not been used 
previously in my host laboratory. The superoxide dismutase inhibitible 
ferricytochrome C reduction assay measures extracellular superoxide release, 
while the DHR123 assay primarily measures intracellular reactive oxygen 
species production. In addition, the purification of patient ANCA was 
optimised, with the removal of fibrin and other impurities from patient plasma 
using sodium chloride precipitation found to be more efficient than the same 
process using ammonium sulphate. This chapter closed with a summary of 
the patient ANCA purified in the course of this project, focussing primarily on 
the inability of a large number of these patient derived antibodies to induce 




Chapter 4 was roughly divided into three sections, each focussing on a 
different aspect of human neutrophil and/or monocyte behaviour with regards 
to the study of ANCAs and their antigens. The first section dealt with the 
expression of human PR3 and MPO on the surface of human neutrophils and 
monocytes in whole blood. Importantly, both PR3 and MPO were found to be 
present on the surface of unprimed whole blood neutrophils. In contrast, only 
PR3 was found to be expressed at reasonably high levels on the surface of 
whole blood monocytes. Interestingly, priming with TNFα did not upregulate 
the expression of PR3 or MPO on the surface of whole blood neutrophils. On 
the contrary, it appeared to significantly downregulate the expression of both 
these proteins. With regards monocytes, pretreatement with TNFα was found 
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to upregulate PR3 membrane expression. Despite detectable PR3 and MPO 
on the surface of whole blood neutrophils and monocytes, stimulation with 
neither anti-PR3 nor anti-MPO IgG induced cell activation as measured by the 
reactive oxygen species dependent oxidation of dihydrorhodamine-123 into 
fluorescent rhodamine-123. 
 
The second section focussed on determining whether GCSF may have a role 
in potentiating the ANCA induced activation of neutrophils. Interestingly, it was 
found that GCSF primes isolated neutrophils for anti-MPO, but not anti-PR3, 
induced neutrophil activation as measure by the production of rhodamine-123. 
Furthermore, it was shown that this was not the result of a GCSF induced 
upregulation of MPO on the surface of the cell. Finally, it was shown that 
GCSF primed mouse neutrophils in vivo, and this relates to results obtained 
from an in vivo passive transfer model of anti-MPO IgG induced NCGN, in 
which GCSF treatment was found to exacerbate disease [239]. 
 
The third and final section examined the role of Class IA PI3K in the ANCA 
induced activation of neutrophils. Using a specific inhibitor, TGX-221, it was 
shown that the loss PI3Kβ/δ activity profoundly, and negatively, affected the 
ANCA induced respiratory burst, thus suggesting a role for this molecule in 




This chapter focussed on the establishment of a humanised mouse model. It 
was found that commercially available umbilical cord blood derived CD34+ 
stem cells provided higher human cell engraftment in adult irradiated NOD-
scid IL2γ-/- mice than CD3+ cell depleted umbilical cord blood cells derived in 
house. Furthermore, it was shown that engrafted mice reconstituted high 
levels of human CD45+ leukocytes by 8 weeks post transfer of stem cells, and 
that these levels did not appear to increase further by 12 weeks. In addition, it 
was confirmed that these mice possessed human T cells and B cells in their 
bone marrow, spleens and peripheral blood. 
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Chapter 6 
 
Chapter 6 concerns itself with the reconstitution of human neutrophils by 
humanised mice. Humanised mice, between 2 and 6 months post 
engraftment, were found to reconstitute human CD45+CD66b+ neutrophils at 
very low levels, with these cells comprising, on average, less than 1% of the 
total human CD45+ cells in their peripheral blood. Treatment of these mice 
with human pegylated GCSF for 5 days increased the number of human 
neutrophils, with these cells comprising, on average, 2.6% of the human 
peripheral blood cells post treatment. Furthermore, GCSF served to prime the 
human neutrophils in vivo, as measured by CD66b, CD63 and CD11b 
upregulation, together with CD62L shedding. In addition, the human 
neutrophils of mice that received subsequent LPS treatment showed further 
CD66b and CD63 upregulation, as well as further CD62L shedding. 
Importantly, LPS was also shown to induce human neutrophil trafficking to the 
lungs. Taken together these results showed that reconstituted human 
neutrophils were responsive to inflammatory stimuli in vivo. In addition, 
humanised mouse human neutrophils were shown to undergo respiratory 
burst and degranulation in response to fMLP and E.coli stimulation in vitro. 
Finally, human neutrophils reconstituted by humanised mice were shown to 




The final results chapter details attempts to induce anti-PR3 and anti-MPO 
IgG associated disease in humanised mice. Despite the presence of 
functional human neutrophils, these mice did not show signs of disease when 
administered LPS, GCSF and patient derived ANCA, elements shown to work 
together to induce disease in a purely mouse model of anti-MPO IgG 
associated NCGN [23, 239]. Two separate experiments were carried out, 
differing in both the patient derived ANCAs used and the concentration 
administered. The engraftment levels of the mice were tested both before and 
after the experiments, with human monocytes confirmed to be present in the 
peripheral blood of mice in the second experimental group. Interestingly, it 
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was shown that different subsets of human monocytes were present, and that 
these responded to GCSF, LPS and IgG treatment by significantly increasing 
in number. 
 
8.2 Limitations and implications 
 
In vitro results: ANCA and it’s antigens 
 
The results detailed in chapter 3 and 4 are based on the in vitro study of cells, 
together with, either polyclonal antibodies derived from human blood, or 
monoclonal antibodies. The main limitation found with regards polyclonal 
patient derived ANCA, is that not all patient ANCA activates the neutrophil 
respiratory burst in vitro, and of those that do less than 21% induce a notably 
strong response (based on results using the more sensitive DHR123 assay). 
It is difficult to say whether this is due to a) the assays used, b) an issue 
arising from the neutrophil isolation techniques employed or c) the antibody 
preparation itself. Each of these potential issues, however, will be addressed 
below: 
 
a) It is possible that ANCA does not mediate enthothelial cell damage via the 
respiratory burst, and, if that is indeed the case, the ability or inability of ANCA 
to induce the release of reactive oxygen species is largely irrelevant. Indeed, 
results, available in abstract form, from a mouse with neutrophils that lack the 
ability to undergo a respiratory burst suggest that this may be the case [220]. 
As this has not been confirmed however, the neutrophil respiratory burst 
remains a major readout of ANCA induced neutrophil activation.  
 
b) That the process of isolation affects the activation status of neutrophils is 
well documented, and has already been discussed in some detail (Chapter 3 
and 4). As demonstrated in Chapter 3, neutrophils isolated using 
Polymorphprep did not undergo activation in response to ANCA, as measured 
by the DHR123 assay. However, when neutrophils were isolated using a 
modified Ficoll method, a robust ANCA induced response could be achieved, 
again using a DHR123 assay. This suggests that the way in which the 
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neutrophils are purified has a profound affect on their ability to respond to 
ANCA. Therefore, it is possible that a larger number of patient purified ANCA 
might activate neutrophils if the right isolation technique was found. However, 
it also suggests that it is possible that the in vitro activation of neutrophils by 
ANCA is unphysiological to the point of irrelevance.  
 
The expression of PR3 and MPO on human neutrophils in whole blood was 
examined in Chapter 4 with both of these ANCA antigens found to be present 
on the membrane of resting neutrophils. Indeed, in contrast to results with 
isolated cells [14, 26, 67, 68], TNFα was not only unnecessary for PR3 and 
MPO expression, but actually significantly downregulated their expression. 
This result further suggests that ANCA assays using isolated neutrophils do 
not reflect the in vivo behaviour of these cells.  
 
c) The use of whole IgG preparations is a limitation in and of itself. Although 
patients possess a wide array of antibodies with varying specificities, for in 
vitro assays it would be useful to have antibodies specific for the ANCA 
antigens. This would allow greater certainty with regards the response being 
the result of anti-PR3 or anti-MPO antibodies, as opposed to a yet 
undiscovered antibody specific to another antigen that may be unique to 
patients, as well as allowing a more precise control over the concentration of 
ANCA added to the cells. This particular limitation is overcome here by the 
use of monoclonal anti-PR3 and anti-MPO antibodies, however, as these 
antibodies have mouse Fc receptors and are specific for one particular 
epitope, they do not accurately reflect patient ANCA. Furthermore, with recent 
work showing that IgA may also play a role in ANCA associated vasculitis 
[73], focussing solely on anti-PR3 and anti-MPO IgG is somewhat limiting.  
 
It is clear that ANCA assays, like all assays, have a number of intrinsic 
limitations that must be taken into account when interpreting data. However, 
with appropriate controls, and in vivo data to confirm in vitro results, they can 
provide a wealth of information on ANCA:antigen interactions, and 
subsequent pathogenic responses. Indeed using these assays, GCSF and 
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PI3Kβ/δ have been implicated in ANCA associated vasculitis (Chapter 4). 
With regards GCSF, this cytokine has been shown to prime neutrophils for an 
anti-MPO IgG induced response, and its ability to exacerbate disease has 
been confirmed in vivo using a passive transfer model of ANCA induce NCGN 
[239]. Thus, the combination of in vitro and in vivo results strongly suggest 
that GCSF should be given with great caution to neutropenic patients 
suffering from ANCA associated vasculitis. 
  
In vivo results: Humanised mouse models 
 
Both anti-PR3 and anti-MPO antibodies have been shown to activate 
neutrophils in vitro. However, while, at the outset of this project, it had already 
been confirmed that anti-MPO antibodies are capable of inducing NCGN in 
mice (Discussed in Chapter 1), there had been little corresponding in vivo 
data to confirm the pathogenicity of anti-PR3 antibodies. It must be noted 
however, that with the recent publication by Little et al. showing that anti-PR3 
antibodies induce mild disease in humanised mice, this is no longer the case 
[326]. As the difficulties involved in developing an animal model of anti-PR3 
induced disease is often attributed to the differences in human and mouse 
PR3, particularly the lack of PR3 on mouse neutrophil membranes [299], it 
was thought, at the beginning of this project, that the development of a 
humanised mouse model with functional human neutrophils expressing PR3 
had the potential to overcome this issue, and thus could be used to establish 
a disease model. Furthermore, and representing an advancement on the 
current models, a humanised mouse model could be used to study human 
neutrophil:ANCA interactions in vivo. However, despite the successful 
establishment of a humanised mouse model with functional human 
neutrophils expressing PR3 and MPO, the passive transfer of patient ANCA 
together with a proinflammatory stimuli, in the form of exogenous human 
GCSF and LPS, failed to induce pathology in this study. This is in contrast to 
the previously mentioned study by Little et al. in which anti-PR3 antibodies 
together with LPS induced disease [326].  
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There are number of potential reasons for the lack of success of this model, 
and these are discussed in detail in Chapter 7. However, even had anti-PR3 
IgG induced disease in the humanised mice, or indeed, if the existing model 
established by Little et al. could be optimised to provide a more robust 
disease model, a number of limitations would still need to be faced. First and 
foremost of these are complications involved in examining human cells 
interacting with a mouse environment, particularly with regards mouse 
endothelium.  It is likely that human leukocyte:mouse cell interactions differ 
from human neutrophil:human cell interactions, and thus results may not be 
directly translatable. However, it is possible that the transplantation of further 
human tissues into mice could partially overcome this issue. In addition, the 
full functionality of humanised mouse human neutrophils remains to be seen. 
While they appear to mirror all human neutrophil responses tested thus far, it 
is still possible that they have defects that have yet to be identified. In 
addition, the lack of available knockout mice would make the study of 
signalling difficult using this model. Finally, disease induced by the passive 
transfer of anti-PR3 and anti-MPO IgG, as proposed here, would provide a 
model of antibody induced disease without any cellular component. 
Furthermore, as T and B cell response remain suboptimal in humanised mice, 
it is unlikely that an autoimmune model could be developed in the near future.   
 
Although a humanised mouse model of ANCA associated vasculitis was not 
established, data showing that humanised mice reconstitute a population of 
functional human neutrophils represents an important advancement in the 
study of humanised mouse models. That said, it must be noted that the 
system described here remains limited by the low numbers of neutrophils 
found in the peripheral blood, even following GCSF administration. However, 
the confirmation that humanised mice can support human neutrophil 
reconstitution, may serve as the basis for further improvements to this in vivo 
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8.3 Future work 
 
As mentioned above the use of whole IgG preparations in ANCA studies may 
be at least partially responsible for the inability of a large number of patient 
derived ANCA to induce neutrophil activation in vitro. In addition, the use of 
whole IgG preparations may also have been partially responsible for the lack 
of disease observed in humanised mice. Therefore, affinity purifying patient 
plasma would provide polyclonal anti-PR3 or anti-MPO specific patient 
antibody, and thus may allow more potent neutrophil activation. However, 
even if this did not turn out to be the case, the use of antibodies of known 
concentration and specificity would allow for more controlled assay conditions, 
and this would beneficial to the study of ANCA. 
 
PI3Kβ/δ have been implicated in the pathogenesis of ANCA associated 
vasculitis, with the inhibition of this molecule preventing the ANCA induced 
activation of neutrophils (Chapter 4). However, this result is preliminary, and 
much work is still required in order to determine if PI3Kβ/δ does have a role in 
ANCA signalling. Not only do the in vitro results presented here need to be 
confirmed, both in the ferricytochrome C assay as well as in a separate assay, 
but in vivo confirmation would also be necessary before PI3Kβ/δ could be said 
to be important, or indeed unimportant, in ANCA pathogenesis. As both PI3Kβ 
and PI3Kδ deficient mice have already been derived [253, 334], a passive 
transfer, or a bone marrow transplant, model of anti-MPO induced NCGN 
could be used to address the need for in vivo data, and thus determine if 
PI3Kβ, PI3Kδ or both represent potential therapeutic targets in ANCA 
associated vasculitis treatment. 
 
The low number of human neutrophils reconstituted by humanised mice is a 
limiting factor with regards the use of this model. Thus, increasing the number 
of human neutrophils reconstituted represents an important avenue for future 
research, both with regards to improving humanised mouse models in 
general, and in successfully establishing a humanised mouse model of ANCA 
associated vasculitis specifically. As discussed in Chapter 1, the use of mice 
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transgenic for human cytokines has led to improvements in human cell 
engraftment. Thus, it is possible that with the correct mixture of human 
cytokines present, including human GCSF, greater human neutrophil 
engraftment could be achieved. In addition, it is likely that mouse innate 
immune cells that remain present post human cell engraftment play a role in 
preventing substantial human myeloid cell engraftment. With regards 
neutrophils, this may be related to regulatory systems, which serve to prevent 
the release of excessive numbers of neutrophils from the bone marrow into 
the circulation [335]. In this scenario, mouse neutrophils would be 
preferentially released into the circulation with human neutrophils retained in 
the bone marrow. Indeed, this might fit with the need for exogenous human 
GCSF to induce the release of human neutrophils, and thus provide 
peripheral blood human neutrophils for study. To test this theory, and to 
potentially improve human neutrophil engrafment, a mouse specific neutrophil 
depletion antibody could be used to remove mouse neutrophils from the 
circulation, and thus allow for the release of human neutrophils from bone 
marrow storage.  
 
While a humanised mouse model with functional human neutrophils was 
established, using the passive transfer of patient ANCA into these mice failed 
to induce disease. Despite this, the humanised model described in this thesis 
still has the potential to allow the study of human neutrophils in vivo, both with 
regards to normal human neutrophil behaviour and, more specifically, with 
regards human neutrophil:ANCA interactions. For example, the use of 
intravital microscopy could provide data on the behaviour human neutrophils 
in vivo, with the use of blocking strategies allowing the elucidation of 
molecular mechanism involved in the adhesion of these cells to the 
endothelium. However, for this to be achieved some method of identifying 
human cells would first need to be established. The transduction of human 
CD34+ cells with green fluorescent protein (GFP) prior to engraftment has 
already be shown [336], and it is possible that this technique may be modified 
to allow the reconstitution of human neutrophils with a GFP tag. This would 
most likely involve a significant amount of time to achieve and thus, in the 
short term, injecting engrafted mice with fluorescently labelled antibodies 
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would allow the identification of human neutrophils using intravital microscopy 
techniques. In addition, and as mentioned earlier, it would be preferable to 
have human endothelium present in these mice and, as human skin has 
already been successfully transplanted into NOD-scid IL2γ-/- mice [133], this 
should be possible. Thus, despite it’s limitations, this model may still allow us 
to probe human neutrophil responses in vivo, both with regards to their ability 
to confer protection, and induce pathology. Furthermore, these humanised 
mice may provide a model to test therapeutic interventions that target human 
neutrophils. 
 
8.4 Concluding remarks 
 
This thesis was divided into two interconnected sections. The first was 
concerned with establishing assays and antibody purifications, which could 
then be used in the pursuit of the main goal of the thesis, and the focus of the 
second section, which was attempting to establish a novel model of ANCA 
associated vasculitis. Although the main goal of the thesis was not achieved 
in the manner set out, various important, and novel, discoveries were 
reported. These include: 
 
• The discovery that PR3 and MPO are expressed on the surface of 
resting human neutrophils, and, importantly, that TNFα negatively 
regulates their expression 
 
• The discovery that GCSF potentiates the anti-MPO induced respiratory 
burst in a manner independent of membrane MPO expression. 
 
• The novel finding that GCSF, given in vivo, induces CD11c 
upregulation by mouse neutrophils 
 
• The discovery that PI3Kβ/δ inhibition prevents the ANCA induced 
respiratory burst, and thus may have a role in ANCA associated 
vasculitis pathogenesis 
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• The discovery that humanised mice have functional human neutrophils 
that expand in number in response to human GCSF, are activated by 
human GCSF and LPS, migrate to the lungs in response to LPS and 
are capable of undergoing robust effector responses in vitro 
 
• The discovery that the passive transfer of patient ANCA does not 
induce disease in humanised mice. Whether this is due to limitations 
associated with the humanised mouse model and/or the ANCA 
preparations used, or whether this may suggest that ANCA are not 
pathogenic in and of themselves, remains to be seen. 
 
Thus, results arising from this work provide many future avenues of research 
both in the field of ANCA associated vasculitis, and with regard the study of 
human neutrophils in vivo. 
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